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ABSTRACT 
Objectives: 
The primary objective of this study was to assess whether active tuberculosis (TB) 
accelerates the course of HIV-1 infection by measuring progression to AIDS and 
mortality in HIV-infected patients. Secondary objectives were to evaluate whether TB 
should be considered an AIDS-defining illness in an area with a high prevalence of 
TB, and to assess the risk factors for developing TB in HIV-1 infected patients. 
Setting: 
New Somerset and Groote Schuur Hospital adult HIV clinics, Department of 
Medicine, Faculty of Health Sciences, University of Cape Town. 
Design: 
Prospective patient cohort study with five years of follow-up. 
Sample: 
Adult HIV-infected patients presenting to the two HIV clinics between 1992 and 
1996. 
Methods: 
The TB case definition was a positive culture or a compatible clinical picture 
combined with a positive smear or a histologic diagnosis. TB patients were treated 
with 6-month short course regimens. 
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The Kaplan-Meier method was used to estimate the overall survival times of 
tuberculosis and non-tuberculosis patients. The generalized log rank test was used to 
compare the survival curves of these two groups. 
The Cox proportional hazards regression method was used to determine the risk of 
death associated with tuberculosis while adjusting for potential confounding variables 
(i.e. age, CD4+ count, history of an AIDS-defining illness, use of co-trimoxazole 
prophylaxis, and antiretroviral therapy, etc.). 
The Kaplan-Meier method was used to evaluate the prognosis of HIV-infected 
patients with TB vs the prognosis of HIV-infected with other HIV ( or AIDS, as 
defined by the WHO or the CDC staging systems) related diseases at baseline. The 
generalized log rank test was used to compare the survival curves of the TB group 
vs the other groups. 
Predictors of active TB in HIV-infected patients were assessed using univariate and 
multivariate logistic regression models. 
Results: 
Between 1992 and 1996, 609 HIV-infected patients were recruited; of whom 158 
(25.9%) were diagnosed with active TB, and 451 (74.1 %) were free of active TB by 
the end of the study. In the TB group, 113 (71.5%) patients presented with active TB 
at baseline (i.e. prevalent cases) and 45 (28.5%) were free of TB at inclusion but 
developed active disease during follow-up (i.e. incident cases). Follow-up in the two 
groups was similar (mean = 11.5 and 14.6 months in cases and non-cases 
xv 
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respectively; p = 0. 7). The proportion of patients lost to follow-up in the two groups 
was not significantly different [59 (37%) cases vs 153 (34%) non-cases; p = 0.5]. In 
the general cohort 38 patients were suspected for TB but did not fulfill TB case 
definition and were thus excluded from the study. Of those with TB, 90 (57%) 
presented with pulmonary TB without evidence of extrapulmonary involvment, 37 
(23.4%) presented with pulmonary and documented evidence of extrapulmonary 
involvement and 31 (19.6%) presented with extrapulmonary alone. Active 
tuberculosis was confirmed in 69 (43.7%), 80 (50.6%) and 9 (5.7%) patients by 
culture, smear, and histologic diagnosis respectively. 
The risk of developing active TB was significantly increased by: WHO stages 3 or 4, 
CD4 count <200 cells/µL, presence of one or more AIDS-defining illness at baseline, 
residence in lower socioeconomic areas and member of a high prevalence TB 
population. 
The proportion of patients presenting at baseline with advanced immunosuppression 
(i.e.CD4+ T-lymphocyte count < 200 cells/µL) was higher in TB cases [71 (45%)] 
than in non-cases [145 (33%)] [p < 0.001]. TB cases had significantly lower median 
CD4+ lymphocyte counts compared to non-cases; [130 vs 295 cells/µL respectively; p 
< 0.01]. The proportion of TB cases presenting with an AIDS-defining illness at 
baseline was also higher than that of non-cases [17 (10.8%) TB cases vs 24 (5.3%) 
non-cases;p = 0.012]. 
During the course of follow-up, TB cases developed new AIDS-defining illness more 
frequently than non-cases; (risk ratio RR = 4.10, 95% confidence in~erval = 2.65-
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6.07). The median time of progression to AIDS was significantly different between 
the two groups. TB cases progressed to AIDS faster than non-cases (median time to 
AIDS = 6 and 14.5 months respectively; p < 0.05). Even after adjusting for 
confounding, TB was an independent predictor of AIDS (RR= 1.61; 95% confidence 
interval= 1.08-2.41; p = 0.02). 
There was significant depression of CD4+ T-lymphocyte count at the time of 
diagnosis of active TB. Median CD4+ T-lymphocyte counts before, at and after 
diagnosis of active TB were significantly different (p = 0.035). 
TB cases had a reduced survival relative to non-cases; (23.9 and 47.7 months 
respectively, p < 0.001). Active TB was an independent predictor of mortality even 
after adjusting for confounding; risk ratio (RR) = 2.37 (95% confidence interval = 
1.46, 3.86). However, after controlling for the transient reduction in the CD4+ T-
lymphocyte count induced by active tuberculosis the risk ratio was reduced to 1. 70 
(95% confidence interval = 1.05-2.77). Other factors associated with increased 
mortality were CD4+T-lymphocyte count :$; 200 cells/µ, and history with 
opportunistic infections at inclusion. Only co-trimoxazole prophylaxis was associated 
with reduced mortality. 
The prognosis of TB patients was different from the prognosis of patients with AIDS 
(P < 0.0001). Survival of TB cases was comparable to survival of patients with oral 
hairy leukoplakia or oral candidiasis (WHO stage 3, CDC stage B). 
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Of the 158 HIV-infected patients with TB, 71(44.9%) patients used co-trimoxazole 
prophylaxis and 87 ( 5 5 .1 % ) did not. Co-trimoxazole prophylaxis reduced the 
incidence of AIDS-defining illnesses which could be prevented by co-trimoxazole 
(risk ratio = 0.23; 95 % confidence interval = 0.06-0.84; p = 0.017). Co-trimoxazole 
prophylaxis was protective against mortality even after adjusting for confounding 
(risk ratio= 0.53; 95% confidence interval= 0.30-0.94; p = 0.03). The better outcome 
in patients given co-trimoxazole prophylaxis was achieved despite their lower CD4+ 
lymphocyte count at baseline than patients not given the drug. 
Conclusion : 
Active TB accelerates HIV-1 disease progression as indicated by the increased 
incidence of AIDS-defining illness and the increased mortality following TB diagnosis 
observed in patients of this cohort. All HIV-infected patients should thus be routinely 
screened for TB and effective prophylaxis should be considered to prevent TB. 
According to the findings of this study, HIV-infected patients presenting with WHO 
stages 3 or 4, a CD4 count < 200 cells/µL, presence of one or more AIDS-defining 
illness, residence in lower socioeconomic area or who belong to communities with 
higher TB prevalence must be considered as candidates for developing active TB. 
These categories of HIV-infected patients should be specifically targeted for TB 
prophylaxis. 
Co-trimoxazole prophylaxis reduces the frequency of AIDS-defining illness and 
improves the survival of HIV-infected patients with CD4+ T lymphocyte < 200 or 
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with TB. Its administration to HIV-infected patients with CD4+ T lymphocyte < 200 
or with TB is strongly recommended. 
Despite the accelerated course of HIV infection following its diagnosis, however, TB 
prognosis in this cohort was significantly better than that of the other AIDS-defining 
illnesses. Thus in endemic areas TB should not be included in the case definition of 
AIDS. 
XIX 
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1. INTRODUCTION 
This thesis sets out to examine, by way of a prospective cohort study, the prognostic 
effect of tuberculosis in adult patients with Human Immunodeficiency Virus (HIV-1) 
infection in Cape Town. 
The foundations of this thesis have been laid over the past 14 years, during the course 
of which a total of more than 8,868 visits were made by a cohort of more than 1288 
patients who were seen or treated in the two HIV clinics at the New Somerset (NSH) 
and Groote Schuur (GSH) hospitals, two tertiary hospitals affiliated to the Faculty of 
Health Sciences, University of Cape Town. 
When the first AIDS cases were identified in Cape Town in 1984, a multidisciplinary 
HIV clinic was developed and supervised by the late Dr. Frank Spracklen at the New 
Somerset Hospital; followed by a second clinic at the Groote Schuur Hospital. These 
clinics drew patients from across the sociodemographic spectrum of the Western Cape 
province [ 1]. 
Cape Town is at the intersection of two epidemics: tuberculosis prevalence and 
incidence rates are among the highest in the world, and HIV infection is rapidly 
spreading in the population and reaching exponential growth. A surge of tuberculosis 
1 
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can be anticipated, especially in the Black* population, as HIV becomes more 
prevalent, and more HIV infected persons develop significant immune compromise. 
Data from New Somerset Hospital, one of the study sites, revealed a large increase in 
tuberculosis admissions between 1990 and 1995. This increase was entirely accounted 
for by HIV positive patients, whereas the number of HIV negative patients with 
tuberculosis remained unchanged (2). The overall HIV prevalence rate among patients 
admitted to Somerset Hospital with tuberculosis and prior unknown HIV status was 
39 % in 1994-1996: 37 % in Coloured and 53 % in Black patients (2). 
Worldwide, many investigators have assessed the survival times of patients with 
HIV/AIDS and the factors which influence their prognosis. A clear understanding of 
the prognosis of patients with HIV/AIDS, and the factors that influence survival, 
allows an insight into the pathophysiology of this disease, evaluation of the impact of 
new treatments and the development of interventions which may improve survival of 
current or future patients. 
* Under apartheid, South Africans were classified into four "race" groups: Asian, 
Black, Coloured, and White. These groups signify, to varying degrees, differences in 
socioeconomic status, cultural practices and urbanisation. 
2 
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Factors associated with survival in patients with HIV/ AIDS can be summarized, 
according to the available evidence gained from a large number of studies done so far 
in different settings, as: 
A : Strone evidence for association with decreased survival : 
1. Greater age [3-11]; 
2. Initial AIDS-defining illness [3-14]; 
3. Increased number of subsequent AIDS-defining illnesses[3 ,5, 14]; 
4. Lower CD4+ lymphocyte count at diagnosis [3,6-7,13-15]; 
5. Loss of CD4+ cells after diagnosis [17-18]; 
B: Inadequate evidence for association with decreased survival : 
1. Pregnancy [19]; 
2. Poorer socioeconomic circumstances [15,20-24]; 
3. Irregular follow-up care [25]; 
4. Co-infection with other viruses [26-31]; 
5. Increased number of sexual partners following diagnosis [32-34]; 
6. Depression [35]; 
7. Smoking [36]; 
8. Recreational drug use [33]; 
9. Greater alcohol intake [33]; 
C: Evidence aeainst an association 
1. Gender [3,4,11,36]; 
2. Ethnic origin (within developed countries) [3,4,7,9,12]; 
Persons with HIV infection are at risk of developing numerous AIDS-defining 
illnesses. A large percentage of individuals with HIV infection suffer AIDS-defining 
3 
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illness before death. Of importance in the wide spectrum of these diseases is 
tuberculosis, which has been reported as the most common serious HIV-related 
complication worldwide. 
The prognosis of HIV-infected patients with tuberculosis has been difficult to assess. 
Firstly, tuberculosis occurs commonly in non-immunocompromised persons and 
therefore a diagnosis of tuberculosis does not necessarily indicate immunodeficiency. 
Secondly, active tuberculosis, if not treated, can decrease the number of circulating 
CD4+ T-lymphocytes, thereby interfering with one of the best predictors of survival 
in HIV infection. If active tuberculosis is successfully treated, however, a significant 
increase in the CD4+ T-lymphocyte may be achieved [18]; and this may have a 
positive impact on the prognosis of HIV-infected patients. 
The clinical importance of tuberculosis in the spectrum of AIDS-related disease is 
reflected in the revised case definition of AIDS of the Centers for Disease Control and 
prevention (CDC) (Appendix I). This definition includes pulmonary tuberculosis as 
an AIDS-qualifying diagnosis in HIV-infected patients. This is due to the fact that in 
the USA and the other developed countries TB confers a prognosis similar to the other 
AIDS-defining conditions [37]. 
Given the exponential growth of HIV infection in Cape Town and the persistently 
high notification rate of tuberculosis [Table 1 ], evidence of the association between 
active tuberculosis and HIV-infection may be easier to study in such a setting. The 
Cape Town population includes a wide spectrum of people with different 
characteristics. Furthermore, the Western Cape has one of the best-functioning TB 
4 
INTRODUCTION CHAPTER a 
notification systems in Africa. This makes possible thorough, comparative 
investigation into the role which tuberculosis may have on the progression of HIV 
infection. 
As discussed later, the findings of the studies done so far regarding the prognosis of 
HIV-related tuberculosis are inconsistent and, in some cases, contradictory. There is a 
need for further studies in a high tuberculosis prevalence setting where TB occurs in 
HIV-infected patients at different levels of immune suppression, and where childhood 
infection may mean better TB immunity. Such studies may shed light on the 
mechanisms of interaction between these two intracellular pathogens, and lead to 
novel strategies to improve survival of HIV-infected patients with tuberculosis. 
Table 1.1 
Notification of tuberculosis in the Western Cape, per 1000 of population: 1989-96. 
Population 1989/90 1990/91 1991/92 1992/93 1993/94 1994/95 1995/96 
Group 
White 0.2 0.17 0.20 0.23 0.19 0.17 0.20 
Coloured 4.19 4.33 4.22 4.13 3.82 4.02 3.92 
Asian 0.55 0.47 0.22 0.06 0.22 0.23 0.15 
Black 8.89 9.02 8.32 8.67 7.53 7.93 8.11 
Total 3.94 4.05 3.89 3.91 3.55 3.72 3.74 
( Mi11istry of Health, Cape Tow11 ). 
1-2 AIM: 
. 
The aim of this study was to measure the survival time, incidence of AIDS-defining 
illness and mortality rate, and their associations with various risk factors, among HIV 
patients co-infected with active tuberculosis and HIV in two adult HIV clinics 
affiliated to the University of Cape Town. 
5 
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1-3 OBJECTIVES: 
A. Main objectives 
1. To assess whether HIV-infected clinic patients with active tuberculosis have 
an overall shorter survival than HIV-infected patients without active 
tuberculosis. 
2. To determine whether HIV-infected patients with active tuberculosis develop 
other AIDS-defining illnesses at a greater rate than HIV-infected patients 
without active tuberculosis. 
3. To assess whether site of tuberculosis (pulmonary / extrapulmonary or both) 
influences or predicts the survival of HIV-patients with active tuberculosis. 
B. Primary objectives: 
1. To measure the risk of developing active tuberculous disease in HIV-infected 
clinic patients. 
2. To ascertain predictors of active tuberculous disease m HIV-infected clinic 
patients. 
3. To ascertain whether active tuberculosis, at the time of diagnosis, induces a loss in 
the circulating CD4+ T lymphocytes in HIV-infected clinic patients. 
4. To describe the sociodemographic profile of HIV-infected patients with active 
tuberculosis compared with HIV-infected patients without active tuberculosis. 
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1-4 STRUCTURE OF THESIS: 
This thesis is divided into five parts. Chapterl (above) gives an introduction to the 
setting in which this study was done along with a brief history of the two HIV 
clinics from which the study cohort was drawn. Chapterl also includes an 
introduction to the problem and a summary of the factors so far known to be 
associated with survival in patients with HIV/AIDS. The aim and objectives of the 
thesis are set out. 
Chapter 2 is a review of the literature, particularly of studies of relevance to the 
objectives of this study. 
Chapter 3 describes the methods, measurements and statistical techniques used in 
data analysis. This chapter also specifies the confounding and effect modifier 
variables which might influence the association between active tuberculosis and 
HIV infection. 
Chapter 4 sets out the results. The baseline characteristics of the patients are 
described, with a brief discussion of the differences observed between the two 
comparison groups (i.e. active TB cases and "controls" without TB). Results of 
the survival analysis are presented in tabular and graphical format. 
In chapter 5, the findings and limitations of this study are discussed and compared 
with the findings of other studies done in different countries. Recommendations 
for health care policy and further research are included at the end of this chapter. 
7 
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In chapter 5, the findings and limitations of this study are discussed and compared 
with the findings of other studies done in different countries. Recommendations 
for health care policy and further research are included at the end of this chapter. 
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2. L I T E RA T U R E REVIEW 
In the last decades of this century AIDS has emerged as a major cause of morbidity 
and mortality in many countries. It is estimated that there are about 22 million persons 
in the world living with HIV/AIDS. 14 million of them are thought to be in sub-
Saharan African countries, representing about 63% of the world's total cases. In urban 
centers of central Africa 5 to 20% of the sexually active population is infected with 
HIV [38]. 
On the other hand, tuberculin surveys have shown that it is likely that one third of the 
world's population, i.e. 1700 million people, has been infected with the tubercle 
bacillus. From this infected pool, 8-10 million people develop active tuberculosis 
annually resulting in 2.9 million deaths. As the disease is a chronic one and treatment 
is often delayed or inadequate, there is more than this number of patients with 
infectious disease. As, on average, each such person infects 20 people annually, about 
100 million people are added to the infected pool each year [39]. The number of new 
tuberculosis cases occurring each year was predicted to increase from 7.5 million (143 
cases per 100,000) in 1990 to 8.8 million (152 per I 00,000) in 1995 and 10.2 million 
(163 per 100,000) in the year 2000. 2.5 million persons were estimated to have died of 
tuberculosis in 1990, 3 million in 1995, with 3.5 million deaths from tuberculosis 
9 
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predicted to occur in 2000 (Table 2.2). Tuberculosis is responsible for 1 in every 4 
preventable adult deaths, despite being one of the most cost-effective of adult diseases 
to treat. 
2-1 HIV-RELATED TUBERCULOSIS EPIDEMIOLOGY 
Since the mid- l 980s it has been evident that the HIV/ AIDS pandemic is having a 
devastating effect on the prevalence of tuberculosis. The reason for concern is that 
persons infected with both the tubercle bacillus and HIV have a much higher chance 
of developing active tuberculosis than HIV-negative persons. It is estimated that only 
5 percent of persons who have successfully overcome the primary infection develop 
active post-primary tuberculosis during the remainder of their lives, which may 
extend over several decades. By contrast, about 50 per cent of HIV-positive persons 
infected with the tubercle bacillus develop the disease over a life span considerably 
shortened by the other effects of HIV. Thus some 8 per cent of HIV-positive persons 
infected by the tubercle bacillus develop active tuberculosis annually, a 20-fold higher 
rate than in the HIV-negative groups [40]. 
Dolin et al. have noted that 95 per cent of cases of tuberculosis in the dually infected 
population are the result of the HIV infection while the remaining 5 per cent would 
have occurred if the patients had not been infected with HIV [ 41]. From data on the 
prevalence of both infections, it was calculated that, in mid-1994, about 5 .6 million 
people worldwide were dually infected [ 42], and that HIV caused an additional 
450,000 cases of tuberculosis in 1994, with over 300,000 of these in the sub-Saharan 
Africa. In that year, at least 5 per cent of all cases of tuberculosis worldwide and over 
10 
LITERATURE REVIEW CHAPTERm 
20 per cent of cases in Africa were HIV-related. It has been estimated that by the year 
2000 there will be 1,410,000 cases of HIV-related tuberculosis worldwide (604,000 in 
Africa); accounting for about 14 per cent of all cases of tuberculosis (Table 2.1 and 
Table 2.2). 
In summary, the HIV pandemic will worsen the tuberculosis situation in developing 
countries in three ways: (1) by reactivation of latent tuberculosis infection among 
dually infected persons; (2) by new infection with tubercle bacilli and rapid 
progression to active disease in HIV-infected persons; and (3) by increasing the 
number of cases in the general population whose infection and disease will result 
from transmission from HIV-positive individuals developing tuberculosis by either 
reactivation or recent infection [ 42]. 
11 
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Table 2.2 
Estimated world tuberculosis mortality and HIV-attributed tuberculosis mortality 1990-2000, by 
region 
Deaths in 1990 Deaths in 1995 Deaths in 2000 
Region Total Attributed Total Attributed Total Attributed 
To HIV To HIV To HIV 
South-East 1,087,000 23,000 1,225,000 88,000 1,383,000 200,000 
Asia 
Western 644,000 7,000 716,000 11,000 789,000 24,000 
Pacific• 
Africa 393,000 77,000 581,000 150,000 823,000 239,000 
Eastern 249,000 4,000 290,000 6,000 338,000 15,000 
Mediter-
ranean 
Americasb 114,000 4,000 121,000 9,000 129,000 19,000 
Easternc 29,000 <200 30,000 < 600 32,000 <900 
Europe 
Industriali- 14,000 < 500 14,000 1,000 15,000 2,000 
zed 
countriesd 
All 2,530,000 116,000 2,977,000 266,000 3,509,000 500,000 
regions 
% deaths attributable to ( 4.6 % ) ( 8.9 % ) ( 14.2 % ) 
HIV 
Increase since 1990 17.7 % 38. 7% 
( Bulletin of WHO 1992:72). [a] Excluding Japan, Australia and New Zealand. [b] Excluding USA 
and Canada. [ c] Eastern Europe and independent states of former USSR. [ d] Wes tern Europe, USA, 
Canada, Japan, Australia and New Zealand. 
Although HIV-infected tuberculosis patients respond well to antituberculosis 
chemotherapy, they have a high short-term mortality [ 43,44]. In Zaire, the case 
fatality ratio among HIV-seropositive patients was 31.3% one year after diagnosis 
compared to 4.4 % for HIV-seronegative patients [ 43]. Similar results were reported 
from Central Africa Republic, Zambia and Kenya [ 44]. Furthermore, data from some 
programmes in East Africa suggest that mortality among tuberculosis patients has 
increased significantly since the mid 1980s. A number of reports further suggest that 
tuberculosis is a common life-threatening complication associated with HIV infection 
in Africa. In a retrospective cohort study of 249 HIV-seropositive and 310 HIV-
14 
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seronegative women of childbearing age in Zaire, 11 % of HIV-seropositive women 
died during 2 years of follow-up while none of the HIV-seronegative women with 
proven tuberculosis were dead at the end of the study [45]. 
Exogenous infection also occurs in HIV-infected individuals and leads to a greatly 
accelerated progression from infection to disease. In an outbreak of HIV-related 
tuberculosis due to an unusual multi-drug resistant strain of M.bovis, five HIV-
positive persons briefly exposed to the source case presented with extensive disease 
due to the same bacillus 2 to 10 months later [46] . 
Before the onset of the HIV pandemic the incidence rate of tuberculosis was constant 
or in slight decline in the developing nations, but owing to population growth, the 
number of cases of the disease was increasing. Future trends of TB in the world will 
be determined by the annual tuberculosis infection rate, the prevalence of tuberculosis 
infection in the age group principally at risk and the HIV prevalence rate. Schultzer et 
al. have calculated that, given an optimistic scenario of a one per cent annual 
tuberculosis infection rate, a 45 percent prevalence of tuberculosis infection in the at-
risk age group and a 2 percent prevalence of HIV infection, there will be a 68 per cent 
increase in the number of cases of tuberculosis from the 1980 figure by the year 2000. 
A worse-case scenario with corresponding values of 2, 60 and 20 percent would lead 
to a 12-fold increase in cases of tuberculosis over the same time period, amounting to 
an eventual incidence rate over 4,000/100,000 in the at-risk age range, and about 
2,000/100,000 of the total population. This implies that one in 50 of the population 
would develop tuberculosis each year [47]. 
15 
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In industrialized nations, tuberculosis is an uncommon disease. However several 
developed countries have reported a rising incidence in recent years. Several lines of 
epidemiological evidence support the hypothesis that the HIV epidemic is an 
important underlying cause of the resurgence of TB in the developed countries. In the 
United States the cities with the largest numbers of AIDS cases had the greatest 
increases in reported cases of tuberculosis. In New Yark, the city with the largest 
number of patients with AIDS, the number of reported cases of tuberculosis increased 
by 68% in 1980 to 1989. In addition the incidence of tuberculosis in patients with 
AIDS was 500 times the incidence of tuberculosis in the general population. The risk 
of active tuberculosis among HIV-infected persons with positive tuberculosis skin 
tests was estimated to be 8% per year [48-49]. In France, 19.9 tuberculosis cases per 
100,000 population were reported in 1992, a 6.6% increase compared to the previous 
year [50]. Table 2.3 shows increase in tuberculosis incidence in some European 
countries. 
Table 2.3 
Increase in the incidence of tuberculosis in some industrialized countries. 
Country Increase ( % ) Time period 
Austria 5 1998-90 
Denmark 20 1986-92 
Ireland 9 1988-91 
Italy 27 1988-92 
Netherlands 19 1987-92 
Norway 21 1988-92 
Spain 28 1990-92 
United Kingdom 5 1987-91 
USA 20 1985-92 
f 
( World Health Organization, 1994) 
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2-2 HIV AND TB IN AFRICA 
Tuberculosis associated with HIV is reaching epidemic proportions in many African 
countries [ 43,51,52]. Here HIV infection is often associated with tuberculosis, leading 
to a negative effect on the outcomes of both diseases. Studies from the United States 
and Africa have shown higher mortality rates among patients with tuberculosis and 
HIV infection than among patients with tuberculosis but without HIV infection, 
although in the United States this difference has been attributed by some studies to 
complications of HIV related infections other than tuberculosis [53]. It is not clear if 
this is also the case in the developing countries [54]. Higher mortality rates from 
tuberculosis in the developing countries have been attributed to treatment program 
failures such as drug shortages, non-compliance or higher level of initial resistance, 
unavailability of short-course rifampicin regimen, any or all of which could lead to 
the apparent failure of anti-tuberculosis therapy [55]. It was estimated that in 1992 
alone, HIV infection was responsible for an additional 150,000-250,000 cases of 
tuberculosis in Africa, and that the HIV prevalence m African patients with 
pulmonary tuberculosis was noted to be as high as 70% [ 44]. 
Tuberculosis has become by far the commonest opportunistic illness in HIV infected 
patients in Africa. HIV seroprevalence rates of greater than 40% are common among 
patients with tuberculosis in many African countries. In Kampala, Uganda, 66% of 
newly diagnosed tuberculosis patients were HIV-positive [56]; in Zambia, 60% of 
tuberculosis patients were HIV-infected [51] and in Kenya, 30 % of newly diagnosed 
tuberculosis patients in Nairobi hospital were HIV-seropositive. Overall, these rates 
are much higher than those seen in the general population. For example, in Ivory 
17 
LITERATURE REVIEW CHAPTER ~ 
Coast, 26 % of2043 tuberculosis patients and 7.2 % of2127 blood donors were HIV-
seropositive [57]. 
In South Africa, Wood and Post in their follow-up of a cohort of 150 HIV infected 
patients presenting with pulmonary tuberculosis to a Cape Town HIV clinic between 
1989 and 1994, have demonstrated an overall mortality rate of 41/100 person years 
[58]. Slavik et al. carried out a retrospective cross-sectional study in Pretoria to 
determine the prevalence of HIV positivity in patients with tuberculous 
lymphadenitis. HIV was often associated with extrapulmonary forms of tuberculosis, 
lymph nodes being the commonest site affected in their patients. They observed that 
54.3 % of the patients who had lymph node biopsies were HIV positive. Their study 
showed significant increases in HIV positivity among study cases over 9-years period 
(p < 0.0001). They concluded that the escalation in HIV positive cases in 1993 and 
1994 was due to the increasing association between HIV infection and tuberculosis 
being seen in South Africa, and emphasised the importance of screening patients with 
tuberculosis for HIV infection [59]. 
In four Ugandan hospitals located outside Kampala, the HIV seroprevalence among 
1072 new patients with tuberculosis tested in an unlinked anonymous manner was 
43% compared to 16% among 3324 women attending antenatal clinics at the same 
hospital [56]. Based on these data, it is possible to estimate that between 30% and 
40% of incident tuberculosis cases in Africa are attributable to HIV infection. 
The burden of the additional HIV-related cases of tuberculosis has been felt in several 
African countries and health services are being severely stretched. Reported cases of 
18 
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tuberculosis in four African countries with reliable reporting systems, Tanzania, 
Burundi, Malawi and Zambia, showed increases of 86%, 140%, 180%, and 154% 
respectively between 1984 and 1990 [44]. In Zaire, HIV prevalence in patients with 
confim1ed tuberculosis was 17 % in outpatients and 33% in inpatients [43]. This high 
HIV seroprevalence among inpatients with TB has important implications, as 
inpatients consume more resources. 
The complications of HIV-positive status include a 5-8% annual risk and a 30% or 
greater lifetime risk of developing tuberculosis for those with a positive tuberculin 
skin test [55]. Other studies have demonstrated that HIV-infected patients have an 
incidence rate of active tuberculosis between 3.1 and 7.9 cases per 100 person years 
[60]. 
In one African study, a case fatality rate of 77% in patients infected with both HIV 
and tuberculosis was reported compared to 11 % in patients with tuberculosis without 
HIV [61]. HIV-positive tuberculosis patients in Africa are almost four times as likely 
to die of tuberculosis than HIV-negative patients within 13 months of diagnosis, 
mostly during the first month of treatment [55] . In addition, the long term survival of 
the cured patients may be shortened because of the synergistic immune suppressive 
action of the HIV and M tuberculosis [55]. Thus, even if treated, tuberculosis may 
have a devastating effect on the health and life span of young adults who are essential 
to the economic _stability of their community. 
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2.3 HIV and TB in South Africa 
South Africa is considered to have one of the fastest growing HIV epidemics in the 
world, with close to 15,000 people infected every month [62]. The countrywide HIV 
prevalence for South African adults is based on the sampling of women attending 
ante-natal clinics, which have been considered as suitable sentinel sites for HIV 
prevalence in South Africa (Fig 2.3). These prevalences were estimated at 14.17% in 
1996, and 16.01 % in 1997 [63]. This indicates a significant increase compared to 
1995 (prevalence= 10.44%) and 1994 (prevalence= 7.57 %). HIV prevalence was 
shown to be rising in all age groups [Table 2.5]. Within South Africa, large regional 
variation of HIV positivity has been observed, ranging from 6% in the Western Cape 
to 26 % in KwaZulu-Natal (Fig 3,4). 
Several models have been proposed to predict the extent of the AIDS epidemic in 
South Africa. The Doyle model predicts that between 18 % and 27 % of the South 
African population will be HIV-infected by the year 2010 [64]. Data available from 
country-wide surveys and from sentinel sites have reinforced these predictions. 
Projections for Soweto, based on the Doyle model, have been within the same range 
of prevalence rates as those experienced at Baragwanath hospital [65]. 
20 
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FIG 2.3 
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Table 2-4 
Prevalence of HIV infection in South Africa by age: 1994-1996 
AGE GROUP 1994 % (95% C.I) 1995 % (95% C.I) 1996 % (95% C.I) 
<20 6.5 (5.5-7.5) 9.5 (8.2,10.9) 12.8 (11.3,14.2) 
20-24 8.9 (8.0,9.9) 13.1 (12.0,14.3) 17.5 (16.3,18.8) 
25-29 8.6 (7.3,10.3) 11 (9.8, 12,3) 15.2 (13.8,1.5) 
30-34 6.4 (5.3,7.5) 8 (6.8,9.3) 12.1 (10.7,13 .6) 
35-39 3.7 (2.3,5.1) 7.4 (5.5,9.3) 9.7 (7.0,11.5) 
40-44 5.3 (3.2,7.4) 4.4 (2.0,6.8) 9.9 (5.8,14.1) 
45-49 0.4(0.1, 1.2) 7.5 (0.1,19.4) 5.8 (2 .3,9.4) 
Source: Epidemiological comments, October 1996 
21 
LITERATURE REVIEW CHAPTER~ 
Fig 2.4 
HIV incidence rates In South Africa by province, 1994-1997 
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(Department of Health, annual antenatal survey) 
It is estimated that about two thirds of adult South Africans have been exposed to TB. 
There is thus a large pool of people harbouring dormant TB bacilli. In 1993 the 
national TB incidence rate was 225/100,000 population, rising to 362/100,000 by 
1996 (Table 2.5). More than the quarter of these cases were HIV positive. The impact 
that HIV will have on the increase of TB in South Africa will largely depend on 
whether the national TB control programme can improve current cure rates, which are 
well below the ideal of greater than 80%. In 1996 the cure rate of sputum smear 
-positive pulmonary TB (the form of TB which is most infectious) varied in the 
different provinces from 33.5% to 65%. This is slowly improving with the 
implementation of the directly observed treatment strategy. If the dismal cure rates of 
1996 are not improved it is estimated that TB will increase approximately threefold 
22 
LITERATURE REVIEW CHAPTERE 
by 2005. If the ideal cure rates are achieved, however, then the increase could be 
limited to approximately 50% by 2005. 
Table 2.5 
Annual TB incidence and effect of mv infection in South Africa (1996) 
Province TB incidence per 100,000 Proportion ofIDV+(%) 
Wes tern Cape 559 12 
Eastern Cape 504 20.4 
KwaZulu/Natal 381 45 
Gauteng 375 25 .2 
Northern Cape 340 13.6 
Free State 282 32.1 
Mpumalanga 286 39.5 
North West 271 25 .9 
Northern Province 260 16.7 
Total 362 27 
Source: Epidemiological comments, October 1996 
Tuberculosis incidence and prevalence rates for the Cape Town area are difficult to 
obtain. Population statistics for many of the townships where tuberculosis is highly 
prevalent are rough estimates, since the Black population is highly mobile. In 1995, 
the estimated overall tuberculosis incidence rate was 372/100,000, ranging from less 
than 25/100,000 for Whites and Asians to approximately 400 and 800/100,000 for 
Coloureds and Blacks respectively. In certain high-density residential areas in Cape 
Town, an incidence rate as high as 1339/100,000 has been reported [66]. Of interest 
though is that the Coloured population has the highest rates (713/100,000 compared 
with national average of 225/100,000 population in 1993) despite the fact that their 
socioeconomic conditions have been a bit better than those of Black population [67]. 
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Wood et al. have reported a changing pattern in the patient profile, from a 
predominant homosexual to a heterosexual pattern over an 11-year period in the three 
main population groups attending their HIV clinics, which are the major HIV referral 
clinics in Cape Town. This has resulted in significant changes in patient demography 
and HIV presentation, and an increase in the frequency of both pulmonary and 
extrapulmonary tuberculosis. They reported a strong interaction between tuberculosis 
and HIV, with pulmonary tuberculosis as the commonest opportunistic infection in 
their patients [2]. Drug-resistant tuberculosis was frequently encountered in small 
number of White male homosexuals. In contrast, HIV infection in the Black and 
Coloured patient population was not associated with an increased rate of multi-drug 
resistant tuberculosis [2]. 
2.4 PATHOGENESIS AND CLINICAL COURSE OF HIV-1 
The origin ofHIV-1 has been widely debated but still remains an unresolved question. 
Desrosiers argued that there are two possibilities for the origin of HIV-1: "one 
possibility is that the virus has always been present in human population, in one form 
or another, but may have gone unrecognized due to an extremely low prevalence 
and/or its confinement to isolated population. In this model, features of modem 
society, urbanization of populations in developing countries, and extensive world 
travel would have introduced the virus into developed countries. The virus would then 
be spread by sharing of drug paraphernalia and sexual promiscuity. Alternatively, 
HIV-1 may have entered human population from another species relatively recently. 
Increasing prevalence and high mortality would then be consequences of infection of 
the new host to which the virus was not fully adapted." They argued further that" The 
24 
LITERATURE REVIEW CHAPTER ~ 
most likely possibility is a combination of these two : that the virus has been entering 
the human population from an animal reservoir (through the butchering of monkeys, 
for example) but has been unable until recently to spread from initial limited foci of 
infection" [68]. 
HIV-1 can infect a wide range of cells. These include B cells, natural killer cells, 
precursor CD4+ bone marrow cells, and CD8+ T cells [69]. 
HIV-1 exhibits strong tropism for CD4+ cells, including lymphocytes and 
macrophages, and a capacity to persist and replicate in the face of humoral and 
cellular immune responses, and is . associated with the development of progressive 
immunologic deterioration [70]. Host factors play an important role in determining 
rates of disease progression in HIV-I-infected individuals. HIV-1 is able to subvert 
the host immune system by infecting CD4+ T cells that normally orchestrate immune 
responses and by inducing the secretion of pro-inflammatory cytokines that the virus 
can utilize for its own replication [71] . Certain chemokine receptors serve as 
necessary co-factors for HIV entry into its target. Ligands for these receptors can 
modulate the efficiency of HIV infection and thus influence on the pathogenesis of 
HIV disease [71]. 
The ultimate consequence of infection with HIV is profound immunosuppression that 
is the result of both quantitative and qualitative abnormalities of the helper/inducer 
subset of T lymphocytes [72]. The initial pathogenic event in HIV infection is binding 
of envelope glycoprotein of HIV to the CD4 receptor molecule present on the surface 
of CD4+ T cells and monocyte/macrophages [72]. It has been shown that the CD4 
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which is present on the surface of CD4+ T lymphocytes and cells of the 
monocyte/macrophage lineage are the primary receptor for HIV-1 [72]. In vivo the 
reservoir for HIV infection in the peripheral blood is the CD+ T cell, whereas in other 
tissues the monocyte/macrophages may play a substantial role. As disease progresses 
in HIV-infected individuals, the viral burden in the peripheral blood CD4+ T cells 
increases [72]. 
However CD4+ T lymphocytes and macrophages differ in several important ways. 
HIV-1 infection of CD4+ T cells in vitro leads to extensive cell death, whereas HIV 
infection of monocyte/macrophages produces a more limited cytopathicity in vitro 
[73]. In CD4+ cells, virions are released almost exclusively at the plasma membrane, 
whereas in monocyte/macrophages, HIV-1 particles are often released within intra-
cytoplasmic vacuoles. CD4+ T cells and monocyte/macrophages also differ in their 
ability to sustain replication of particular HIV isolates [73]. In contrast to the situation 
with macrophages, HIV requires that CD4+ T lymphocytes be activated for optimal 
replication [7 4, 7 5]. It has been demonstrated that there is a little or no replication of 
HIV in lymphocytes in resting peripheral blood mononuclear cell cultures 
(PBMC)[74]. Since most lymphocytes in the blood are in a resting state, only a small 
fraction is a suitable target for infection. However, both lymphocytes and 
macrophages are targets of HIV -1 in tissues [7 4]. Certain tissue-specific disease 
manifestations of HIV infection such as encephalitis [76] and interstitial pneumonia 
[77] are associated with extensive infection of the macrophages. 
Productive infection of human T lymphocytes by HIV-1 is dependent upon 
proliferation of the infected cell. Non-proliferating T cells can be infected by HIV-1 
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and harbour the vims in an inactive state until subsequent mitogenic stimulation. 
Mitogenic stimulation of infected quiescent cells induces re-initiation of DNA 
synthesis from partial reverse transcripts. It was shown that HIV-1 DNA synthesis is 
initiated in infected quiescent T cells at levels comparable with those of activated T 
cells [78]. The ability of HIV to replicate in the CD+ T lymphocyte and mononuclear 
phagoctes is strongly influenced by immuno-regulatory cytokines [71]. These 
cytokines play a role in the regulation of HIV expression in the tissues. The mitogenic 
signal provided by interleukin-2 (IL-2) leads to both cell proliferation and vims 
replication in the T-cell [79]. Other HIV-inductive cytokines (viz. TNF-a or P) can 
increase vims expression both in the T-cell or mononuclear phagocytes (MP). It has 
been shown that the mechanism of action of TNF-a involves the activation of the 
cellular transcription factor NF-kB present in the enhancer region of the HIV proviral 
LTR. Furthermore, some cytokines (viz. IL-1, IL-3, and IL-6) have up-regulatory 
effects on HIV production. Thus HIV expression is under the control of a complex 
network of immunoregulatory cytokines [71]. 
The effect of cytokines in vivo in the spreading of HIV remains, however, largely 
unknown. Cytokines may play a role in tissue damage associated with opportunistic 
infections and may be involved in the development of many clinical manifestations 
associated with HIV-1 infection ( e.g. HIV-related encephalopathy and in cachexia), 
and may stimulate the growth of malignant cells in some AIDS-defining conditions 
(e.g. Kaposi's Sarcoma or lymphomas) [80]. Thus the activation of HIV from latent or 
chronically infected cells in vitro by mitogens and cytokines represents a potential 
mechanism whereby HIV infection in individuals progresses from an asymptomatic 
carrier state to clinical AIDS. The release of the vims from activated cells can lead to 
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the spread of the virus to other target cells and result in both a qualitative or 
quantitative defect in immunocompetent cells and subsequent immunosuppression 
[80]. 
The pathogenic events that occur from initial infection with HIV-1 to the development 
of clinical disease can better be understood by the schematic diagram below [Fig 2.5] 
which was proposed by Panataleo et al. [81], and Table-2.6 [82]. 
Fig 2.5 
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Table 2.6 
Pathologic conditions associated with HIV-1 
Primary infection 
Mononucleosis-like syndrome: 
CHAPTERS 
Fever, malaise, pharyngitis, lymphadenopathy, headache, arthralgias, diarrhoea, 
maculopapular rash, meningoencephalitis 
Clinical latency 
Often none, but can include: 
Fatigue, mild weight loss, generalized lymphadenopathy, thrush, oral hairy leukoplakia, 
shingles 
Clinical disease 
200-500 CD4+ T cells/µL: 
Generalized lymphadenopathy, oral lesions (thrush, hairy leukoplakia, aphthous ulcers) 
Reactivation of herpes zoster (shingles), thrombocytopenia, molluscum contagiosum, basal 
cell carcinomas of the skin, headache, condyloma acurninata, reactivation of latent M. 
tuberculosis 
< 200 CD4+ T cells/µL 
Protozoa) infections: 
Pneumocystis carinii, Toxoplasma gondii, lsospora belli, Crytosporidia, 
Microsporidia 
Bacterial infections: 
Mycobacterium avium intracellulare 
Fungal infections: 
Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum 
Viral infections and malignancies: 
Cytomegalovirus (CMV), recurrent bouts of oral or genital herpes simplex virus, 
lymphoma ( mostly EBV, some HHV-8),Kaposi's sarcoma (HHV-8), Anogenital 
carcinoma (HPV) 
Neurological symptoms 
Aseptic meningitis, myelopathies such as vacuolar myelopathy 
Pure sensory ataxia, paresthesia/dysesthesia, 
Peripheral neuropathies such as acute demyelinating polyneuropathy, monoeuritis, 
multiplex, and distal symmetric polyneuropathy 
Myopathy 
AIDS dementia complex 
Tindall C, Cooper DA. AIDS 1991 
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Primary infection of humans with HIV-1 is associated with an acute mononucleosis-
like clinical syndrome which appears approximately 3-6 weeks following infection. 
The severity and persistence of symptoms vary considerably. Significant declines in 
the levels of CD4+ T lymphocytes in the peripheral blood occur in the first 2-8 weeks 
following HIV-1 infection [81]. 
The acute syndrome associated with primary HIV-1 infection is accompanied by a 
burst of viral replication that can be detected in the blood approximately 3-6 weeks 
following infection (Table 2.6) [82]. During this period, infectious virus and viral 
protiens can be readily detected in the cell-free plasma as well as in cerebrospinal 
fluids, and the number of virions in cell-free plasma can reach 106 to 107 per milliliter 
[83]. 
Aprroximately 3-6 weeks after the infection with HIV-1, specific antiviral immune 
responses can be detected [82]. These antiviral immune responses are associated with 
a precipitous decline in plasma viraemia burden in PBMCs, resolution of the clinical 
syndrome, and a temporary stablization of the number of CD4+ T cells [74]. Both 
humoral and cellular immune responses can be detected. Multiple factors probably 
contribute to the decline in viral titer, including the responses of the two arms of the 
immune system, the secretion of virus-suppressing cytokines, and the possible 
exhaustion of suitable CD4+ target cells. Koup et al. have shown that that the initial 
decline in plasma viremia is associated with the appearance of HIV-specific, CD8+ 
cytolytic T cells, whereas the first neutralizing antibody is not detected for several 
additional weeks [84]. The vast majority of infected individuals develop detectable 
antibody responses within 3 months of infection [84]. 
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Following the induction of an immune response to HIV-1 in humans, there is usually 
a relatively long period that is characterised by few clinical manifestations [Fig 2.6]. 
Clinical symptoms are usually mild. Current estimates for the average time from 
infection with HIV-1 to the development of the clinical conditions that define AIDS is 
9 (range 2-20) years [85]. The time interval from infection to development of 
opportunistic disease varies greatly from one patient to another [83]. However, the 
estimated time has gradually increased since AIDS was recognized. This may be due 
both to better detection of infection and to antiretroviral therapies and effective 
prophylaxis for life threatening opportunistic infections. 
Fig 2.6 
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Throughout the latent period, there is usually a steady decline in the numbers of 
CD4+ lymphocytes [Fig 2.6]. The asymptomatic phase may be either much shorter or 
absent. According to the 1993 revised definition of AIDS by the Centers for Disease 
Control and Prevention CDC [appendix I], even if the individual is otherwise 
completely asymptomatic, a diagnosis of AIDS is made if the CD4+ T-cell count falls 
below 200 per microliter. 
2.5 HOST RESPONSE TO TUBERCULOSIS 
The causative agent of tuberculosis was discovered by Robert Koch in 1882. Very 
shortly afterwards, Paul Ehrlich discovered the "acid-fastness" of the tubercle bacillus 
and introduced a staining technique [88]. 
Mycobacterium tuberculosis a complex unicellular organism contains a single circular 
chromosome with many antigenic proteins and sugars. There are two types of 
antigens: cytoplasmic (soluble) and cell-wall lipid-bound (insoluble) antigens. The 
soluble antigens can further be divided into those that remain within the cell 
cytoplasm until released by autolysis or mechanical dismption and those that are 
actively secreted by living whole cells [89]. 
Pathogenicity (patho: a Greek word meaning disease) has been defined as the quality 
of a micro-organism of being capable of causing disease; a quality that varies in 
degree [90]. Thi? property depends on the susceptibility of the host as well as the 
aggressiveness of the invading organism. The pathogenicity of M tuberculosis is 
primarily due to its ability to penetrate and survive within the macrophages [91]. Cell-
mediated immunity is the defense mechanism which the targeted cell uses to prevent 
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M tuberculosis penetration. This cell-mediated immune response to M tuberculosis 
serves two purposes: either to enhance the ability of the macrophage to inhibit or 
destroy M. tuberculosis or to detect macrophages and other cells that are not 
controlling intracellular bacillary replication and to lyse them [92]. This may results 
in releasing M. tuberculosis such that it can be engulfed by immunologically effective 
phagocytes. Dannenberg has shown that the products of cell lysis inhibit M. 
tuberculosis growth and generate an environment that is deleterious to M. tuberculosis 
growth and survival [93]. 
The immunological phenomena against M tuberculosis comprise three steps: 
(1) recognition (2) response and (3) reaction to M tuberculosis. M tuberculosis 
recognition is a property of lymphocytes [92]. The lymphocytes are divided into two 
main sets: the B-cells and the T-cells. The former mature into anti-M. tuberculosis 
secreting plasma cells, while the latter are involved in the initial recognition of M. 
tuberculosis, the regulation of the immune response by secretion of hormone-like 
chemical messengers called cytokines and in cell-mediated cytotoxity [92]. 
The T-cells are divisible into subsets according to their functions and by the presence 
of certain markers; namely, the cluster differentiation (CD) antigens detectable by 
means of monoclonal antibodies. The principal T-cell subsets are those bearing either 
the CD4 or CD8 markers. The former includes the helper and inducer cells while the 
latter includes s~ppressor and cytotoxic cells. The activities of the different subsets of 
T-cells are largely due to the cytokines that they produce [94]. A number of well 
characterised cytokines produced by cells of the immune system are termed 
interleukins. Mosmann and Moore have shown that CD4+ T-helper (TH) cells mature 
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along separate pathways, resulting in cell populations with quite different functions 
[95]. These are recognised by the nature of cytokines that they secret and are termed 
THI and TH2. Helper T-cells are also divisible according to differences in the 
structure of the receptor molecules that bind to M tuberculosis. These receptors 
consist of two protein chains which, in most cells, are of types termed alpha and beta 
but a minority of these cells have gamma and delta chains. The latter, termed gamma-
delta (y-8) cells are usually CD4-/CD8- but a minority are CD8+ [95]. 
Each lymphocyte bears a receptor that binds to just one of the thousands of possible 
M. tuberculosis determinants or epitopes. There are many sub-populations of 
lymphocytes, each specific for just one epitope. Small numbers of M. tuberculosis-
specific lymphocytes proliferate to form clones of cells of sufficient numbers to 
mediate an effective immune response [96]. Before M tuberculosis is able to induce 
such clonal proliferation it must be presented to the lymphocytes in a special way. 
This is the task of the antigen presenting cells (APCs) which include cells of the 
monocyte/macrophage series, dendritic cells of lymph nodes and scattered lymphoid 
tissues and the Langerhans cells of the dermis. Other cells may, under certain 
circumstances, also serve as APCs. The APCs engulf M. tuberculosis which contain a 
multitude of epitopes [97). Some of these epitopes are actively secreted and some are 
somatic, and only released within lysosomes. 
M tuberculosis epitopes are presented on the surface of the APC in close relation to 
host molecules which are products of the major histocompatibility complex (MHC) 
[98]. There are two types of such molecules: Class I, and class II. The Class II 
molecules are principally found on cells with specific M. tuberculosis presenting 
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functions and activate the CD4+ helper/inducer T-cells. Class I molecules are present 
on all cells and activate the CD8+ suppressor/cytotoxic T-cells [99]. Binding of M. 
tuberculosis-specific lymphocytes to the epitope/HLA complex causes a signal to be 
delivered by the APC to the lymphocyte, inducing the latter to secret interleukin-2 
(IL-2) which mediates lymphocyte division and clonal expansion. Epitopes from M 
tuberculosis within phagosomes are presented by MHC Class II molecules while 
those from M tuberculosis that lie freely in the cytoplasm of the cell are presented by 
class I molecules. This difference in presentation enables the immune system to 
decide whether to enhance the microbicidal power of the cell or to destroy it and 
thereby liberate its contents [99]. 
Macrophages belong to the same cell lineage as the blood-borne monocytes. 
Macrophages are phagocytic cells, but, unlike the other major class of phagocytes, the 
polymorphonuclear leukocytes, they are long-lived cells which settle in a given tissue 
or organ and adapt to the local environment. Thus, alveolar macrophages, osteoclasts, 
Kupffer cells of the liver and Schwann cells of the nerves are all specialized 
macrophages. Macrophages do not express their full antimicrobicidal potential unless 
they are activated. Such activation is mediated by gamma interferon (IFN-y) which is 
secreted by the expanded population of CD4+ helper T-cells [ 100]. 
In addition to its microbicidal activity, the macrophage synthesizes and secretes many 
important compqunds that affect the pathogenesis of M tuberculosis . These include 
some of the acute-phase reactant proteins, and protease that liquefies necrotic tissue 
and thereby contributes towards a cytokine termed tumour necrosis factor (TNF-a) 
[101]. TNF-a is an important mediator of tissue-necrotizing immunopathology. The 
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systemic release TNF-a 1s responsible for extreme wasting with advanced 
tuberculosis [102]. 
An important characteristic of chronic tuberculosis is the formation of the granuloma. 
Macrophages in granulomas are termed epithelioid cells. Many cytokines, including 
TNF-a, are involved in granuloma development and regulation [103]. 
In order to survive within a macrophage, the M tuberculosis must be able to resist 
destruction by the wide range of killing mechanisms of the infected cell. These 
mechanisms include enzymes such as lysozyme, lipases and phosphatases. The 
process of phagocytosis begins by engulfing M. tuberculosis by the cell membrane. 
The phagosome then fuses with the lysosomes which contain the bactericidal agents 
[103] . M. tuberculosis can survive within the phagosome either by inhibiting the 
phagosome/lysosome fusion, or by covering itself with a protective layer that absorbs 
or neutralizes the bactericidal agents or, it may escape from the vesicle and lie freely 
in the cytoplasm of the cell [103]. M. tuberculosis is able to escape from the 
phagosome and replicate in the cytoplasm [104]. This happens when the cell becomes 
immunologically effete and unable to control intracellular growth or when 
M tuberculosis enters cells other than the macrophages [104]. 
If the macrophage cannot control M tuberculosis growth, it is killed with release of 
the M tuberculosis which initiates an inflammatory response which, in tum, attracts 
blood-borne phagocytes and other white cells, including natural killer cells and y-8 T-
cells. The latter cells recognize certain M. tuberculosis components and cause the 
formation of a low-turnover ganuloma of the M tuberculosis type. This to some 
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extent limits the progression of the disease process before the development of the 
specific immunity mediated CD4+ T-cells. Early recognition of M. tuberculosis by y-
8 cells is required for subsequent activation of antigen-specific a-P CD4+ T-cells 
[104,105]. 
However, protective cell-mediated reactions are not the only immune phenomena 
associated with M tuberculosis. Others, such as immunosuppression and delayed 
hypersensitivity [106], also occur and make the process more complex. These other 
reactions are of great relevance to the pathogenesis of the disease. 
2.6 EFFECT OF THE HOST RESPONSE TO TUBERCULOSIS ON HIV-1 
PATHOGENECITY AND DISEASE PROGRESSION 
In immunocompetent individuals, following aerosol infection and phagocytosis by 
pulmonary macrophages, Mycobacterium tuberculosis will elicit a cell-mediated 
immune reaction in lung tissue and regional lymph nodes. CD4 T-lymphocytes are 
important regulators of the induced immune response [ 102]. Cell-mediated immunity 
involves an incompletely understood interplay between THI CD4+ T-cells that 
produce interferon-y and interleukin (IL)-2, cytokine-activated macrophages that 
produce TNF-a, IL-1 and IL-6, and cytotoxic CD4 T-cells [103,104]. Cell mediated 
immunity leads to granuloma formation at the site of infection, and macrophage 
activation results in killing of phagocytosed mycobacteria. Delayed hypersensitivity, 
an important mechanism for clearing mycobacteria that escape killing by cell-
mediated immunity, acts by macrophage lysis. 
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Although the cellular immune activation of T cells and macrophages in response to 
tuberculosis is beneficial to the host in terms of the control and killing of 
Mycobacterium tuberculosis, it is deleterious in terms of HIV-1 disease. Among 
immune responses to Mycobacterium tuberculosis, a number of cytokines are 
produced in large amounts in affected organs [71]. Several of these cytokines have in 
vitro up-grading (TNF-a, IL-6) or bifunctional (IL-10, IFN-y) activities on HIV 
replication. This cytokine network, which is involved in the regulation of normal 
immune responses, may play a role in the pathogenesis of human immunodeficiency 
virus (HIV) infection, by altering the replication of HIV in target cells. In vitro data 
suggest that certain cytokines like TNF-a, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-6 (IL-6) could up-regulate HIV 
expression in T-cells and macrophages [69,71,78,79,81]. 
Several studies have suggested that tuberculosis may increase the ability of HIV to 
replicate in the CD4+ T cells by activating T cells and macrophages that may harbour 
latent HIV -1. The extent to which HIV -1 replication is altered following the cellular 
activation induced by tuberculosis has been documented in many studies. 
In a study from Uganda, Wallis et al. found that antigen-induced blastogenesis (a 
phenomenon that increases with stage of HIV infection, decreases in response to 
antiviral therapy, and predicts progression to AIDS) and production of TNF-a were 3-
10 times greater in HIV-1-seropositive patients with pulmonary tuberculosis 
compared to HIV-I-positive controls without tuberculosis. They argued that this 
result was "most likely a consequence of the cell-mediated cytotoxicity directed 
against M. tuberculosis-infected macrophages" [107]. 
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Garrait et al. assessed the role of pleural fluids recovered from seronegative patients 
with TB on HIV replication in acutely infected blast cells. They observed that 
tuberculous pleural fluids stimulated HIV replication in vitro. TNF-a, IL-6, IFN-y, 
and granulocyte-macrophage colony-stimulating factor (GM-CSF) were detected in 
tuberculous pleural fluids. They observed further that anti-TNF-a and anti-IL-6 Abs 
decreased HIV replication by 60% and 90%, respectively, and that unstimulated 
tuberculous pleural lymphocytes were productively infectable by HIV [108]. 
In addition, it has been shown that the onset of Mycobacterium tuberculous disease in 
HIV-patients results in a significant increase in plasma HIV load. One study 
suggested that antigen- speci fie activation of HIV-infected CD4 cells by 
Mycobacterium tuberculosis enhances viral replication and makes CD4 more 
vulnerable to HIV infection. In a study by Galetti et al., in which plasma viral load 
was measured in HIV-infected individuals before, during, and after the development 
of TB; a 5- to 160-fold increase in viral replication was observed during the acute 
phase of MTB disease. Their study demonstrated that Mycobacterium tuberculosis 
induced HIV replication in CD8+ T cell-depleted lymphocytes from HIV-infected 
individuals with a history of purified protein derivative (PPD) positivity but not in 
those who were PPD negative. Furthermore, this induction of HIV replication was 
observed to correlate with the level of cellular activation. In their in vitro acute HIV 
infection model, Mycobacterium tuberculosis increased HIV replication in PBMC 
from healthy do12,ors with a history of PPD positivity, but not in PBMC from PPD-
negative donors. This induction of viral replication also correlated with cellular 
activation. They concluded that "Mycobacterium tuberculosis increased HIV 
replication both in vivo and in in vitro. This Mycobacterium tuberculosis-mediated 
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viral production likely occurs through antigen-specific activation and infection of 
responding T cells" [109] . 
Mycobacterium tuberculosis was also reported to enhance HIV -1 replication by 
transcriptional activation. Zhang et al. found a striking increase from 4- to 208-fold 
in p24 levels in bronchoalveolar lavage fluid from involved sites of Mycobacterium 
tuberculosis infection vs uninvolved sites in three HIV+ patients. They used an in 
vitro cell culture model to determine if tuberculosis could activate replication of HIV-
1. Mononuclear phagocyte cell lines U937 and THP-1 infected with HIV-lJR-CSF, in 
vitro and stimulated with live M. tuberculosis H37Ra, had a threefold increase in p24 
in culture supematants. Using the HIV-1 long terminal repeat with a chloramphenicol 
acetyltransferase (CAT) reporter construct, they have shown that M. tuberculosis 
increased transcription 20-fold in THP-1 cells, and that cell wall components 
stimulated CAT expression to a lesser extent. Furthermore, they observed that 
antibodies to TNF-a and IL-1 inhibited the increase in CAT activity of the HIV-1 
long terminal repeat by M. tuberculosis from 21-fold to 8-fold. They argued that 
"stimulation of HIV-1 replication by M tuberculosis may exacerbate dysfunction of 
the host immune response in dually infected individuals" [110]. 
Similar findings were observed in SIV/mac-infected monkeys. Zhou et al. [111] have 
explored T cell responses to AIDS viruses using a SIV/mac animal model. In their 
study, T cell act!vation correlated with a marked increase in viral loads in SIV /mac-
infected monkeys. In addition they observed a prolong T cell activation which 
coincided with an enhanced decline of CD4+ PBL counts and an accelerated 
progression to clinical AIDS in the co-infected monkeys. Within 2 to 7 months after 
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BCG coinfection, all chronically SIV /mac-infected monkey died from SIV induced 
AIDS including tuberculosis-like disease. They argued that "Mycobacterium-driven T 
cell activation may be the mechanism underlying the enhanced pathogenicity of AIDS 
virus infection in the coinfected individuals" and that the results of their model 
"strongly support the hypothesis that active coinfection with HIV and Mycobacterium 
can impact remarkably on the AIDS virus-induced disease" [111]. 
In brief, Mycobacterium tuberculosis permits an enhanced HIV replication at the site 
of mycobacterial infection with a subsequent increase of viral load in HIV-infected 
subjects. The cytokines produced during the immune response to Mycobacteria might 
result in both activation of latently infected cells and induction of virus expression, as 
well as in an increased replication from infection of newly activated cells. In addition, 
Mycobacterium tuberculosis partially suppresses factors responsible for controlling 
HIV replication such as IL-10 [95]. These factors combined could participate in an 
increased viral burden subsequent to the development of tuberculosis and might 
partially explain HIV-1 disease progression following the onset of tuberculosis. These 
findings may explain not only why HIV progresses more rapidly in regions where 
much of the population is chronically infected with Mycobacterium tuberculosis, but 
also why HIV seems to be more easily transmitted within these populations. 
2.7 THE CLINICAL IMPORTANCE OF TUBERCULOSIS IN HIV 
INFECTION 
Given the aforementioned facts, tuberculosis is thus of a particular importance in 
HIV-1 infection. In addition, tuberculosis is frequently found in HIV-infected patients 
and usually occurs in HIV-infected patients without pre-existing AIDS; occurring in 
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50%-67% of HIV-infected patients [ 111]. This is presumably because Mycobacterium 
tuberculosis is more virulent than other HIV-associated pathogens, such as 
Pneumocystis carinii pneumonia and M. avium complex [112]. Tuberculosis 1s 
therefore more likely to cause disease at an early stage of immunodeficiency and to 
provoke poor prognosis [113-115]. 
An important clinical implication of the above is that delayed diagnosis of 
tuberculosis in patients with HIV infection could lead to a significant increase in 
mortality. Of 52 such patients with tuberculosis evaluated at one medical center, 25 
( 48%) either died with untreated tuberculosis or began to receive anti tuberculosis 
therapy more than three weeks after presentation. Forty-five percent of those whose 
diagnosis was delayed died of tuberculosis, as compared with 19 % of those in whom 
the diagnosis was made rapidly, suggesting that delayed diagnosis results in increased 
mortality. Delayed diagnosis was not due to atypical manifestations of tuberculosis 
but due to errors in management in 84% of the patients [116]. 
The diagnosis of tuberculosis may thus permit early identification of HIV infection, 
the institution of antiretroviral therapy and counselling to reduce both the 
transmission and the pathogenecity of the virus. 
2.8 CLINICAL DIAGNOSTIC FEATURES OF HIV- RELATED TB 
Similar to tuber~ulosis in HIV negative patients, the lung is the commonest site of 
tuberculosis in HIV infection. Pulmonary tuberculosis may occur at all stages of HIV 
infection, occurring in 42-80 % of cases in Africa, and 77 % of cases in Brazil 
[57,117,118]. The clinical and radiographic presentation of pulmonary tuberculosis, 
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and the diagnostic yield of smears, however, vanes with the degree of immune 
compromise. The most common features accompanying the presentation of HIV-
associated tuberculosis in Africa are oral candidiasis, generalized lymphadenopathy 
and recent history of herpes zoster [43,51] . In the USA, sputum smears have been 
found to be positive in 31-82% of HIV-seropositive patients with pulmonary 
tuberculosis, with the higher fractions in less immunocompromised individuals (those 
with typical reactivation tuberculosis) and the lower fractions in advanced HIV 
disease [119]. In developing countries, rapid diagnosis of pulmonary tuberculosis is 
based on simple diagnostic techniques: sputum smear microscopy and chest 
radiography, when available. In a series of 62 HIV-positive patients from Zambia 
sputum smears were positive in 63% of culture proven pulmonary tuberculosis cases, 
but showed a low number of bacilli ( defined as 1 to 10) in 35%, as compared to 82% 
and 25%, respectively, in 61 HIV-seronegative patients [51]. 
The tuberculosis detection rate based on sputum smear examination may thus be 
comparable to that described for HIV-seronegative patients, at least during the early 
stage of HIV disease. On the other hand, when the immune system is severely 
compromised, the sensitivity of sputum smear examination may be reduced [120] . 
However, it has been observed that even in absence of cavitation and without 
liquefaction necrosis, the profound impairment of the immunity seen in HIV infection 
may permit tubercle bacilli to multiply in such large numbers as to become visible on 
smear examination [ 119,121]. 
In a radiological investigation of 963 HIV-infected adults at three central African 
hospitals, Tshibwa-Tuma et al. showed that HIV-infected group of patients with 
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tuberculosis had a significantly higher proportion of lymphodenopathy than HIV-
negative TB patients (26% vs 13%; p = 0.001), pleural effusions (16% vs 6.8%; p = 
0.001), miliary shadowing (9.8% vs 5%; p = 0.001), an interstitial pattern (12% vs 
7%); p = 0.01) and consolidation (10% vs 3%; p = 0.001). There was significantly 
less cavitation (33% vs 78%; p = 0.001) and atelectasis (12% vs 24%; p = 0.001) seen 
in the HIV-positive group compared to the HIV-negative group of TB patients. These 
patterns of radiographic changes were consistently seen across all three hospital sites 
(122]. In Uganda, chest X-ray findings not typical of tuberculosis were observed in 
41 % of HIV-seropositive TB patients as compared to only 16% of HIV-negative TB 
patients (56]. 
Cavitation is less common in HIV-infected patients with tuberculosis and may range 
between 16% and 48%, whereas usually more than half of the immunocompetent 
patients develop pulmonary cavities [ 43,52]. The lack of cavitating lesions in HIV-
infected patients probably depends on the host's altered immune response; an 
abnormal interaction between host and bacillus results in an outcome different from 
the expected (52]. Upper lobe involvement is seen less frequently in HIV-seropositive 
patients, whereas hilar or mediastinal lymphadenopathy is common (43,52]. In a study 
of tuberculosis in Haiti involving 10 patients with AIDS, 57 HIV-seropositive patients 
without AIDS, and 158 seronegative patients, a post-primary pattern was seen in 20%, 
51 % and 80% of patients respectively, whereas an atypical primary-like pattern was 
seen in 80%, 30 % and 11 % respectively, which supports the observation that the 
more advanced the stage of disease, the more common the atypical presentation. In 
this study cavities were significantly less common in HIV-seropositive patients, while 
hilar or mediastinal adenopathy without parenchymal infiltrates was more common 
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[121]. In Brazil, an atypical chest X-ray was reported from 81 % of AIDS patients as 
compared to 6% of non-HIV infected persons. Similarly, observations from the USA 
suggest that the chest radiographic manifestations of HIV-related pulmonary 
tuberculosis reflect the stage of HIV infection, with a typical reactivation pattern early 
in the course, and an atypical one in the more advanced stages [118]. 
Table 2.7 
Estimated frequency of chest radiograph findings in patients with tuberculosis with and without 
HIV infection in developing countries 
Chest radiograph Finding HIV(+) Patients(%) 
Typical pattern• 46-59 
Atypical patternb 40-81 
Upper lobe infiltrates 50-69 
Cavitations 16-48 
( Bulletin of WHO 1992:72) 
a Post-primary pattern : upper lobe infiltrates, cavitations. 
b Primary-like pattern : intrathoracic adenopathy, with or without parenchymal 
disease , localized non-cavitary disease in middle or lower lobes , isolated 
pleural effusion or no abnormalities. 
HIV(-) Patients(%) 
80-85 
6-16 
72-90 
35-87 
Extrapulmonary tuberculosis is a common finding among HIV-infected patients in 
developing countries. Available information shows that HIV-seroprevalence is higher 
in patients with extrapulmonary disease than in those with pulmonary disease alone 
[ 43,51]. In Africa during the pre-AIDS era only a small fraction of cases occurred 
with extrapulmonary or combined pulmonary and extrapulmonary features [123-124]. 
A change in the distribution has occurred in recent years. In a series of HIV-related 
tuberculosis cases from the Central African Republic 31 % had at least one 
extrapulmonary site of disease [124]. In two other series from Malawi and Kenya, 
57% and 53%, respectively, of HIV seropositive patients had extrapulmonary 
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tuberculosis, compared to 20% and 19% of HIV seronegative patients [117,124]. In 
the USA, one study has shown that only 38% of tuberculosis diagnosed in patients 
with advanced HIV infection occurred in the lung alone, while 30% were entirely 
extrapulmonary and 32% both pulmonary and extrapulmonary [125]. 
Lymphadenopathy, both intra-and extrathoracic, remains the most frequent form of 
extrapulmonary tuberculosis reported from the Central African Republic, Zambia, 
Kenya, and Brazil [43,51,118,126]. 
Disseminated miliary forms of TB are also frequent in HIV positive patients [ 17 ,45]. 
However, mycobacteraemia may be difficult to diagnose in developing countries in 
the absence of routine blood cultures [45,52,120] Virtually all organs have been 
reported as extrapulmonary sites of tuberculosis, including the gastrointestinal tract, 
liver, meninges, genito-urinary tract, peritoneum, and bone marrow [15,45,47]. 
2-9 SURVIVAL OF PATIENTS WITH HIV-RELATED TUBERCULOSIS 
The HIV epidemic has had a major impact on the incidence, mortality and the case 
fatality rate of tuberculosis. It is unclear, however, whether tuberculosis affects the 
course of HIV disease, and there is sparse and insufficient evidence on whether 
tuberculosis shortens survival in patients with HIV infection. One review concluded 
that there was no noticeable decrease in survival attributable to tuberculosis in 
patients with HIV infection [125]. The authors of this overview may have based their 
conclusion on the following. Firstly, in patients who had died with both AIDS and 
tuberculosis the cause of death was almost invariably attributed to AIDS and not to 
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to active tuberculosis. However, the validity of a cause of death diagnosis may be 
limited when there are several possible causes of death. Secondly, studies from Brazil 
[126], Spain [128], and Europe [129] have indicated that patients with tuberculosis as 
the AIDS defining disease survive longer than other AIDS patients. Some authors of 
these studies argued that since clinical tuberculosis may be manifested earlier than 
other AIDS defining diseases in HIV infection, the apparently longer survival in these 
patients may be due entirely to earlier diagnosis of AIDS [126]. 
However, different findings from those of the reviews cited above have been 
documented in other studies. In HIV-infected patients, some studies have suggested 
that survival is shorter in patients with active tuberculosis than in patients without 
active tuberculosis [130,131]. This higher mortality occurs despite adequate response 
to antituberculosis therapy in most cases. 
2-10 SURVIVAL OF PATIENTS WITH HIV-RELATED TUBERCULOSIS 
IN DEVELOPED COUNTRIES 
So far, the major studies assessing the role of tuberculosis in HIV progression have 
been reported from developed countries. Whalen et al. , in a retrospective cohort study 
at four U.S. medical centres comparing the survival (and incidence rate of 
opportunistic infections) in 106 HIV-infected patients with active tuberculosis 
("cases") with that of 106 HIV-infected patients without tuberculosis ("controls"), 
reported an overall shorter survival among cases than controls. Active tuberculosis 
was associated with an increased risk of death during the follow-up period ( odds ratio 
= 2.17) even after controlling for confounding [130]. 
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Furthermore, the incidence rate of new opportunistic infections in active tuberculosis 
subjects was 4 infections per 100 person-months compared with 2.8 infections per 
100 person-months in subjects without TB (incidence rate ratio= 1.4, 95% confidence 
interval [CI] = 0.94-2.11 ). They concluded that "although active tuberculosis may be 
an independent marker of advanced immunosuppression in HIV-infected patients, it 
may also act as a cofactor to accelerate the clinical course of HIV infection" [130]. 
In France, in a similar study of HIV infected subjects, Leroy et al. compared survival 
of 104 "cases" with active tuberculosis with 620 "controls" without active 
tuberculosis [ 131]. They reported an increased mortality in cases compared to controls 
(risk ratio = 1.5, 95% confidence interval = 1.2-2.1) even after controlling for 
differences at entry. In this study the risk of AIDS-defining opportunistic infection or 
a decrease to fewer than 50 CD4+ cells/mm3 was slightly but not statistically greater 
in tuberculosis patients than in controls. Tuberculosis disease thus reduced survival 
but did not affect the occurrence of subsequent opportunistic infections or rate of 
CD4+ count decline. 
LIMITATIONS OF THESE STUDIES: 
1. To assess the role of tuberculosis disease on the course of HIV infection, the 
ideal study design would be to compare HIV disease progression in 
tuberculosis patients and patients without tuberculosis in an incident cohort 
followed prospectively from HIV seroconversion. The retrospective nature of 
the above studies raises the question of accuracy and completeness of the data 
and precluded the collection of potentially important variables. For example, 
in the first study the authors reported that chest radiograph interpretations 
were available for analysis on only a subset of the study subjects. 
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2. The case definition used in these studies systematically excluded subjects with 
culture-negative tuberculosis. If this exclusion was associated with mortality, 
and if culture negative tuberculosis cases have lower mortality, then a 
selection bias may have occurred. This may, partially or completely, explain 
the observed results of a poorer survival of tuberculosis patients and may 
preclude the generalizability of the findings of these studies to patients with 
tuberculosis diagnosed differently. 
3. It was observed in these studies, and in other studies of relevance from 
Western countries, that most of the HIV-infected patients were predominantly 
intra-venous drugs users. There has been a suggestion of higher mortality in 
injecting drug users with HIV, arising from drug overdose and violence, 
including homicide and suicide. In addition, compared with other patients 
acquiring HIV infection through other modes of transmission, they have been 
reported to experience a faster rate of CD4 lymphocyte decline, which could 
explain a shorter survival time in this group. Whalen et al. argued that 
assuring compliance with primary tuberculosis prophylaxis or complete and 
regular follow-up is challenging in such patients [130]. If the proportion of 
such patients is not the same among "cases" of active tuberculosis disease as 
among "controls" without active tuberculosis disease, and if " controls" 
preferentially received antiretroviral therapy and tuberculosis prophylaxis, or 
are more compliant with prescribed therapy, the beneficial impact of therapy 
alone may account for differences in survival. 
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4. The above two studies produced conflicting results regarding the occurrence 
of opportunistic infections. The Leroy study [ 131] did not show an accelerated 
progression of HIV related opportunistic infection in relation to tuberculosis 
disease. In contrast, the findings of the Whalen study (130] indicated greater, 
though not significant, occurrence of opportunistic infections in tuberculosis 
patients than in controls. This increased occurrence of opporunistic infections 
among tuberculosis patients could, however, be partially or wholly attributable 
to detection bias where tuberculosis patients may have been followed more 
closely than controls. 
5. It is presumed that more than 90% of tuberculosis cases that occur each year 
in the western countries are the result of remote rather than recent infection 
with Mycobacterium tuberculosis (123]. Reports of AIDS-associated 
tuberculosis from western countries suggest that remote infection might be 
responsible for the development of disease in HIV-infected patients. This fact 
may complicate determining with certainty the pathogenesis of tuberculosis in 
HIV/AIDS-infected patients from the western countries. In western 
populations, the prevalence of pre-existent tuberculosis infection is low, and 
usually most of the patients develop tuberculosis after AIDS is diagnosed, 
unlike patients from developing countries. 
Whilst the annual incidence of tuberculosis fell to around 10/100,000 in some 
developed countries, it remained at over 200/100,000 in sub-Saharan Africa 
before the advent of HIV (133]. The annual risk of infection with 
Mycobacterium tuberculosis in sub-Saharan Africa remains extremely high; 
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at over 1 % per year in some large surveys and probably even higher in poor 
areas, indicating that tuberculosis has never been adequately controlled in 
these countries. This implies there may be a differential immunity against TB 
between HIV-infected patients from developed countries, where TB is 
uncommon, and those from developing countries where most patients are 
exposed to TB. Furthermore, most deaths in developed countries have been 
reported to occur from complications of HIV disease and not directly from 
complications of tuberculosis, a result which may be limited to patients from 
developed countries. By contrast, active tuberculosis has been reported as the 
commonest cause of death in HIV-infected patients in African countries 
[51,52,53,55,65,61,62]. These differences might have some implications for 
the differences reported in survival after the diagnosis of active tuberculosis in 
patients in the two settings. 
6. These studies included only patients with both tuberculosis and AIDS as 
defined by the CDC surveillance criteria, by which the AIDS definition was 
expanded to include tuberculosis as an AIDS-qualifying condition. By 
disproportionately focusing on cases of tuberculosis occurring in patients with 
AIDS, an advanced stage of HIV infection, these retrospective analyses may 
have underestimated the frequency but overestimated the severity of 
tuberculosis as an HIV-related illness. 
In the most comprehensive prospective study based on a large population cohort of 
European AIDS patients from 52 centres in 17 countries, in which 5249 patients who 
were alive and free of tuberculosis one month after diagnosis of AIDS, enrolled 
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between 1979 and 1989, followed up untill 1992, a seemingly paradoxical result 
occurred [127]. Patients who developed active tuberculosis at some point during their 
follow-up survived longer after their diagnosis of AIDS than patients who remained 
free of tuberculosis. However, the authors argued that the observed results may 
alternatively be explained by other factors that were not measured, such as severe 
immune suppression or malnutrition that may have induced both active tuberculosis 
and death in AIDS patients. 
Similarly, in a most recent study done in the USA, Munsiff et al. found that 
tuberculosis was not an independent predictor of increased non-tuberculosis-related 
mortality in HIV-seropositive. The non-significant association between TB and 
mortality in that prospective study was observed despite the fact that TB was shown 
to be an independent predictor of subsequent AIDS-defining illness (RR, 4.1; 95% 
confidence intervals 1.9-8.7) [134]. 
2-11 SURVIVAL OF PATIENTS WITH HIV-RELATED TUBERCULOSIS 
IN DEVELOPING COUNTRIES 
The association of tuberculosis with the immunodeficiency that was later recognized 
as HIV infection was first recorded among Haitian immigrants to the USA [113], but 
it rapidly became clear that tuberculosis was also a major feature of HIV infection in 
Africa. Most of the research work on the effect of HIV on tuberculosis in developing 
countries comes from studies in Zaire, Cote d'Ivoire, Kenya, Zambia and Tanzania. It 
is difficult to obtain clear evidence from these studies or to pool the results of the 
survival of HIV infected patients with active tuberculosis in one representative 
estimate owing to the following : 
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1. Most of these studies focused on the contribution of HIV infection to the 
apparently increasing incidence of tuberculosis in central Africa, and the 
redirection of public health priorities towards tuberculosis as the major 
treatable and preventable complication of the AIDS epidemic 
[43,45,47,51,52,55,56,57]. Only few of these studies have addressed the 
question of the prognostic effects of tuberculosis in HIV progression. 
Furthermore, most of these few studies have compared the survival of HIV 
positive and negative patients with tuberculosis, rather than comparing 
survival of HIV positive patients with and without active tuberculosis. In other 
words, the major concern of these studies was the effect of HIV infection on 
the incidence and natural history of tuberculosis, rather than vice versa. 
2. In the studies mentioned above, only patients with smear positive tuberculosis 
were included. The diagnosis of tuberculosis in these studies depended heavily 
on microscopy of the sputum smear. However, studies from USA and Europe 
have cast some doubt on its sensitivity. As cited in the last section, the rate of 
concentrated sputum smear positivity in HIV positive patients with pulmonary 
tuberculosis confirmed by culture is very low compared with HIV negative 
patients. Indeed For every case of sputum-smear-positive tuberculosis, there 
are many cases of sputum-smear-negative and extrapulmonary tuberculosis. 
Direct measurements of the concentration of viable tubercle bacilli in sputum 
confirm that HIV positive patients excrete significantly fewer organisms/ml 
sputum than HIV negative patients with culture confirmed pulmonary 
tuberculosis [53,62]. It has been reported that nearly half of HIV positive 
patients with tuberculosis will have no clinical features specifically suggestive 
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of tuberculosis [53,61,62]. The systematic exclusion of smear negative 
tuberculosis patients from these studies may have introduced a bias towards 
not including those with more advanced immunodeficiency who are likely to 
be smear negative. This bias may be responsible for the observed results in 
studies from developing countries. 
3. Rifampicin in HIV-infected patients with TB has been shown to improve early 
mortality [55]. In addition to its anti-mycobacterial action, some authors 
argued further that rifampicin has a broad-spectrum antibacterial activity as 
well. In African countries this intervention, which is relatively expensive, is 
not as widely used as compared to developed countries. This, to some extent, 
may explain the poor prognosis of HIV-infected patients with TB in Africa. 
From the above discussion, it is clear that the evidence for the role of tuberculosis in 
HIV progression gained so far from studies conducted in developed and developing 
countries is inconsistent and somewhat inadequate. As discussed above, factors such 
as the wide spectrum from which the patients of these different studies were drawn, 
application of non-comparable and different techniques and methods in patient 
recruitment, follow-up and diagnosis, and other differing factors such as HIV subtype, 
exposure to endemic diseases, nutritional status, and access to medical treatment, 
might be responsible for the inconsistent and contradictory results. It is apparent that 
further HIV positive cohort studies are needed, to delineate the sequence of 
immunologic events before and immediately after tuberculosis and to explore the 
mechanism of interaction between HIV and tuberculosis. 
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2-12 VALIDITY OF HIV/AIDS STAGING SYSTEMS IN THE AFRICAN 
SETTING 
The CDC revised the classification system for HIV infection [3 7] to emphasize the 
clinical importance of the CD4+ T-lymphocyte count in the categorization of HIV-
related clinical conditions. This classification system, which was introduced in 1993, 
replaced the system proposed by CDC in 1986. Consistent with the 1993 revised 
classification system, CDC has also expanded the AIDS surveillance case definition 
to include pulmonary tuberculosis as an AIDS-qualifying clinical condition. This 
definition also adopted staging systems for HIV disease that distinguish three stages 
of CD4 depletion: 500/ml or above, 200-499/ml, and below 200/ml. This proposal 
permits staging using clinical data, where the patient is staged in one of three 
mutually exclusive stages. In this staging system, tuberculosis is considered as an 
AIDS-qualifying illness. In the revised staging system, CDC has mentioned that the 
inclusion of pulmonary tuberculosis as an AIDS-qualifying condition was " based on 
the strong epidemiologic link between HIV infection and the development of 
tuberculosis", and that "persons co-infected with HIV and tuberculosis have a 
substantially increased risk of developing active tuberculosis compared with persons 
without HIV infection". Another reason cited by CDC was that the addition of 
pulmonary tuberculosis was expected to have a substantial impact on the number of 
AIDS cases included in AIDS surveillance. 
In Africa, by contrast, tuberculosis develops among HIV-infected persons across a 
broad range of CD4 counts, and is not necessarily linked to a specific stage of HIV 
disease and may not predict immunosuppression level in HIV-infected patients. In a 
study conducted in Kinshasa, Mukadi et al. observed that tuberculosis cases were 
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distributed nearly equally across the different stages of HIV disease [135]. Although 
patients infected with HIV and Mycobacterium tuberculosis were at increased risk of 
developing active tuberculosis, and this risk increases with increasing CD4 depletion 
or immunosuppression, the diagnosis of tuberculosis alone was not helpful in the 
staging of HIV disease. 
Thus, it may be reasonable to regard tuberculosis as an AIDS-defining condition in 
developed countries, as proposed by the CDC, but not in Africa where tuberculosis is 
endemic. Tuberculosis in Africa, or any other setting where tuberculosis is prevalent, 
may not be associated with reduced survival as the case in the developed countries. 
An ideal staging system for HIV should be universally applicable, reflect the 
pathophysiology of the disease, and simple to apply. A staging system for HIV should 
ideally have several important characteristics. Its mutually exclusive categories should 
reflect the entire range of clinical outcomes, from asymptomatic infection to serious 
disease, be clinically relevant and reflect increasing severity of illness, should include 
inexpensive and available laboratory tests, and should be associated with prognosis. 
The WHO stated that such a system could aid the study of the natural history of the 
disease, establish reliable prognoses, improve the clinical care of infected people, and 
provide a basis for the stratification of patients in vaccine and drug trials. Different 
stages could be used to provide standarized criteria to evaluate HIV disease 
progression in efficacy trials of therapeutic drugs or vaccines. 
A number of studies have been undertaken to test the utility of the proposed staging 
systems [139,140,141,142]. The following limitations of the CDC staging system and 
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the studies on which this staging system and its successive revisions was based (in 
addition to the ones cited above) can be argued: 
1. The CDC expanded definition reqmres laboratory confirmation of HIV 
infection in persons by applying CD4+ count techniques, which are 
impractical due to their unavailability in poor countries. 
2. The follow-up period of patients in these studies was relatively short. 
Significant differences in the risk of progression from HIV-seropositivity to 
AIDS, on the basis of clinical criteria alone, may be apparent only with 
prolonged observation. 
3. The number of subjects was relatively small, and this may have limited the 
power of these studies to detect statistically significant differences between the 
first stages and the last one which, according to the CDC staging system, 
included pulmonary tuberculosis as an AIDS defining condition. 
4. The possibility of some misclassification bias cannot be excluded, because 
many of these studies were not designed specifically for the purpose of 
validating this staging system. The criteria for AIDS-staging may not have 
represented common manifestations of the disease in this population or any 
other population, especially those in African or other developing countries. 
5. There remains the possibility of underreporting of the clinical endpoint, AIDS. 
Although these studies used several methods to identify their cohorts members 
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who had progressed to AIDS, disease may have not been reported because of 
reporting delays, emigration from the study region, or incorrect cause of death 
recorded on the death certificate. 
6. Most of these studies were based on cohorts with predominantly either 
homosexual men or intra-venous drug users. Furthermore, such drug users 
present unique considerations in the staging of HIV infection and AIDS. 
Clinical signs such as lymphadenopathy and fever have been reported to be 
less specific for HIV infection among intra-venous drug users than in other 
high risk groups, because of the frequent association of such signs and 
symptoms with drug use itself. Survival of these patients may be confounded 
by the effect of drug use, which, in general, may explain the shorter survival 
of this subgroup [139]. This again leads one to question the generalisability of 
the findings of these studies to African or any other developing countries 
patients, where risk behaviours are different. 
7. The recent changes in the CDC system, which expanded the AIDS 
surveillance case definition and increased the number of AIDS-defining 
illnesses, particularly tuberculosis, may further limit its utility as a universal 
staging system. Initially, this system was designed for public health 
surveillance and did not predict progression from HIV seropositivity to AIDS 
by category. More important, international acceptance of the revised system 
has been limited because of concerns that some of the changes, particularly the 
diagnosis of AIDS on the basis of laboratory criteria alone, may not reflect the 
pathophysiology of the disease. Because the epidemiology of HIV infection in 
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the developed countries is often markedly different from that of developing 
countries, this staging system, which defines tuberculosis as an AIDS-defining 
condition, must be evaluated among populations with different disease profiles 
or behavioural risks, viz. heterosexual, non- risk behaviour patients. 
Very few studies have been done in Africa to evaluate HIV staging systems. Lifson et 
al. carried out a study in Kigali, Rwanda to evaluate the WHO staging system in 412 
HIV-infected women recruited from prenatal and paediatric clinics [143]. On the basis 
of this evaluation, they proposed an HIV staging system for sub-Saharan Africa which 
included pulmonary tuberculosis as an AIDS-defining illness. They argued that 
"although tuberculosis may develop at an earlier stage of immune suppression, it may 
also be associated with a worse survival once it occurs" and that, according to 
previous data from their cohort, "5 (42%) of 12 HIV-infected women with pulmonary 
tuberculosis and no known extrapulmonary disease died within 15 months". They 
further argued that "in addition to death directly caused by tuberculosis, progression 
of HIV disease may be accelerated if tuberculosis adversely affects the immune 
system or enhances HIV expression. If so, this accelerated progression may lead to an 
increased risk for death from other immuno-deficiency-associated illnesses". 
However, this study suffers from the following limitations: 
1. The study was exclusively based on a cohort of women recruited from prenatal 
and paediatric clinics. It has been observed that pregnancy induces immune 
depression in HIV-infected women pregnant women [19]. The reduced 
survival observed in this group might have been influenced by the immune 
depression which might have been experienced by these patients, and which 
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may confound the association between the excess mortality and pulmonary 
tuberculosis. 
2. The shorter survival observed in this cohort was based on a very small sample; 
twelve patients only. 
3. HIV-patients with active tuberculosis respond well to antituberculosis therapy, 
and usually experience an improved survival [55,61]. The authors of this 
study have not provided information regarding use of or compliance with 
antituberculosis therapy. It is difficult to exclude these factors as an alternative 
explanation for short survival observed in this study. 
In general, the HIV-staging system proposed in the Lifson study, which defined 
pulmonary tuberculosis disease as an AIDS-defining condition, might have been 
based on patients with pulmonary tuberculosis who experienced poor survival for 
reasons other that pulmonary tuberculosis itself. Since factors such as advanced 
immune suppression were not controlled for in this study, it is difficult to disentangle 
their effect from the effect of pulmonary tuberculosis on survival. Thus, it is difficult 
to generalize the results of this study to other patients from sub-Saharan African 
countries. 
In conclusion, where to place active tuberculosis disease in the HIV-staging system, 
particularly in African patients, remains a question of interest, since the answer to this 
question may have serious implications for the management and care delivered to 
patient in the African setting. 
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2-13 SITE OF DISEASE IN HIV-ASSOCIATED TUBERCULOSIS AND 
SURVIVAL 
In previous studies of tuberculosis in HIV infected subjects, several predictors of 
poorer survival have been identified. These predictors included multiple drug 
resistance [144-145] and depressed immune status as measured by CD4+ count 
[43,55,146]. 
In addition to the above predictors of survival in HIV-infected patients with active 
tuberculosis, the site of tuberculosis disease has been shown to be an important 
prognostic factor. Shafer et al. have reported poor survival related to extrapulmonary 
tuberculosis [147]. Whalen et al. have shown that the site of extrapulmonary disease 
is an important prognostic factor, especially when the disease involves the meninges, 
blood, or bone marrow [136]. Among all HIV-infected patients with tuberculosis in 
their study, about 10% were diagnosed with tuberculous meningitis, which was 
associated with a poor prognosis. The mortality rate was high (44%) and the relative 
risk for death from tuberculous meningitis was high (relative risk = 3.9) compared 
with patients with pulmonary involvement alone. 
Although some studies have thus reported poor survival related to extrapulmonary 
disease, this has not been evaluated in the context of other predictors of survival. 
There exists a need to ascertain whether (and which) site of tuberculous disease is 
associated with poorer survival in HIV-infected patients, particularly in TB endemic 
areas. 
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3. METHODS 
3.1 STUDY DESIGN 
Prospective patient cohort study. 
3.2 POPULATION AND SAMPLING 
This study took place at the adult HIV clinics of University of Cape Town affiliated 
hospitals, New Somerset (NSH) and Groote Schuur (GSH). These clinics, which were 
established in 1984 (NSH) and 1992 (GSH), serve patients from across the 
sociodemographic spectrum of the Western Cape province. At that time, no other 
facilities in the public sector were available. All adult HIV seropositive patients 
presenting as an outpatient or inpatient from January 1992 to December 1996 were 
included in the study. 
Inclusion criteria for patients were: 
1. Confirmed HIV infection; 
2. At least 18 years of age; and 
3. Seen at one of the study sites on more than one occasion between 1992 and 
1996. 
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To identify cases of pulmonary and extrapulmonary tuberculous disease among all 
patients in the cohort, the records completed by the clinicians during the follow-up 
were used. The tuberculosis case definition used was a positive culture or a 
compatible clinical picture combined with a positive smear or a histologic diagnosis. 
Patients diagnosed with active tuberculosis were treated with 6-month short course 
regimen. Both antiretroviral and co-trimoxazole therapies were self-administered. Co-
trimoxazole was prescribed for both TB cases and non-cases when CD4+ T 
lymphocyte count reached 200 cells/µL. 
Patients were excluded from the study if: 
1. Active tuberculosis had been diagnosed before 1992; 
2. Tuberculosis diagnosis was not confirmed, and 
3. They did not have a CD4+ lymphocyte count done within the 6 months before 
or after tuberculosis diagnosis. 
HIV diagnosis was confirmed by ELISA and/or Western blot on 2 separate blood 
specimens by the Department of Virology, University of Cape Town. 
Clinicians enrolled and followed the patients using a standard computerised format 
for recording epidemiologic, medical and biologic information. Follow-up was 
repeated at least _every 6 months, and a repeated search for patients lost to follow-up 
was carried out to confirm their vital status. Demographic details, HIV risk 
behaviours, clinical diagnosis and follow-up visits were prospectively collected and 
entered into a computer database (Epi Info 6.01). The HIV clinic's records were the 
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primary source of information about sex, sociodemographic or ethnic group, date and 
place of birth, migration status, date of tuberculosis diagnosis, site of tuberculosis, 
results of mycobacteriologic evaluations, type and duration of antituberculosis 
therapy, status of tuberculosis at the most recent follow-up, and date of death. 
At each attendance, patients were examined for HIV related manifestations and staged 
using the proposed WHO clinical HIV staging system (Appendix II). CD4 + T-cell 
counts were measured approximately 6 monthly, by flow cytometry at the South 
African Institute of Medical Research (SAIMR) laboratory, Cape Town or the 
Department of Immunology, University of Cape Town. 
3.3 MEASUREMENTS 
Using the computer database and chart review of patients at each clinic, it was 
possible to glean the sociodemographic information, CD4+ lymphocyte count, date of 
death, treatment for HIV infection, and occurrence of AIDS-defining illnesses, as 
defined by CDC classification for HIV infection [ 1]. CD4 + counts were checked for 
validity by comparing each measured CD4+ count with the preceding and succeeding 
count to ascertain that the CD4 at date of diagnosis value was consistent with the 
preceding and succeeding counts. Tuberculosis was further classified as pulmonary 
and extrapulmonary according to the radiologic, microbiologic and clinical 
examinations. 
The list of patients dually infected with tuberculosis and HIV was cross-checked 
against the Provincial Tuberculosis Registry and were found in that database. 
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3.4 DEFINITION OF CASES AND NON-CASES (CONTROLS) 
In this patient cohort study, the "exposure" is active tuberculosis . Patients who had 
received a confirmed diagnosis of active tuberculous disease ( exposed = "cases") 
were compared with HIV-infected patients without tuberculous disease (unexposed = 
"controls"). All the patients seen at the two hospitals' HIV clinics between 1992 and 
1996 with confirmed HIV positive status and who remained free of active tuberculosis 
until the end of the study were thus included in the study as controls. 
The person-month total for each comparison group was defined as the time each 
patient contributed to the total person-months of his/her group from date of inclusion 
into the study to date of death or censoring, summed across the total number of 
patients in the group. 
Comparisons between "cases" and "controls" included baseline characteristics 
(sociodemographic features and risk behaviour, history of AIDS-defining illnesses, 
treatment of HIV infection, and CD4+ lymphocyte count). The incidence density rate 
of AIDS-defining illnesses in the two groups was defined as the number of AIDS-
defining events occurring in patients without an AIDS-defining illness at baseline per 
100 person-years of follow-up. Follow-up of a patient was defined as the period from 
inclusion to December 1996, to the date of last visit before the study endpoint, or to 
death. 
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RE: Analysis 
Many thanks for the detailed message. 
To make th ings easier, I will re-write the analysis stuff that I sent you. You just need to re-produce it 
and you will be safe; if you decide that MH is the way to go, which I think is the appropriate analysis . 
Will get to you later this day. 
Best 
MB> Date: Mon, 27 Aug 2007 10:19:21 +0200> From: gasnat.shaboodien@uct.ac.za> To: 
motasimb@hotmail.com> Subject: RE: Analysis> > Salaam Motasim,> let's finish the business section 
first? .... :-)>Weare looking into maybe using your Mantel-Haenszel analysis for my work. As there 
might be possible confounders in the groups it might be better to use the MH test. What I know about 
stats can be written on a pinhead, so to answer you questions I went online to try and find out what 
exactly Mantel-Haenszel was ..... phew! .. ... I think I got the gist of it. .. l th ink the one website said that if 
confounders exist/or might exist MH would be the appropriate test to do in most study types, right? 
Well , you saw the groups we're dealing with as well as the questions we're asking ... so maybe MH 
would be the better way to go?(OK, wait... l I've made a decision ... please use MH, it seems more 
robust.. ). Bongani has also said that maybe we should look into using the MH data. I have a Q for 
you .... there was no diff. in the OR, p-values, Cl of the MH or Chir-square, so does it matter which one 
we use? > Hope you don't think I'm an idiot but would you mind listing the pros vs cons for using MH 
instead of Chi-sqaure? If you put down the issues in point form I can address each issue, because 
right now I don't know what the issues ar with either of the tests.I've just always used chi-square. > 
One more thing , I've tried to work out the power calculations for the study but have hit a brick 
wall. .. would you mind doing that for the two studies kanalla? Do we have sufficient power to detect an 
association if one existed?The (1) replicative study comprises the HIV-DCM+ (n=99) and the 
HIV-DCM- (n=117) groups and the (2) HIVAC study comprises the HIV+DCM+ (n=30), HIV+DCM-
(n=38) and HIV-DCM- (n=117) groups. >> Phew, I think that's about it....hope I made some sense .... if 
not, I'm sorry for confusing you! ... >> As for Ramadaan? .... everyone is gearing up for Ramadaan here 
in Cape Town ... all you hear are people talking about what they're going to be eating, drinking, 
doing .... it's really a very special time of the year here in CT ... I wouldn't want to be anyhwere else!. .. . am 
I making you miss CT??? .... :-)) well the days have definitely gone shorter for one ... no more fasting 
16-18 hours!. .. . it's now just over 12 hours .. > As for the weather? .. .for the past few years we only really 
started getting summer in November, so I'm expecting a cold Ramadaan with a few warm days (22 
degrees ) thrown in just for the heck of it... .we're all still wearing boots, rain coats,scarves,etc and it 
doesn't look like we'll be packing these away any time soon .... hmmm nice, hot soup to go with all that 
deep fried 'baddies' .... can't wait...>> What is Ramadaan like in the UK?> Keep well.> Salaam!> 
Gasna> > > >» motasim badri <motasimb@hotmail.com> 2007/08/24 05:40 pm»»> Salam 
Gasnat> > In fact I was waiting for both , but as you suggest we can do them bit by bit. Will add my 
descriptive notes on the tables . > I am still have to hear from you about the Qs I sent you earlier 
alongwith these analysis. They will help me write the more> appropriate notes on them . I will answer 
your Qs in details after you answer mine. Please note Monday is a holiday, > but I promise to dedicate 
the whole of Tuesday for you . By the way, how do you expect Ramadan to be in RSA; hot or cold?>> 
> Fi aman ellah> MB>>> Date: Fri, 24 Aug 2007 13:20:12 +0200From: 
gasnat.shaboodien@uct.ac.zaTo: motasimb@hotmail .comSubject: Fwd: RE: AnalysisSalaam 
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Patients were considered "free of tuberculosis" at the time of last follow-up if all 
microbiologic evaluations were negative. Moreover, to make an exhaustive study of 
proven tuberculosis cases in HIV-seropositive patients, all patients diagnosed with 
active TB were reviewed to confirm if the case definition was fulfilled. 
3.5 STATISTICAL ANALYSIS 
Using EPI INFO ver 6.01 and STATISTICA, the following analytic techniques and 
procedures were carried out: 
1. Chi-square test for categorical data and Student's t test for continous variables 
were used for comparing the distributions of sociodemographic factors, risk 
behaviours, AIDS-defining illnesses, and other variables known to influence 
the outcome, i.e. potential confounders and effect modifiers. Differences 
observed were reported with 95 percent confidence interval. 
2. Active tuberculosis cumulative incidence was calculated as the number of new 
cases of active tuberculosis developed during the study period divided by the 
total number of HIV patients, excluding those diagnosed with active 
tuberculosis at inclusion. 
3. To ascertain the variables predictive of active tuberculosis in HIV-infected 
patients, logistic regression analysis was performed. In this regression 
analysis, variables were assessed for significance using stepwise, forward and 
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backward stepping procedures. Initially, all predictors were forced into the 
model. Then, in forward selection procedure, predictors were added one by 
one to the model in the order of the magnitude of their contribution (F to enter 
statistic corresponding top< 0.15). Variables were not included if they did not 
exceed the specified F to enter-statistic. Variables stayed in the model once 
they were included. The backward procedure involved elimination of 
individual predictors from the full model starting with the variable with the 
lowest contribution to the model. Elimination stopped when the remaining 
model exceeded a specified model statistic (F to enter statistics corresponding 
top <0.1). In the stepwise procedure, variables were included in the model as 
in forward selection but at each inclusion the contributions of all the variables 
in the model at that stage was assessed and elimination occurred as in the 
backward procedure. 
4. The overall survival times for tuberculosis and non-tuberculosis subjects were 
estimated using the Kaplan-Meier method .The generalized log rank test was 
used to compare the survival curves. 
5. To determine the unadjusted risk of death associated with tuberculosis and to 
adjust for potential confounding variables, the Cox proportional hazards 
regression technique was used. Proportionality of the Cox model was checked 
using the plot of log [-log (survival distribution)] versus log (months) to 
examine whether survival profiles of the groups included in the model were 
parallel lines. The models included a priori variables known or thought likely 
to be associated with outcomes of interest. Age, CD4+ count, history with an 
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AIDS-defining illness at baseline, and use of preventive and antiretroviral 
therapy were included as possible confounders and effect modifiers. Ninety-
five percent confidence intervals around the risk ratio were calculated using 
Rothman's appoximation method [2]. 
6. Similar analysis was done to assess the risk of TB m developing AIDS-
defining illness. The Kaplan-Meier method was used for comparing 
progression to AIDS between TB cases and non-cases who were free of AIDS 
at inclusion. Log rank method was used to compare the survival curves. The 
Cox proportional hazards regression method was used to adjust for 
confounding. 
7. To assess whether active tuberculosis disease by itself might have induced a 
loss of CD4+ counts at the time of active tuberculosis diagnosis, the 3 
consecutive CD4+ counts 3-6 months before, at and after the date of diagnosis 
of active disease where compared using Friedman and Wilcoxon signed rank 
nonparametric tests [3]. The choice of using these tests was based on the 
finding that the CD4+ counts, when tested for normality using Shapiro-Wilks 
test [3], were significantly non-normally distributed. 
8. To avoid using a baseline CD4+ count that might have been influenced by 
active tuberculosis disease, as the findings of the above analysis may suggest, 
and which may affect the estimates of the other variables included in the 
regression model, a further Cox proportional hazards regression analysis was 
done, including the CD4+ counts 3-6 months before or after, rather than at the 
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date of diagnosis of active tuberculosis. Using this method, it was possible to 
estimate parameters for TB and CD4+ lymphocyte count ( and other variables 
included in the model) "adjusted for" for the transient reduction in the CD4+ 
lymphocyte count caused by active tuberculous disease. 
9. To compare the incidence of new AIDS-defining illnesses in TB cases against 
that of and non-cases, the incidence density ratio (IDR) and 95% confidence 
intervals were calculated. The incidence density ratio was calculated as the 
number of AIDS-defining illnesses occurring in each group divided by the 
total person-months of each group [ 4]. This analysis was done to obtain an 
unadjusted incidence density ratio. To adjust for factors known to alter disease 
progression, the analysis was stratified according to known use of 
antiretroviral therapy, age and CD4+ count. Adjusted incidence density ratios 
were calculated using the Mantel-Haenszel formula. Furthermore, the 
modifying influence of antiretroviral therapy on the effect of active 
tuberculosis on the incidence of AIDS-defining illnesses was assessed in 
stratified analysis, using the test for homogeneity of the incidence density ratio 
across strata [ 5]. 
10. The modifying influence of history of AIDS-defining illness and low CD4+ 
lymphocyte count at inclusion on the effect of active tuberculosis on mortality 
was assessed in stratified analyses using the Breslow-Day test for 
homogeneity of the relative risk across strata [6] . Furthermore, the likelihood 
ratio test was used to test for confounding. The Cox proportional hazards 
regression was used to assess the significance of interaction between TB and 
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CD4+ lymphocyte count, and TB and history with AIDS-defining illnesses 
respectively while adjusting for other predictors of survival. The difference 
between the log-likelihood of the model containing the interaction term and 
that of the model without the interaction term was assessed for significance 
using the chi-square test. 
11. To assess the effect of socioeconomic status on survival, a classification 
method was developed to categorize patients into two mutually exclusive 
groups of a lower and higher socioeconomic status. This scheme is discussed 
in appendix III. The Kaplan-Meier method was used for comparing survival of 
lower and higher demographic status groups. The Log rank method was used 
to compare the survival curves, and the Cox proportional hazards regression 
method was used to adjust for confounding. 
12. To assess the validity of the WHO [appendix I] and CDC [appendix II] staging 
systems, survival of cases with tuberculosis was plotted against survival of 
controls without active tuberculosis. Survival of both groups was measured as 
time from inclusion to death / censoring or end of the study. Using the WHO 
and CDC staging systems, controls were staged into one of the 4 stages 
(WHO) and the 3 stages (CDC) at their inclusion into the study. They were 
followed from this initial stage till their death or censoring. If ~ case with 
tuberculosis presented with an AIDS-defining illness at inclusion, this case 
was staged in stage 4 (WHO) and stage C (CDC). The Kaplan-Meier method 
was used to plot the graphs of survival of active tuberculosis group versus 
other groups with different stages (WHO staging in the first graph and CDC 
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staging in the second) of HIV infection at inclusion. The Log-rank test was 
used to test for significance of differences in survival between the TB group 
and the other groups in the two staging systems. When the survival curve of 
the TB group overlapped with the survival curve of another group, the 
prognosis of these two groups was considered similar. Similarity in prognosis 
was thus the criteria used to judge in which stage of the different stages of the 
WHO and the CDC HIV staging systems should TB be included. 
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4. RES ULT S 
Of the 609 HIV patients who enrolled and followed between 1st January 1992 and 31st 
December 1996, 158 (25.9 %) patients with active tuberculosis met the study 
inclusion criteria and were enrolled as cases. The comparison group included the 
remaining 453 (74.1 % ) HIV-infected patients without active tuberculosis ("controls"). 
In the general cohort from which the members of this study were drawn, 38 patients 
were treated for tuberculosis but did not fulfill the case definition and, therefore, were 
excluded. 
4.1 TUBERCULOSIS DIAGNOSIS: 
Of the 158 active tuberculosis cases, 90 (57%) presented with pulmonary tuberculosis 
without evidence of extrapulmonary involvement; 37 (23.4 %) presented with 
pulmonary tuberculosis and documented evidence of extrapulmonary involvement; 31 
(19.6%) presented with extrapulmonary disease only. 
Of the 158 TB cases, active disease was confirmed in 69 (43.7 %), 80 (50.6 %) and 9 
(5.7%) patients by culture, smear and histologic diagnosis respectively (Fig 4.1). 
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Fig4.1 
Methods of tuberculosis diagnosis (n=158) 
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CULTURE SMEAR HISTOLOGY 
Table 4.1 specifies the source of specimen and method of TB diagnosis. It is clear that 
sputum was the main source of specimen [115 (72%) cases] in confirming the 
diagnosis of TB in this cohort. 
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Table 4.1 
Source of specimen used for confirming TB diagnosis (N= 158) 
Source Smear Culture Histology Total O/o 
Sputum 69 46 115 72 
Lymph node 11 6 17 10.7 
Blood 4 4 2.5 
Pleura 10 3 13 8.2 
Bone marrow 0.94 
Stool 2 0.94 
Urine 0.94 
Cerebrospinal fluid ., 3 1.9 .) 
Pericardia! fluid 1 0.94 
Pus 0.94 
Total 69 80 9 158 100 
Patients who were smear ( +) and culture ( +) were recorded as being culture ( +) only. 
4.2 GENERAL CHARACTERISTICS AT BASELINE 
4.2.1 Gender and age 
TB cases and non-cases were similar in gender (Table 4.2.1-a) and age (Table 4.2.1-
b). 
Table 4.2.1 (a) 
Gender of cases and non-cases ( N= 609 ) 
Characteristic 
Male 
*Chi-square test 
Cases 
( n=158) 
(n) 
79 
(%) 
50 
Non-cases 
(n=451) 
(n) 
251 
92 
(%) p-value* % Difference (C.I.) 
58 .09 -8 (-17.0,1.0) 
RESULTS 
Table 4.2.1 (b) 
Age distribution of cases and non-cases ( N = 609 ) 
Cases 
Characteristic ( n=l58) 
Age (years), Mean (standard deviation) 32 (9.1) 
*Chi-square test 
4.2.2 Sexual preferences and risk behaviours 
Non-cases 
(n=451) 
32 (8.8) 
CHAPTER~ 
p-value* 
0.9 
In spite of significantly different proportions of sexual preferences of cases and non-
cases across the different categories of sexual preference, heterosexuality 
predominated in the two groups (Table 4.2.2). None of the comparison group subjects 
were intravenous dmg users, and only one of cases was. The proportions of subjects 
in the two groups who acquired the disease through contaminated blood transfusion 
were small relative to other risk factors. 
Table 4.2.2 
Sexual preferences and risk behaviours of cases and non-cases (N = 609) 
Cases Non-cases 
Characteristic ( n=l58) (n=451) 
(n) (%) (n) (%) p-value* % Difference (C.I.) 
Homosexual 10 6.3 88 19.6 .00 -13 .3 (-18.6,-8.0) 
Heterosexual 125 79 305 67.6 .01 11.4 (3 .8,19.0) 
IVDU 1 0.6 
Blood T/F 2 1.3 7 1.6 .9 -0.3 (-2.4, 1.8) 
Unknown 20 12.7 51 0.11 .00 12.6 (7.3,17 .8) 
*Chi-square test T/F: transfusion IVDU: Intra-venous drug users 
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4.2.3 Distribution by race group 
The majority of the patients in the two groups were Black, followed by Coloured, 
whites and Asian patients. More white patients were reported as non-cases than cases. 
The proportions of Coloured and Asian patients were not significantly different in the 
two groups. Black patients were more likely to belong to active tuberculosis group. 
Table 4.2.3 
Race groups of cases and non-cases ( N = 609 ) 
Cases Non-cases 
Characteristic ( n=158) (n=451) 
(n) ('Yu) (n) ('V.,) p-value* % Difference (C.1.) 
White IO 6.3 95 21 .00 -14 (-20.0,-9.0) 
Coloured 30 19 116 25.8 .08 -6.8 (-14.1,0.5) 
Black 107 67.7 221 48.8 .00 18.9 (10.3,27.5) 
Asian 11 7 19 4.4 .2 2.6 (-1.8,7.0) 
*Chi-square test 
4.2.4 Marital status 
Among the two groups of the study, marital status was not significantly different. 
Most of the cases and the non-cases were unmarried. 
Table 4.2.4 
Marital status of cases and non-cases ( N = 609) 
Cases Non-cases 
Characteristic ( n = 158) (n = 451) 
(n) (%) (n) (%) p-value* % Difference 
Single 107 67.7 333 73.7 .15 -6 (-14.4,2.4) 
Married 33 20.9 93 20.5 .92 0.4 (-6.9,7.8) 
Unknown 18 11.4 25 5.8 .02 5.6 (0.21,10.9) 
*Chi-square test 
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4.2.5 Employment status 
Unemployment, at time of inclusion into the study, differed significantly within and 
between the two study groups. Fewer cases were employed compared with non-cases. 
Of the other known occupation categories. 
Table 4.2.5 
Employment status of cases and non-cases ( N = 609 ) 
Cases Non-cases 
Characteristic ( n=l58) (n=451) 
(n) (%) (n) (%) p-value* % Difference 
Employed 29 18.4 170 37.5 .00 -19.1 (-26.5,-11.6) 
Unemployed 97 61.4 181 40 .00 21.4 (12.6,30.2) 
Student 9 5.7 29 6 .9 -0.3 (-4.5,3 .9) 
Pensioner 0.6 4 0.9 .8 -0.3 (-18.9,18.3) 
Homemaker 2 1.2 11 2 .8 -0.8 (-2.9,1.3) 
Disability 2 1.2 8 1.8 .9 -0.6 (-2 .7, 1.5) 
Unknown 18 11.5 50 11.8 .9 -0.3 (-6.1 ,5.5) 
4.2.6 Occupational status · 
Unskilled patients predominated in both groups. The proportion of unskilled patients 
was significantly higher in thew case group than the non-case group. 
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Table 4.2.6 
Occupational status of cases and non-cases ( N = 609) 
Cases Non-cases 
Category ( n=158 ) (n=451) 
(n) (%) (n) (%) p-value* % Difference 
Professional/Managerial 4 2.5 30 5.5 .00 -3 (-5.3,-0.7) 
White-collar/ Middle-management 3 1.9 35 7.7 .00 -5 .8 (-9 .1,-2.6) 
Skilled/ Artisan 5 3.2 27 5 .3 -1.8 (-5 .2,1.6) 
Semi-Skilled 9 5.7 40 8.8 .2 -3 .1 (-7 .6,1.4) 
Unskilled 137 86.7 319 73 .00 0,20.4) 
4.2.7 Number of dependants 
In both groups, patients were most likely to have no children /dependants. Very few 
supported a spouse only. Cases were significantly more likely than non-cases to have 
one child, and approximately similar proportions of 2 children, or 3 children and 
more. 
Table 4.2.7 
Number of dependants of cases and non-cases ( N = 609 ) 
Cases Non-cases 
Characteristic ( n =158) ( n = 451) 
(n) (%) (n) (%) p-value* % Difference (95%C.I.) 
Spouse Only 1 0.6 5 .4 -0.4 (-1.9,1.1) 
1 child 39 24 .7 78 17 .03 7.7 (0.1,15.3) 
2 children 23 14.6 77 17 .5 -2.4 (-8.9,4.1) 
3 children and more 31 19.6 62 13 .7 .07 5.9 (-1.1,12.9) 
None 64 40.5 229 51.7 .00 -11.2 ( -20, 1 - 2.3) 
*Chi-square test 
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4.2.8 Education level 
The patients in both groups were more likely to be uneducated than to have had 
primary, secondary or tertiary educational level. Non-cases were more likely to have 
a primary education than TB-cases. However, no significant differences were 
observed between the two groups at higher levels of education, i.e. secondary and 
tertiary education. 
Table 4.2.8 
Education level of cases and non-cases ( N= 609 ) 
Characteristic 
Primary 
Secondary 
Tertiary 
None 
Unknown 
*Chi-square test 
(n) 
33 
26 
3 
75 
21 
Cases 
( n = 158) 
(%) (n) 
20.9 40 
16.5 72 
1.9 19 
47.5 190 
13.2 130 
4.2.9 Medical insurance coverage 
Non-cases 
( n = 451) 
(%) p-value* % Difference (95% C.I.) 
8.8 .00 -12.1 (-19.0,-5 .0) 
15.9 .87 0.6 (-6.1,7.3) 
4 .22 -2.1 (-4.9,0.7) 
42 .3 5.5 (-3.5 ,14.5) 
29.3 .00 -16.1 ( -22.9,-9.9) 
The majority of patients did not have medical aid scheme coverage. The proportion of 
non-cases who were members of some medical aid scheme was greater than that of 
cases. 
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Table 4.2.9 
Medical insurance coverage of cases and non-cases ( N = 609 ) 
Cases Non-cases 
Characteristic ( n = 158) (n=451) 
(n) (%) (n) (%) p-value* % Difference (95% CJ) 
Medical insurance 4 2.5 44 9.7 .00 -7.2 (-10.9,-3.5) 
* Chi-square test 
4.3 THE CLINICAL CHARACTERISTICS AT BASELINE 
4.3.1 Use of antiretroviral therapy and co-trimoxazole prophylaxis 
Use of antiretroviral therapy and co-trimoxazole prophylaxis after inclusion into the 
cohort, differed significantly between the two groups. Zidovudine was the major 
antiretroviral used in this cohort and was more likely to be used in non-cases. Only 3 
non-cases used didanosine. Co-trimoxazole prophylaxis, in contrast, was more likely 
to be used in cases with TB. 
Table 4.3.1 
Antiretroviral therapy and co-trimoxazole prophylaxis usage among cases and non-cases 
(N = 6 09),1992-96 
Cases Non-cases 
Characteristic ( n = 158) ( n =451) 
(n) (%) (n) (%) p-value* % Difference ( 95% C.I ) 
Antiretroviral therapy 3 1.9 44 9.7 .00 -7.8 (-11.3,-43) 
Co-trimoxazole 71 44.9 116 25.6 .00 19.3 (10.6,28.0) 
*Chi-square test 
4.3.2 CD4+ T-lymphocyte count at baseline 
At the time of inclusion in the study, cases had significantly lower median CD4+ 
lymphocyte counts compared to non-cases. A significant difference also existed in the 
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various levels of CD4+ count with which the patients presented, with cases having a 
higher proportion in the lowest stratum (~200 cells /µL) and a lower proportion in the 
highest stratum(> 400 cells /µL) . 
Table 4.3.2 
CD4+ Count (Cells/µL) at baseline of cases and non-cases ( N = 609) 
Characteristic Cases Non-cases Difference ( 95% C.I ) 
( n=158) (n=451) p-value 
CD4 Count 
Median 130 295 0.00 -165 (-245,-86) 
Lower quartile 43 158 0.00 -115 (-227.34,-210.66) 
Upper quartile 241 460 0.00 -219 (-329,-130) 
Minimum 1 
Maximum 999 1244 .00 -245 (-329,-130) 
(n) (%) (n) (%) p-value % Difference (95%C.I) 
:s; 50 43 27 35 7.8 0.00 19.2 (13.4, 25 .0) 
:s;200 71 45 149 33 0.00 12 (6.24,17.76) 
201-400 45 29 155 34 0.26 -5 (-10.29,0.3) 
>400 42 26 147 33 0.02 -9 (-14.29, -3 .71) 
4.3.3 AIDS-defining illness at baseline 
At inclusion into study, cases presented with AIDS-defining illnesses more frequently 
than non-cases. 
Table 4.3.3 
History of AIDS-defining illnesses at baseline in cases and non-cases ( N = 609 ), 1992-96 
Disease 
AIDS-defining illnesses 
*Chi-square test 
Cases 
( n=158) 
(n) 
17 
(%) 
10.8 
Non-cases 
(n=451) 
(n) 
24 
99 
(%) 
5.3 
p-value* % Difference ( 95% C.I ) 
.01 5.5 ( 1.3,9.8) 
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4.3.4 INCIDENCE OF TUBERCULOSIS 
From January 1992 to December 1996, active tuberculosis was reported in 158 
patients among the 611 subjects of this study. Of these 158 patients, 113 were 
diagnosed with active of tuberculosis at the time of their inclusion into the study, and 
45 patients were free of active tuberculosis at inclusion but developed active 
tuberculosis during the course of follow-up. Excluding the 113 patients who were 
diagnosed with tuberculosis at inclusion, and dividing the remaining 45 patients who 
developed tuberculosis during the follow-up period by the cohort of 498 who were 
free of active tuberculosis at inclusion, a cumulative incidence of active tuberculosis 
of 45 per 498 or 9 percent ( or 9036/100,000) during the 5 years can be calculated. 
4.3.5 PREDICTORS OF INCIDENT ACTIVE TUBERCULOSIS 
To study the factors which were significantly predictive of the occurrence of active 
tuberculosis in this cohort, and to measure the risk of disease associated with each of 
these factors, univariate and multivariate logistic regression analyses were carried out. 
Table 4.3.5 shows the variables which were significantly associated with developing 
active tuberculosis in this cohort. In univariate analysis, co-trimoxazole prophylaxis 
was negatively associated with active tuberculosis (p = 0.0043), but not after 
adjusting for other variables in the multivariate model. 
Although not statistically significant in the logistic regression model, the odds of 
active tuberculosis increased by 1 % percent for every I-year age increase. It is more 
meaningful, however, to measure the odds of active tuberculosis disease by taking a 
10 year age increase the unit of increment rather than a one year age increase. This 
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resulted in an odd ratio of 4.67, i.e. a more than a 4-fold increase in the odds of active 
tuberculosis for every I Oyear increase in age. Although neither age nor co-
trimoxazole prophylaxis were significant in the multivariate model, they were 
retained owing to their importance in obtaining valid estimates for the other variables 
in the model. 
As shown in the table below, CD4 :::; 200 cells/µL and a history of AIDS-defining 
illnesses at inclusion were highly associated with developing active tuberculosis. 
Although higher education was not significantly associated with active tuberculosis in 
the univariate model, it emerged as a significantly protective variable against 
developing active disease after controlling for the other predictors of active disease in 
the multivariate model. Stage 3 or 4, race (Black or Coloured), and area of residence 
(lower sociodemographic area) variables were predictive of active disease in both 
analyses. 
It is noteworthy that although stage of disease, level of CD4 count, history of AIDS 
variables are closely related measures of immunodepression, their simultaneous 
inclusion in one model is not likely to result in multi-collinearity, as the Cox 
proportional hazards regression technique is a non-parametric analysis . Thus the 
estimates provided for these variables in the different multivariate analyses done in 
this study are valid estimates and are not affected by multi-collinearity. 
101 
RESUTS CHAPTERE_ 
Table 4.3.5 
Predictors of incident tuberculosis (n = 45) in HIV-Infected cohort, 1992-96 (N = 496). 
Univariate models Multivariate model 
Variable OR 95%C.I. p OR 95%CI 
Stage 3 or 4 1.96 (1.46,263) 0.00 2.07 ( 1.37 ,3 .11) 
CD4::;200 cells/µ L 2.23 (1.2,4.14) 0.01 6.79 (1.49,3.89) 
History of AIDS 1.22 (0.28,5.39) .79 5.41 (1.04,8,15) 
Age>32 years 1.17 (0.63,2.19) .61 1.01 (0.5,2.04) 
Co-trirnoxazole prophylaxis 0.40 (0.22,0. 75) 0.00 0.91 (0.42, 1.94) 
Race group (Black or Coloured) 1.56 ( 1.02,2.40) 0.04 2.24 (1.39,3.60) 
Higher education 0.76 (0.56, 1.02) 0.06 0.71 (0.49,0.99) 
Residence (lower socioeconomic area) 2.29 ( 1.19,4.39) 0.01 3.41 ( 1.58, 7.41) 
Logistic regression analysis 
4.4 MORTALITY 
Table 4.4 
Mortality in mv positive cohort, 1992-96 
Died 
Cases 
( n = 158) 
(n) 
50 
(%) 
32 
Non-cases 
( n = 451) 
(n) 
53 
(%) p-value % Difference ( 95% C.I) 
11.7 .00 20.3 (12.2,27.9) 
p 
0.00 
0.01 
0.04 
0.97 
0.79 
0.00 
0.04 
0.00 
Of the 609 patients 103 (17%) died over the five year period: 50 (31.7%) cases and 53 
(11.7%) non-cases. The mortality rate was thus higher in cases than in non-cases 
(2.8/100 vs 0.8/100 person-months; risk ratio (RR) = 2.29 (95% confidence interval 
(CI) 1.61-3.25). 
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4.4.1 AIDS-defining illness at baseline: 
When stratifying by history of AIDS-defining illnesses, among patients without an 
AIDS-defining illness a at inclusion, mortality was higher in cases than in non-cases 
(RR = 3.03, 95 % confidence interval CI 2.04-4.49; p < 0.001). In patients with a 
history of AIDS-defining illnesses at inclusion, mortality was not significantly higher, 
in cases than in non-cases (RR 1.09, 95 % confidence interval CI 0.63-l.87;p = 0.77). 
This heterogeneity of the RR across the strata of history of AIDS-defining illness at 
inclusion suggests that the association of active tuberculosis with mortality may be 
confounded or modified by history of AIDS-defining illness at inclusion. The 
following Breslow-Day test for the homogeneity of the RR across the strata of AIDS-
defining illness at baseline was done to investigate this suggestion. 
Table 4.4.1.1 
Effect of history with an AIDS-defining illness on the association of TB with mortality. 
AIDS-defining illness = Y AIDS-defining illness = N 
y 
TB 
N 
Died 
y N 
10 7 17 y 
TB 
13 11 24 N 
23 18 
RR= 1.09 (0.63, 1.87) 
P = 0.77 
RR (crude)= 2.69 (1.91,3.79) 
RR (Mantel Haenszel) = 2.34 (1.71 ,3.22) 
P = .000 
Breslow-Day test for homogeneity of RR across strata 
103 
Died 
y N 
40 101 
40 387 
80 488 
RR= 3.03 (2.04,4.49) 
P = 0.000 
141 
427 
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Under the null hypothesis that the RR is constant (homogeneous) across the strata, 
Breslow-Day test statistic = 4.98, which is significant at one degree of freedom (p = 
0.025). Therefore, the hypothesis of the homogeneity of the RR across strata (history 
with baseline AIDS-defining illness: yes vs no) is rejected. Thus a baseline history of 
AIDS-defining illness modified the effect of active tuberculosis on mortality in this 
cohort. 
The crude and adjusted (Mantel-Haenszel) estimates of the RR were also slightly 
different, indicating some confounding. This was further investigated using a Cox 
proportional hazards regression model [Table 4.4.1.2]. 
Table 4.4.1.2 
Modelling the effect of history of an AIDS defining illness on the association between TB and 
mortality 
Model 
1- Tuberculosis 
2- Tuberculosis + 
history with AIDS 
3- Tuberculosis + 
history with AIDS + 
Interaction term 
(Tuberculosis * history with AIDS) 
Cox proportional regression hazards model 
* Chi-square test of significance 
Log-likelihood Log-likelihood Difference* P* 
-370.218 
-368.157 2.061 .15 
-361.698 6.459 0.01 
From the above table, the difference in log-likelihood statistics between the first , 
model (the model containing TB alone) and the second model (the model containing 
TB and history of AIDS) (2.06) is not significant on Chi-square test with one degree 
of freedom (p = 0.15). This indicates that despite the difference between the crude and 
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adjusted RR on the previous analysis, history of an AIDS-defining illness at baseline 
is a not a confounder of the effect of TB on mortality. 
After introducing the interaction term, the difference in the log-likelihood statistic 
(6.49) between the second model (the model containing TB and history of an AIDS-
defining illness) and the third model (the model containing TB, history with an AIDS-
defining illness and the interaction term), was significant (p = 0.01). This confirms 
that history of an AIDS-defining illness at baseline is an effect modifier of the effect 
of active tuberculosis on mortality, in agreement with the Breslow-Day test for 
homogeneity of the RR in stratified analysis. 
4.4.2 CD4 + T-lymphocyte count at baseline: 
When stratifying by level of CD4+ count at baseline, among patients with CD4+ 
lymphocyte count > 200 cells /µ1 at inclusion, mortality was significantly higher in 
cases than in non-cases (RR = 2.94, 95% CI 1.94 - 4.54; p = 0.005). However, this 
significant difference was not observed among patients with CD4+ lymphocyte count 
~ 200 cellsµ/1 at baseline. In this stratum, mortality was higher, but not significantly, 
in cases than in non-cases (RR= 1.39, 95 % CI 0.74 - 2.62; p = 0.2). The following 
test were done to test for confounding/effect modification of CD4+ count ~ 200 cells 
/µL of the association between active TB with mortality 
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Table 4.4.2.1 
Effect of CD4+ count~ 200 cells /µLon the association of active TB with mortality. 
CD4+ count ~ 200 cells I µL CD4+ count > 200 cells I µL 
Died Died 
y N y N 
y 14 57 71 y 36 51 87 
TB TB 
N 20 129 149 N 33 269 302 
34 186 69 320 
RR= 1.39 (0.74,2.62) RR= 2.94 (1.94,4.54) 
P = 0.40 P= 0.000 
RR (crude)= 2.29 (1.61,3.25) 
RR (Mantel Haenszel) = 2.29 (1 .62,3 .23) P = .001 
Breslow-Day test for homogeneity of RR across strata: 
Under the null hypothesis that the RR is constant (homogeneous) across the strata, the 
Breslow-Day test statistic = 11.28, which is highly significant at one degree of 
freedom (chi-square value at one degree of freedom= 3.84). Therefore, the hypothesis 
of the homogeneity of RR across the two CD4+lymphocye strata is rejected. The high 
estimate of the test statistic reflects the degree of heterogeneity of the RR across the 
strata of CD4+ lymphocyte count. Thus, CD4+ lymphocyte at baseline modifies the 
effect of active tuberculosis on mortality in this cohort. Furthermore, the crude and 
adjusted (Mantel-Haenszel) estimates of the RR are similar, indicating that CD4+ 
lymphocyte ::s; 200 at baseline is not a confounder. This was further investigated using 
a Cox proportional hazards regression model [Table 4.4.2.2]. 
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Table 4.4.2.2 
The effect of CD4+ count ~ 200 cells htL on the association of active TB with mortality 
Model 
1- Tuberculosis 
2- Tuberculosis + 
CD4+ count ~ 200 cells h1L 
3- Tuberculoss + 
CD4+ count ~ 200 cells /µL + 
Interaction term (Tuberculosis * CD4+ count ~ 200 cells /µL) 
Bivariate Cox proportional hazards regression models 
*P-value for Wald Chi-square 
Log-likelihood Log-likeli-
hood 
Difference 
-370.218 
-368.548 1.67 
-361.245 7.30 
In the above table, the difference in the log-likelihood statistics between the first 
model (the model containing TB alone) and the second model (the model containing 
TB and CD4+ count ::s; 200 cells /µL) (1.67) is not significant (p = 0.196). This 
indicates that CD4+ count ::s; 200 cells /~LL at baseline is a not a confounder of the 
effect of TB on mortality. After introducing the interaction term, the difference in the 
log-likelihoods between the second and the third model (the model containing TB, 
CD4+ count ::s; 200 cells /µL and the interaction term) (7.303) was significant (p = 
0.006). confirms that CD4+ count ::s; 200 cells /µL at baseline is an effect modifier of 
the effect of active tuberculosis on mortality; in agreement with the Breslow-Day test 
for homogeneity of the RR in stratified analysis. 
The combined effects of these two variables and other predictors of mortality on the 
association between active tuberculosis and mortality in multivariate analysis is 
presented later. 
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4.5 FOLLOW-UP AND SURVIVAL 
Follow-up in the two groups was similar (mean= 11.5 and 14.6 months in cases and 
non-cases respectively; p = 0.7). The proportion of patients lost to follow-up in the 
two groups was not significantly different [59 (37%) cases vs 153 (34%) non-cases; p 
= 0.5]. 
The Kaplan-Meier survival distributions indicate that active tuberculosis cases had an 
overall shorter survival than non-TB controls. The overall median survival was 23.9 
months for prevalent cases ( cases with active TB at inclusion), and 25 months for 
incident cases ( cases free of TB at inclusion but who developed active disease later), 
compared with 47.7 months for non-cases (Fig 4.5.1). Survival of non-cases was 
significantly different from that of prevalent cases (p < 0.001), and from incident 
cases (p < 0.001) of active tuberculosis. No significant difference in survival time 
between prevalent and incident cases of active tuberculosis was observed, (p = 0.8). 
Fig 4.5.1 
Survival of cases and non-cases (N = 609) 
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Fig 4.5.2 
Survival of cases and non-cases ( N = 609) 
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The difference in survival between the prevalent and incident cases of active 
tuberculosis was small. When all TB cases combined were compared to non-cases 
survival times were significantly different (p < 0.001) (Fig 4.5.2). 
Table 4.5.1 
Cumulative probability of survival according to study group and length of survival (N = 609) 
Cumulative probability of survival 
1 Year 2 Year 3 Year 
(percent ± S .E.) 
Cases 69 ± .04 49 ± .08 28 ± 0.2 
Non-cases 92 ± .02 82 ± .03 64 ± .08 
S.E : standard error 
The Kaplan-Meier probabilities of survival (Table 4.5.1) shows that the 1-year 
survival proportion for all cases was consistently less than the 1-year survival for non-
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cases (69% versus 92%); the same relationship was present at 2 years (49% versus 
82%, cases vs non-cases) and 3 years (28% and 64%) respectively. 
Stratified analyses were done to investigate survival differences between cases and 
non-cases at various levels of CD4 + lymphocyte counts. A significant difference in 
survival between cases and non-cases (42 cases vs 147 non-cases) existed at CD4+ 
lymphocyte count> 400 cells/µ L (Fig 4.5.3) and CD4+lymphocyte count 201- 400 
cells/µ L ( 45 cases vs 155 non-cases) (Fig 4.5.4). 
Fig 4.5.3 
Survival of cases and non-cases with CD4+ > 400 cells µ/lat inclusion (n =219) 
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Fig 4.5.4 
Survival of cases and non-cases with CD4 count 201-400 cells/µ L at inclusion (n = 200) 
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However, when stratifying survival by patients with CD4 + count ~ 50 cells/µl ( 43 
cases vs 35 non-cases) (Fig 4.5.5), or CD4 + count ~ 200 cells/µl at inclusion (71 
cases vs 149 non-cases) (Fig 4.5.6), or history of an AIDS-defining illness (17 cases 
vs 24 non-cases) (Fig 4.5.7), no significant difference in survival was observed 
between the two groups. 
Fig 4.5.5 
Survival of cases and non-cases with CD4 +count~ 50 cells µ/I at inclusion (n = 78) 
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Fig. 4.5.6 
Survival of cases and non-cases with CD4 +count=,; 200 cells µ/I at inclusion (n = 220) 
C 
0 
t 
8. 
e 
a. 
iii 
> 
·~ 
:, 
Cl) 
1.0 
0.8 
0.6 
0.4 
0 .2 
• .. 
• .. 
··: 
·· ··: 
·· ···: 
.... 
..... 
......... 
... 
..................... ..... ... .. 
Non-cases 
. ....... Cases 
p = 0.39 
0.0 --- ~--~---~--~---~--~--~---~ 
0 6 12 18 24 30 36 42 48 
Time ( Months ) 
Fig 4.5.7 
Survival of cases and non-cases with an AIDS defining illness at inclusion (n = 41) 
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4.6 Progression to AIDS 
Time to progression to AIDS was compared between cases and non-cases. In cases 
and non-cases who were free of AIDS at time of inclusion into study but developed 
AIDS during follow-up (33 cases vs 34 non-cases), a significant difference was 
observed (Fig 4.6). HIV-infected patients with active tuberculosis were diagnosed 
with an AIDS-defining illness; on average after 6 months, compared with an average 
of 14.5 months for HIV-infected patients without active tuberculosis. 
Fig 4.6 
Time to AIDS of cases and non-cases who were AIDS-free at inclusion (n = 76) 
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To adjust for the factors known to influence the effect of TB to the progression to 
AIDS, the following multivariate Cox proportional hazards regression was done. It is 
clear that even after controlling for age, CD4 count, antiretroviral therapy and co-
trimoxazole prophylaxis, TB was an independent risk 
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Table 4.6 
Predictors of AIDS in TB cases and non-cases; multivariate analysis 
Variable Beta S.E RR RR 95%CI p 
Age >32 0.0168 0.1767 1.01 (0.71,1.44) 0.9 
CD4 < 200 cells/µL 0.8613 0.2019 2.36 (1.59,3.50) 0.00 
Tuberculosis 0.4763 0.2056 1.61 ( 1.08,2.41) 0.02 
Co-trimoxazole prophylaxis -.5363 0.2179 0.21 (0.14,0.33) 0.00 
Antiretrovirals -0.0086 0.0109 0.99 (0.97,1.01) 0.4 
Cox proportional hazards regression analysis. S.E: Standard error. CI : confidence interval 
4.7 INCIDENCE OF AIDS-DEFINING ILLNESS 
In the general cohort, 76 (13.38%) of the 568 patients without an AIDS-defining 
illness at baseline developed at least one AIDS-defining illness. These patients 
developed 90 AIDS-defining illnesses over 8422.1 person-months of observation, 
yielding an incidence density of 1.1 infections per 100 person-months. In the 158 TB 
cases, a total of 47 AIDS-defining illnesses occurred in 33 patients over 1803.4 
person-months of observation, yielding an incidence density of 2.6 AIDS-defining 
illnesses per 100 person-months. In contrast, in the 451 non-cases, a total of 43 AIDS-
defining illnesses occurred in 34 patients over 6618.7 person-months, yielding an 
incidence density of 0.7 infections per 100 person-months. 
The crude incidence density ratio of cases to non-cases of active tuberculosis for 
AIDS-defining illnesses was thus 3.7 (95% confidence interval CI 2.85-6.28); risk 
ratio (RR) = 4.10 (95% confidence interval 2.65-6.07). 
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To assess whether there were factors other than active tuberculosis operating in the 
greater frequency of AIDS-defining illnesses observed in active tuberculosis cases 
relative to non-tuberculosis controls, a stratified analysis was done. Table 4.7.1 shows 
that incidence densities of AIDS-defining illnesses were consistently greater in cases 
than non cases across the different stratum of age, use of antiretroviral therapy and 
CD4+ count. 
Table 4.7.1 
Incidence of AIDS-defining illnesses in TB cases and non-cases (1992-96), stratified by age, use of 
antiretroviral therapy and CD4 + count ~200 
Variable Group (n)* Person Incidence** IDR (95%CI) Adjusted 
months density p-value IDR 
Over all Cases 47 451.7 10.4 1.5 
( 1.02,2.32)*** 
Non-cases 43 635 6.8 p = 0.04 
Age~ 32 Cases 21 260.8 8.1 1.6 
(0.74,3 .19) 
Non-cases 11 210 5.2 p = 0.24 
1.71 
(1.12,2.0) 
Age >32 Cases 26 190.9 13.6 1.8 
(1.08,3.03) 
Non-cases 32 425 7.5 P= 0.022 
Antiretroviral used Cases 2 47 .7 4.2 0.4 
(0.1,1.9) 
Non-cases 14 144 9.7 p = 0.25 
1.58 
(1.03,2.0) 
No antiretroviral used Cases 45 404 11.0 1.9 
(1.18,3.0) 
Non-cases 29 491 5.9 p = 0.007 
CD4+ Count Cases 31 249.8 12.4 1.7 
~200 cells/µ L ( 1.03,2. 78) 
Non-cases 31 421.5 7.4 P = 0.037 
1.59 
CD4+ Count Cases 16 201.9 7.9 1.4 (1.06,2.0) 
>200 cells/µ L (0.67,2.98) 
Non-cases 12 213 .5 5.6 P= 0.37 
*n= number of AIDS-defining illnesses; **(n) per 100 person-months; IDR= Incidence density ratio 
*** Adjusted IDR; Mantel-Haenszel test 
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However in the stratum who used antiretroviral therapy, the incidence of AIDS-
defining illnesses was lower (but not significantly) in cases than non-cases. This 
suggested that use of antiretroviral therapy might have modified the effect of 
tuberculosis on the incidence of AIDS-defining illnesses in this cohort. This was 
further investigated in the following analysis. 
Table 4.7.2 
Effect of antiretroviral therapy on the association of TB on the incidence of AIDS-defining 
illnesses. 
Antiretroviral therapy used Antiretroviral therapy not used 
No.* person-months 
Cases 2 47.7 
Non-cases 14 144 
IDR= 0.43 
95% CI= (0.1-1.9) 
P=0.25 
Adjusted incidence density ratio = 1.58 
95% CI= (1.03-2.0) 
p < 0.05 
No.* person-months 
45 404 
29 491 
IDR= 1.9 
95% CI= (1.18-3.0) 
P= 0.007 
Test for homogeneity of incidence density ratio across strata *No.: Number of AIDS defining 
illnesses 
Under the null hypothesis that the incidence density ratio (IDR) is constant 
(homogeneous) across the strata, the test statistic= 0.6629. From the Chi-square table, 
p(x? > 0.6629) = 0.416. Thus the hypothesis of the homogeneity of IDR for the two 
strata is rejected. This test suggests that antiretroviral therapy, in the stratum who 
used it, eliminated the effect of TB in increasing the incidence of AIDS-defining 
illnesses. The effect of TB in increasing the incidence of AIDS-defining illnesses was 
,however, apparent in the stratum who did not use antiretroviral therapy. Thus 
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antiretroviral therapy modified the effect of active tuberculosis on the incidence of 
AIDS-defining illnesses in this cohort. 
4.8 PREDICTORS OF MORTALITY 
To control further for differences at baseline and known predictors of mortality in 
HIV-infection, a Cox proportional hazards regression analysis was carried out. Below 
are the variables which were significantly associated with survival. Although the 
variables age and antiretroviral therapy were not significantly associated with 
mortality in this cohort, they were retained in the model owing to their importance in 
modelling survival of patients with tuberculosis and HIV infection. 
Table 4.8.1 
Predictors of mortality in cases and non-cases, 1992-96: univariate analyses 
Standard Risk RR 
Beta Error Ratio 95% C.I p 
CD4~200 µ/1 .4047 .2490 1.50 (0.92,2.44) .10 
Antiretroviral therapy -.233 .2557 0.79 (0.48,1.31) .36 
Co-trimoxazole prophylaxis .3593 .1994 0.70 (0.51,0.95) .07 
Tuberculosis .7173 .2033 2.05 (1.38,3.07) .00 
Age > 32 years .0368 .2003 1.04 (0.70,1.54) .85 
AIDS-defining illness .5570 .2378 1.75 (1.10,2.78) .01 
Cox proportional hazards regression models 
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Table 4.8.2 
Predictors of mortality in cases and non-cases, 1992-96 : multivariate analysis 
Standard Risk RR 
Beta Error Ratio 95% C.I p 
CD4:s;200 µ/I .7436 .2823 2.10 ( 1.22,3 .66) .00 
Antiretroviral therapy .2582 .3024 1.29 (0. 72,2.34) .39 
Co-trimoxazole prophylaxis -.916 .2452 0.40 (0.25,0.65) .00 
Tuberculosis .8644 .2489 2.37 (1.46,3.86) .00 
Age> 32 years .2587 .2133 1.30 (0.85, 1.97) .22 
AIDS-defining illness .8227 .2605 2.28 (1.36,3.78) .00 
Cox proportional hazards regression model 
Table 4.8.3 
Predictors of mortality in cases and non-cases, 1992-96: univariate and multivariate analysis 
compared 
Univariate Model Multivariate Model 
Variable RR 95% C.I p RR 95% C.I p 
CD4:s;200 ~1/l 1.50 (1.92,2.44) .10 2.10 ( 1.22,3.66) .00 
Antiretroviral therapy 0.79 (0.48, 1.31) .36 1.29 (0.72,2.34) .39 
Co-trimoxazole prophylaxis 0.70 (0.51,0.95) .OS 0.40 (0.25,0.65) .00 
Tuberculosis 2.05 (1.38,3 .07) .00 2.37 (1.46,3.86) .00 
Age> 32 years 1.04 (0.70,1.54) .85 1.30 (0.85, 1.97) .22 
AIDS-defining illnesses 1.75 (1.10,2.78) .01 2.28 ( 1.36,3. 78) .00 
Cox proportional hazards regression analyses. 
In the multivariate Cox proportional hazards regression analysis that simultaneously 
controlled for a number of predictors, it is evident that even after controlling for 
differences in baseline characteristics and known predictors of mortality in HIV 
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infection, active tuberculosis conferred an independent risk for death in HIV-infected 
patients. 
In this model, CD4 counts :'.5: 200 cells/µl, active tuberculosis and presence of an AIDS-
defining illness at baseline were significantly associated with poorer survival. Co-
trimoxazole prophylaxis was consistently protective against death. Specifically, the 
risk of death increased approximately two fold for a CD4 count :'.5: 200 cells / µL, a 
diagnosis of active tuberculosis and a previous history of AIDS-defining illness. Co-
trimoxazole prophylaxis decreased risk of death by 60% in those who used it 
compared to those who did not. Use of antiretroviral therapy and greater age were not 
significant predictors of mortality in this cohort. 
4.9 EFFECT OF TUBERCULOSIS ON CD4+ T-L YMPHOCYTE COUNT 
This section sets out to assess to what extent active tuberculosis by itself induces a 
loss in CD4+ count by determining (1) the effect of using a CD4 + count before or 
after rather at TB diagnosis, and (2) the impact of TB on CD4 count. 
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Fig 4.9.1 
Test of normality for CD4+ T-lymphocyte count before, at and after the date of tuberculosis 
diagnosis (incident cases only, n = 45) 
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Shapiro-Wilk's test of normality 
(1) Before TB diagnosis date (p<.03) (2) At TB diagnosis date (p<.04) (3) After TB diagnosis date (p <.001) 
CD4+ counts of the 45 incident active tuberculosis cases ± 3-6 months before, at and 
after the date of a confirmed diagnosis of active disease were compared (Fig 4.9.2, 
Table 4.9.1). Non-parameteric analysis based on Friedman nonparametric Anova 
analysis (Table 4.9 .1) was done. The choice of this test was based on the finding that 
CD4+ counts were not normally distributed (Fig 4.9.1). 
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Fig 4.9.2 
Median CD4 + lymphocyte count before, at and after TB diagnosis (n = 45) 
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Further comparisons between the 3 CD4+ counts were done using Wilcoxon Match 
Pairs Test {Table 4.9.2). From this table it is evident that the CD4+ counts 3-6 months 
before, at and after tuberculosis diagnosis were significantly different (p = 0.03). 
However, the CD4+ counts 3-6 months before compared to those 3-6 months after 
active tuberculosis diagnosis date were not significantly different (p = 0.35). 
The significantly different values (p = 0.002) of the CD4+ counts before and at active 
tuberculosis diagnosis date reflect the substantial loss in CD4+ count which active 
tuberculosis disease induced in HIV-infected patients of this cohort. Partial recovery 
in CD4+ count after active tuberculosis diagnosis was apparent in the significant 
difference (p < 0.03) in CD4+ count at compared to that after active tuberculosis 
diagnosis date. 
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Table 4.9.1 
Difference between CD4 counts before, at, and after TB diagnosis date (incident cases , n = 45) 
Variable 
CD4 BEFORE TB 
CD4ATTB 
CD4 AFTER TB 
Average rank Mean 
2.25 
1.59 
2.15 
234.81 
176.7 
205 .72 
S.D 
156.41 
136.27 
180.02 
Median 
242 
157 
167 
QLower 
91 
62 
72 
Q upper 
333 
239 
255 
Friedman ANOV A and Kindall Coefficient of concordance (the ANOV A Chi Sqr. 
(N = 45 , df = 2) = 6.675676 p < 0.03553 Coefficient concordance = .15172 Aver. Rank r = 0.11133 
Friedman nonparametric Anova analysis. S.D: standard deviation 
0 Lower: Lower quarile Q u pper :Upper quartile 
Table 4.9.2 
Comparisons between CD4 counts before, at, and after TB diagnosis date ( incident cases, n=45) 
PAIR OF VARIABLES 
CD4 AT TB vs CD4 BEFORE TB 
CD4 AT TB vs CD4 AFTER TB 
CD4 BEFORE TB vs CD4 AFTER TB 
Wilcoxon nonparametric Matched Pairs Test 
VALIDN 
45 
45 
45 
p 
0.00 
0.03 
0.35 
To account for the apparent loss in CD4+ count which active tuberculosis might have 
induced in the 45 incident and the 113 prevalent cases of active tuberculosis of this 
cohort, another multivariate analysis was carried out. In the following Cox 
proportional hazards regression model, the CD4+ count 3-6 months before or after 
active tuberculosis diagnosis date (for the 45 incident cases) and 3-6 months after 
active tuberculosis diagnosis date (for the 113 prevalent cases) were included in the 
model, rather than the CD4+ counts at diagnosis date, as in the previous analyses. 
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Table 4. 9.3 
CD4 count (3-6) months before or after TB diagnosis date and association with mortality (N = 
158): univariate analysis 
Beta 
CD4 ~ 200 .9078 
Standard 
Error 
.4086 
Cox proportional hazards regression model 
Table 4.9.4 
Risk 
Ratio 
2.48 
RR 
95% C.I. 
( 1.11,5.53) 
p 
.02 
CD4 count (3-6) months before or after TB diagnosis date and other predictors of mortality : 
multivariate analysis 
Standard Risk RR 
Beta Error Ratio 95%CI p 
CD4~200 .6086 .2817 1.84 ( 1.06,3.19 ) .03 
Antiretriviral therapy .0653 .3202 1.07 ( 0.57,1.99) .83 
Co-trimoxazole -.7564 .2483 0.47 ( 0.29, 0.76) .00 
Tuberculosis .5328 .2472 1.70 ( 1.05,2.77) .03 
AIDS-defining illnesses .8277 .2589 2.29 ( 1.38,3.79) .00 
Age>32 years .2077 .2129 1.23 ( 0.81,1.87) .32 
Cox proportional hazards regression model 
Table 4.9.5 
CD4 count (3-6) months before or after TB diagnosis date and other predictors of mortality 
(N=158): univariate and multivariate analyses compared 
Univariate Model Multivariate Model . 
Variable RR 95% C.I p RR 95% C.I p 
CD4~200 ~1/l 2.48 (1.11,5.53) .02 1.84 (1.06,3 .19) .03 
Antiretroviral therapy 0.79 (0.48, 1.31) .36 1.07 (0.57,1.99) .83 
Co-trimoxazole 0.70 (0.51,0.95) .05 0.47 (0.29,0.76) .00 
Tuberculosis 2.05 (1.38,3 .07) .00 1.70 ( 1.05,2. 77) .03 
Age > 32 years 1.04 (0.70,1.54) .85 1.23 (0.81, 1.87) .32 
AIDS-defining illnesses 1.75 (1.10,2.78) .01 2.29 (1.38,3.78) .00 
Cox proportional hazards regression model 
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After controlling for differences at baseline in known predictors of survival in HIV-
infected patients and the depressed level of CD4+ T-lymphocyte count at tuberculosis 
diagnosis, active tuberculosis increased mortality by 70% in HIV-infected patients 
compared to HIV-infected patients without active tuberculosis. 
Table 4.9.6 
Predictors of mortality in cases and non-cases including (1) CD4 count at TB diagnosis and (2) 
CD4 count 3-6 months before or after TB diagnosis : multivariate analyses 
(1) (2) 
Variable RR 95% C.I p RR 95% C.I p 
CD4~200 µ/1 2.10 (1.22,3.66) .00 1.84 (1.06,3.19) .03 
Antiretroviral therapy 1.29 (0.72,2.34) .39 1.07 (0.57, 1.99) .83 
Co-trimoxazole prophylaxis 0.40 (0.25,0.65) .00 0.47 (0.29,0.76) .00 
Tuberculosis 2.37 (1.46,3.86) .00 1.70 ( 1.05,2. 77) .03 
Age> 32 years 1.30 (0.85, 1.97) .22 1.23 (0.81,1.87) .32 
AIDS-defining illnesses 2.28 (1.36,3.78) .00 2.29 (1.38,3.78) .00 
Cox proportional hazards regression analyses 
The multivariate analyses shown in the table above, indicate that the predictive model 
remained essentially the same using CD4 count at or before or after date of TB 
diagnosis. The risk ratio associated with the active tuberculosis and the CD4 count 
were reduced somewhat after adjustment, but remained significant predictors of 
mortality. 
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4.10 Interactions between CD4+ lymphocyte count, baseline AIDS-defining 
illnesses and tuberculosis in the presence of other predictors of mortality 
The Breslow-Day and log-likelihood tests done in a previous section showed that both 
CD4+ lymphocyte ~200 cells/µL and history of AIDS-defining illness were effect 
modifiers of the association of active tuberculosis with mortality. As the parameter 
estimates of the variables included in the model may change in the presence of 
interaction between these two variables and tuberculosis, it was important to test the 
significance of these interactions in the presence of other predictors of mortality 
included in the Cox proportional hazards regression model. Interaction terms were 
created by multiplying each of the two variables with tuberculosis and were included 
in the model. The difference between the log-likelihood of the two multivariate 
models (before and after including the interaction terms) was tested for significance. 
Table 4.10.1 
Testing the significance of the interaction terms. 
Model Interaction term Log-likelihood Difference P* 
Starting model (table 4.28) -503.30 
2 AIDS-defining illness * TB -500.943 2.36 .125 
3 CD4+lymphocyte ~200 cells/µL *TB -500.867 2.43 .121 
4 CD4+lymphocyte ~200 cells/µL * AIDS- -499.185 4.116 .128 
defining illness *TB 
Multivariarte Cox proportional hazards regression models *P Chi-square test 
Model 1 (the starting model [Table 4-28]) included the variables antiretroviral 
therapy, co-trimoxazole prophylaxis, CD4+ lymphocyte count ~ 200 cells/µL, 
tuberculosis, AIDS-defining illness and age > 32 years at baseline. Model 2 included 
all these variables plus the interaction term between AIDS-defining illness and 
125 
RESULTS CHAPTERm 
tuberculosis. Model 3 included the variables in the starting model plus the interaction 
term between baseline CD4 lymphocyte count ~ 200 Cells/µ L and tuberculosis. 
Model 4 included the variables in the starting model plus the interaction term between 
baseline CD4 lymphocyte count ~ 200 Cells/µ L, AIDS-defining illness and 
tuberculosis. 
Form the above table it is clear that none of the interaction terms were significant, i.e. 
they were rejected by the multivariate Cox proportional hazards regression model. 
This is despite the fact that both history of AIDS-defining illness and CD4 
lymphocyte count(~ 200 Cells/µ L) at inclusion where shown in sections 4.4.1 and 
4.4.2 to be effect modifiers and their interaction with TB was shown to be significant. 
This suggests that the heterogeneity of the RR across the strata of CD4 lymphocyte 
count (~ 200 and > 200 Cells/µ L) shown previously in the Breslow-Day stratified 
analysis (section4.4.2); can not be attributed to the modifying effect of CD4 
lymphocyte count ~ 200 Cells/µL at baseline to the association of TB with mortality 
alone, but rather to the modifying effects of the other variables (antiretroviral therapy, 
co-trimoxazole prophylaxis, AIDS-defining illnesses at inclusion or age > 32) not 
control for in that stratified analysis. The interaction between the two variables was 
attenuated after adding the effects of other predictors of survival operating in the 
increased association between active tuberculosis and mortality. This may explain 
why the interaction term was rejected by the multivariate model. The same 
interpretation applies to the rejection of the interaction between the baseline AIDS-
defining illnesses and tuberculosis in the multivariate model. 
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In conclusion, from all the analyses carried out above, active tuberculosis emerged as 
an independent predictor of death in HIV-infected patients after controlling for known 
predictors of mortality in HIV infection; and after examining for interaction effects. 
4.11 EFFECT OF CO-TRIMOXAZOLE ON MORTALITY AND 
MORBIDITY OF HIV-INFECTED PATIENTS WITH TB 
To specifically investigate the effect of co-trimoxazole prophylaxis on the survival of 
HIV-infected patients with active tuberculosis, stratified univariate and multivariate 
analyses were done. In this cohort, co-trimoxazole prophylaxis was started in patients 
with a CD4+ count lower than 200 cells/µL. Survival of 71 HIV-infected patients 
with active tuberculosis and reported use of co-trimoxazole prophylaxis was 
compared with that of the remaining 87 HIV-infected patients with active tuberculosis 
patients for whom use of co-trimoxazole prophylaxis was not reported during follow-
up (controls) . 
The incidence of AIDS-defining illnesses which could be prevented by co-
trimoxazole (Pneumocystis carinii pneumonia, cerebral toxoplasmosis, non-typhoid 
salmonell~sis and bacterial pneumonia) was lower in the co-trimoxazole treated group 
' (3 patients; incidence density= 0.3/100 person-months) than in the untreated group 
(14 patients; incidence density = 2.1/100 person-months; risk ratio = 0.23 ; 95 % 
confidence interval= 0.06-0.84; p = 0.017). 
Mortality was also lower in the co-trimoxazole treated group (14 patients; 1.2/100 
person-months) compared to the untreated group (36 patients; 5 .5/100 person-months; 
p = 0.002). The median survival (Fig 4-11) of the co-trimoxazole treated group was 
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longer than the untreated group (28 versus 16 months; p = 0.03). In the univariate 
analysis (Table 4.11.1 ), use of co-trimoxazole prophylaxis improved survival (risk 
ratio = 0.53; 95% confidence interval = 0.30-0.94; p = 0.03). A similar protective 
effect was found after adjustment for differences at baseline (risk ratio = 0.38; 95% 
confidence interval= 0.23-0.62; p < 0.001) in the multivariate analysis (Table 4.11.2). 
It is noteworthy that the better outcome in patients given co-trimoxazole prophylaxis 
was achieved despite their lower CD4+ lymphocyte count at baseline than that of 
patients not given the treatment (median 174 cells/µl, interquartile range 33-199 
compared to 308 cells/µl, interquartile range 290-745;p<0.001J. 
Table 4.11.1 
Effect of co-trimoxazole on survival of HIV-infected patients with tuberculosis, 1992-96 (N =158) 
Co-trimoxazole 
Beta 
Standard 
Error 
-.6299 .2908 
Risk 
Ratio 
0.53 
RR 
95% C.I .. 
(0.30,0.94) 
p 
.03 
Cox proportional hazards regression univariate model ( including only patients with active TB) 
Table 4.11.2 
Effect of co-trimoxazole on survival of HIV-infected patients with TB controlling for other 
predictors of mortality, 1992-96( N =158) 
Standard Risk RR 
Beta Error Ratio 95%CI p 
CD4:s;200 cells/µL 1.0873 .3491 2.96 (1.49,5.87) .00 
Co-trimoxazole -.9711 .2474 0.38 (0.23,0.62) .00 
AIDS-defining illnesses .7902 .2708 2.20 ( 1.29,3.74) .00 
AGE>32 .0912 .2181 1.09 (0.72,1.68) .67 
Cox proportional hazards regression multivariate model (including only patients with active TB) 
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Patients with active tuberculosis who used co-trimoxazole prophylaxis survived 
significantly longer compared to tuberculosis patients who did not used co-
trimoxazole prophylaxis (median = 28 months versus 16 months respectively, p = 
0.030) (Fig 4.11 ). 
Fig 4.11 
Effect of co-trimoxazole on survival of HIV-infected patients with TB 
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4.12 EFFECT OF SOCIOECONOMIC STATUS ON SURVIVAL 
To investigate the effect of socioeconomic status on survival, a further stratified 
analysis was done. Patients were categorized into two groups; higher socioeconomic 
and lower socioeconomic patients. The first group was chosen as a reference group. 
Employment status, occupation status, education level, medical aid coverage, number 
of dependents and residence in an area characterised by lower socioeconomic status 
(as defined by the Cape Town Metropolitan Council, CMC- Appendix V) and 
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medical aid scheme coverage were used as surrogates for socioeconomic status. This 
scheme eventually resulted in the inclusion of all patients in white race group in this 
cohort in the higher socioeconomic group, and all other race groups in this cohort in 
the lower socioeconomic group. Thus, race group and socioeconomic status in the 
analyses done in this section will be used interchangeably for assessing the effect of 
race or socioeconomic status on survival in this cohort. Survival of higher 
socioeconomic status (50 months) was significantly greater than that of patients in the 
lower socioeconomic status/non-white race group (30 months); (p < 0.001) (Fig 
4.12.1). This difference in survival was similar to that observed when patients were 
categorized according to race group (Fig 4.12.2). 
Fig 4.12.1 
Effect of socioeconomic status on survival of HIV-infected patients, 1992-96 (N = 609) 
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Fig 4.12.2 
Effect of race group on survival of HIV-infected patients, 1992-96 (N = 609) 
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To adjust for other predictors of survival that might have contributed to the observed 
differences in survival between groups, further univariate and multivariate analysis 
were carried out controlling for baseline CD4+ counts, use of antiretroviral therapy, 
co-trimoxazole prophylaxis, age, presence of AIDS-defining illness at baseline, and 
active tuberculosis. In the univariate model, higher socioeconomic status was 
protective against mortality (RR= 0.64, 95% confidence interval 0.42-0.99, p = 0.04) 
(Table 4.12.1). 
Table 4.12.1 
Effect of socioeconomic status on survival of HIV-infected patients (N = 609) 
Beta 
Higher Socioeconomic Status -.4412 
Standard 
Error 
.2175 
Univariatf Cox proportional hazards regression model 
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0.64 
RR 
95% C.I. p 
(0.42,0.99) .04 
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However, after adjusting for other predictors of mortality, no significant difference 
was observed between the two groups (RR= 0.80, 95% confidence interval 0.42-1.57; 
p = 0.53). This indicates that the significant difference in survival observed in the 
above univariate analysis could perhaps be attributed to differences in medical care 
(viz co-trimoxazole prophylaxis), level of presenting immunodeficiency (viz, CD4 T-
lymphocyte count) and severity of disease or co-morbidity (TB, AIDS-defining 
illness), rather than race and socioeconomic differences as shown in Table 4.12.2 
below. 
Table 4.12.2 
Effect of socioeconomic status on survival of HIV-infected patients controlling for other 
predictors of mortality (N = 609) 
Standard Risk RR 
Beta Error Ratio 95% C.I p 
Antiretroviral therapy .2771 .3554 1.31 (0.66,2.65) .43 
Co-trimoxazole prophylaxis -.7870 .2625 .45 (0.27,0.76) .00 
CD4~ 200 /µL .7401 .3432 2.09 (1.07,4.09) .03 
Tuberculosis .7074 .2618 2.02 (1.22,3.39) .00 
AIDS-defining illnesses .7996 .2626 2.22 (1.33,3.73) .00 
Age>32 years .3162 .2248 1.37 (0.88,2.13) .15 
Higher socioeconomic status -.2132 .3399 .80 (0.42, 1.57) .53 
Cox proportional hazards regression model multivariate analysis. 
4.13 EFFECT OF SITE OF DISEASE ON SURVIVAL 
To study the effect of site of active tuberculosis on survival of HIV-infected patients, 
a stratified survival analysis was done. Patients diagnosed with active tuberculosis 
were further stratified according to site of disease into pulmonary and extrapulmonary 
132 
RESULTS CHAPTERm 
groups. Fig 4.13.1 shows no significant differences (p = 0.32) in survival between the 
two groups. 
Fig 4.13.1 
Survival of active tuberculosis patients according to site of disease, 1992-96 ( N =158) 
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The same non significant difference was observed when the two groups were further 
stratified into patients diagnosed with pulmonary, extrapulmonary or both (Fig 4.13.2) 
(p = 0.55). 
Fig 4.13.2 
Survival of active tuberculosis patients according to site of disease 
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4.14 VALIDITY OF HIV STAGING SYSTEMS IN HIGH TB PREVALENCE 
SETTING 
The prognostic utility of the clinical criteria of the WHO and CDC staging systems 
was assessed in this cohort drawn from a high tuberculosis prevalence setting. 
Controls (i.e. non-TB cases) who never developed active tuberculosis during follow-
up were staged into the above two different staging schemes at their inclusion into 
study. Their respective survival times curves from inclusion into the study and the 
initial stage they presented with until death or censoring were plotted against the 
survival curve of patients with active tuberculosis. 
Using the WHO staging system, controls with stage 1 or stage 2 where combined in 
one group as their survival was similar (Fig 4.14.1). Survival of patients with active 
tuberculosis was not significantly different from survival of patients presented with 
stage 3 (p = 0.25), but was significantly better than survival of patients who presented 
with stage 4 ( or AIDS) (p = 0.000) (Fig 4.14.2). This suggests that HIV-infected 
patients with active tuberculosis and no other opportunistic infections have a 
prognosis comparable to that of other HIV-infected patients with no active 
tuberculosis but diagnosed with any of the conditions of WHO stage 3. 
In the CDC staging system, the survival curve of patients with active tuberculosis 
coincides with the survival curve of patients who presented with stage B disease (Fig 
4.14.3). 
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The survival of patents with active tuberculosis only (without other conditions of 
WHO stage 3 or 4, CDC stage B or C) was further compared with the survival of 
patients without active tuberculosis but with other conditions of WHO stage 3, CDC 
stage B. Only patients diagnosed with one of the WHO stage 3, CDC stage B 
conditions were included in this stratified survival analysis. The survival for these 
individual conditions were examined to determine which of these curves was 
asymptotic to the survival curve of the active tuberculosis group. Survival of the 
active tuberculosis group was found to be similar to survival of oral hairy leukoplakia 
and oral candidiasis groups (WHO stage 3, CDC stage B). Survival of these two 
groups was combined into one group and compared with survival of the active 
tuberculosis group. Fig 4.14.4 indicates that in HIV-infected patients with active 
tuberculosis survival is similar to that of patients diagnosed with oral hairy 
leukoplakia and/or oral candidiasis with no active tuberculosis (and no any of WHO 
stage 3 or 4, CDC stage B or C conditions). 
Fig 4.14.1 
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Fig 4.14.2 
Patients with active TB vs patients with other conditions ( WHO staging criteria) (N=609) 
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Fig 4.14.3 
Patients with active TB vs patients with other conditions ( CDC staging criteria) (N= 609) 
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Fig 4.14.4 
HIV-infected patients with active TB vs HIV-infected patients with oral hairy leukoplakia or 
candidiasis ( WHO stage CDC stage B) · • 
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5. D I S C U S S I O N 
This prospective cohort study was undertaken to assess the prognostic effect of active 
tuberculosis on the natural history of human acquired immunodeficiency syndrome in 
patients presenting to the two major HIV clinics in Cape Town by comparing the 
survival experience of a group of 158 HIV-infected patients with active tuberculosis 
with that of a comparison group of 451 HIV-infected patients without active 
tuberculosis. 
The findings of this study reflect the magnitude of the deleterious effect which active 
tuberculosis has on the prognosis of HIV-infected patients. Being done in a setting 
with one of the highest recorded tuberculosis prevalences in the world, this study, by 
documenting the increased incidence of AIDS-defining illness and the reduced 
survival observed in HIV-infected patients with active tuberculosis, illustrates 
dramatically the link between HIV infection and active tuberculosis. 
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5.1 SURVIVAL OF HIV-INFECTED PATIENTS WITH ACTIVE 
TUBERCULOSIS. 
5.1.1 Effect of tuberculosis on mortality 
In this cohort, HIV-infected patients diagnosed with active tuberculosis had a reduced 
survival when compared to HIV-infected patients without active tuberculosis. This 
difference in survival between the two groups was consistent at higher levels of 
presenting CD4 lymphocyte count (201-400 cells/µL or > 400 cells/µL). However, 
this significant difference in survival associated with tuberculosis was not observed 
when patients presented with an AIDS-defining illness or a very low CD4+ 
lymphocyte count (~ 200 cells/µl or ~ 50 cells/µl) at the time of inclusion into the 
study. This may be explained by fact that these patients were already terminally ill, 
with advanced immunosuppression, making it impossible to detect a significant 
difference in survival based on tuberculosis status. 
The reduced survival of HIV-infected patients with active tuberculosis observed in 
this study is in agreement with studies done elsewhere [1,2]. Leroy et al. observed 
that when survival between the two groups (i.e. HIV-infected patients with and 
without tuberculosis) was compared according to the presence of AIDS-defining 
illness at inclusion, there was no significant difference in survival between the two 
groups [1]. In contrast, a significant difference in survival between the two groups 
was observed in the Whalen et al. study, where survival was reduced in tuberculosis 
cases compared with that in controls subjects in patients (1) with AIDS-defining 
illness at baseline [p = 0.001]; and (2) in patients without AIDS-defining illness [p = 
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0.001] [2]. However, non of these studies compared the survival of patients according 
to presenting level of CD4+ lymphocyte count. 
The median survival time of HIV-infected patients with active tuberculosis in this 
cohort is comparable to that reported in developed countries: viz. the USA (21-30 
months) [3,4], and Europe (22 months)[5]. It is, however, significantly greater than 
that reported in sub-Saharan African countries: e.g. Rwanda (15 months) [6]. The 
significantly greater survival of HIV-infected patients with active tuberculosis in this 
cohort than those from Rwanda may be due to differences in the management of 
patients, viz. the wide use of rifampicin and co-trimoxazole prophylaxis in this cohort 
compared to other African countries were neither of these interventions is widely 
used. 
Pozniak et al. Have argued that rifampicin "is a good bactericidal drug with a potent 
sterilizing effect, and the ability to prevent the emergence of drug resistance. In 
addition to acting on rapidly dividing bacilli, it kills so-called "persisters", which 
remain inactive for long periods but have intermittent periods of metabolism, with 
only short drug exposure. This is crucial to its sterilizing ability, and also confirms 
experimental studies of TB of both early bactericidal activity and and sterilizing 
activity"[?]. 
Co-trimoxazole prophylaxis is an effective intervention for improving survival and 
reducing the incidence of the AIDS-defining illnesses frequently diagnosed in HIV-
infected patients from African countries, such as salmonellosis, isosporiasis, cerebral 
toxoplasmosis, and bacterial pneumonia. Evidence of its efficacy in Africa is lacking, 
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it has been thought to be suitable for HIV-infected patients from developed countries 
where the spectrum of AIDS-defining illnesses is different. A total of 71 (45%) TB 
patients in this cohort had co-trimoxazole prophylaxis, which was observed to 
increase survival and reduce mortality (see section 5.3). 
The improved survival in this cohort relative to that of patients from other African 
countries may therefore partially be attributed to these therapies. 
In the analyses done in this study, active tuberculosis was consistently an independent 
predictor of death. The risk ratios calculated in this study, before and after adjusting 
for AIDS-defining illness and CD4+ lymphocyte count, indicate that mortality was 
consistently higher in cases than in non-cases. HIV-infected patients with active 
tuberculosis were shown to have a risk of death twice as high as that of HIV-infected 
patients without active tuberculosis. This higher mortality was more apparent in 
patients without a history of AIIDS-defining illness and in patients with a CD4+ 
lymphocyte greater than 200 cells/µl at inclusion. This indicates that tuberculosis 
increases the risk of death even at the early stages of HIV-infection, and that most of 
deaths occurred in this cohort at the early stages of HIV infection can be attributed to 
tuberculosis . This is in agreement with studies done in Africa were TB was shown, in 
general, to be the primary cause of mortality in HIIV-infected patients, and; more 
specifically, to be responsible for mortality that occurs at the early stages of HIV 
infection [8-11]. Previous epidemiologic studies suggest that tuberculosis may 
accelerate the clinical course of HIIV-infection. In Zaire, the relative risk of death was 
2. 7 in those with active tuberculosis compared with those without active tuberculosis 
[8]. A similar estimate for this odds ratio for death was observed in Whalen study 
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(2.17). These estimates are not different from the estimates of the odds ratio observed 
in this study (2.37 and 1.70; before and after adjusting for the transient reduction of 
the CD4 T-lymphocyte induced by active tuberculosis; respectively) . This indicates a 
consistency in both the direction and magnitude in the measure of effect. 
It has recently been proposed that tuberculosis may enhance the pathogenecity of HIV 
infection and accelerate the course of HIV disease. It was discussed in a previous 
section of this study that the immune activation in response to tuberculosis may play a 
role in the pathogenesis of HIV-1 infection, by altering the replication of HIIV in 
target cells, up-regulating HIV expression in T-cells and macrophages, increasing 
HIIV-1 viral load, and partially suppressing the factors responsible for controlling 
HIV replication. These factors combined could participate in an increased progression 
to AIDS and mortality subsequent to the onset of tuberculosis. Thus 
epidemiologically and biologically plausible that the greater mortality rate that 
occurred in tuberculosis patients relative to the comparison group in this study can be 
attributed to active tuberculosis rather than to differences between the two groups in 
immunosuppression at baseline. 
5.1.2 Effect of tuberculosis on incidence of AIDS defining illness 
It was observed in this cohort of HIIV-infected patients with active tuberculosis 
developed AIDS significantly faster than HIV-infected patients without active 
tuberculosis. This accelerated progression to AIDS after the onset of tuberculosis 
persisted even after controlling for confounding. HIV-infected patients with active 
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tuberculosis in this cohort had 60% higher risk of developing AIDS compared with 
the comparison group of the HIV-infected patients without active tuberculosis. 
In addition, active tuberculosis patients had a higher rate of subsequent AIDS-
defining illnesses than did the comparison group. Incidence of AIDS-defining 
illnesses was consistently higher in cases than non-cases of active tuberculosis even 
after adjusting for CD4+ lymphocyte count, age and antiretroviral therapy. This 
indicates that HIV patients with active tuberculosis tended to develop AIDS-defining 
illnesses at a greater rate than non-cases of active tuberculosis over the same period, 
and after controlling for factors other than active tuberculosis associated with AIDS-
defining illnesses. This finding is similar to that observed in the most recent study 
from the USA. In that prospective cohort study, Munsiff et al. observed that 
tuberculosis was associated with increased risk of development of AIDS-defining 
illness (RR= 4.1; 95% confidence intervals 1.9-8.7) [12]. Whalen et al. observed a 
higher occurrence, though not significantly different, of AIDS-defining illness among 
tuberculosis cases compared to a comparison group of non-tuberculosis cases [2]. 
However, Leroy et al. observed no difference in their study and argued that the 
greater occurrence of AIDS-defining illness in the active tuberculosis patients than in 
the comparison group observed in Whalen's study might have been due to a detection 
bias, whereby active tuberculosis patients might have been followed more closely 
than the patients in the comparison group [2]. 
It is difficult to attribute the higher rate of subsequent AIDS-defining illness occurring 
in patients with active tuberculosis in this study to detection bias, since cases of active 
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tuberculosis were followed in a manner comparable to that of the comparison group 
[median follow-up= 11.5 vs 14.5 months respectively;p = 0.7]. 
However, a history of AIDS-defining illness on its own was predictive of mortality. 
HIV-infected patients with a history of AIDS-defining illness were estimated to have 
a risk of death 200% greater than HIV-infected patients who were free from AIDS-
defining illness at inclusion. 
5.1.3 Effect of tuberculosis on CD4+ T-lymphocyte count 
It could be argued that a single measurement of the CD4+ lymphocyte count is 
insufficient to evaluate the progression of HIV infection, since tuberculosis tends to 
induce by itself a decline in the CD4+ lymphocyte count (1,2]. The two studies 
mentioned above reported depressed immunity among HIV-infected patients at the 
time active tuberculosis was diagnosed. In another study in South Africa, the CD4+ 
lymphocyte count of a group of HIV-infected patients with tuberculosis was 
significantly lower than that of a comparison group with active tuberculosis and 
without HIV infection (median= 230 cells/µL, interquartile range 90-475 vs median= 
630 cells/µL, interquartile range 500-865 respectively,p < 0.0001) (11]. 
A similar result was observed in this study. The CD4+ lymphocyte count 3-6 months 
before the diagnosis of active tuberculosis was significantly higher than the CD4+ 
lymphocyte count at the diagnosis of active tuberculosis. The CD4+ lymphocyte 
count 3-6 months after the diagnosis of active tuberculosis was also significantly 
higher than the CD4+ lymphocyte count at the diagnosis of active tuberculosis. 
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However, no significant difference was observed between the median CD4+ 
lymphocyte counts before and after the diagnosis of active tuberculosis. 
This finding suggests that the reduction in the CD4+ lymphocyte count caused by 
active tuberculosis was transient. Thus it was important to control for this transient 
reduction in the CD4+ lymphocyte count at time of active tuberculosis diagnosis in 
the Cox proportional hazards regression model, to ensure valid estimates for the 
predictors of survival. Unlike the study in this thesis, none of the previous studies 
made this adjustment. 
When usmg the CD4+ lymphocyte count at date of tuberculosis diagnosis, the 
adjusted relative risk of death due to active tuberculosis was 2.37, similar to the 
adjusted risk ratio observed in Whalen's study (2.17), or in the study from Zaire (2.7), 
but greater than that observed in Leroy's (1.59). A somewhat lower risk ratio was 
observed after substituting the CD4 count 3-6 months before or after date of 
tuberculosis diagnosis in the regression model (risk ratio= 1.70). However, the effect 
measure remained significant, and the interpretation unchanged. 
The significant increase in the CD4+ lymphocyte count after the diagnosis of active 
tuberculosis quantifies the rate of increase in circulating CD4+ T lymphocytes after 
antituberculosis therapy. The improvement of the median CD4+ lymphocyte count, if 
sustained, in response to therapy for tuberculosis is likely to have a positive influence 
on the course of HIV infection. Whalen et al., in recent randomized placebo 
controlled trial study done in Uganda, argued that the duration of the positive effect of 
antituberculosis therapy remains to be established especially in areas endemic for 
145 
DISCUSSION CHAPTER~ 
tuberculosis where the high annual risk of infection may affect the risk of tuberculosis 
after preventive therapy has been completed, especially in persons with 
immunosuppression [13]. However, the transient reduction in CD4+ lymphocyte 
count at tuberculosis diagnosis may merely represent migration to the site of 
tuberculous disease 
5.1.4 Other Predictors of mortality 
5.1.4.1 Antiretroviral therapy 
Antiretroviral therapy was not widely used in this cohort. This may be explained by 
the fact that most of the patients in this cohort belong to the lower socioeconomic 
strata of Cape Town and where thus unable to pay for this expensive therapy. As 
reported in section 4.3.1, only 3 (1.9 %) cases of active tuberculosis and 44 (9.7 %) 
non-cases were reported to have used antiretroviral therapy. The association between 
antiretroviral therapy and mortality was consistently non-significant in this study (risk 
ratio RR= 1.29), in one model, and (risk ratio RR= 1.07) in the model that accounted 
for the transient reduction in CD4+ lymphocyte induced by active tuberculosis. 
However, the power of this study to investigate the effect of antiretroviral therapy was 
low. The limited use of antiretroviral therapy and the relatively small sample of HIV 
infected patients with active tuberculosis make it difficult to detect any significant 
association. 
Antiretroviral therapy has been shown to prolong survival in patients with AIDS and, 
in HIV-infected patients without an AIDS-defining condition to delay the progression 
to AIDS [14-17]. Zidovudine, the main antiretroviral used in this cohort, was the first 
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antiretroviral agent shown to be of benefit in the treatment of HIV infection. It was 
shown to decrease transient plasma RNA levels and increase circulating CD4 cells 
count, decrease the number of AIDS-defining illnesses and progression to AIDS, 
prolong survival in persons with AIDS, and decrease progression to AIDS in patients 
with HIV disease [14-17]. However, none of the drugs currently available to treat 
HIV-infected patients can eradicate infection, although they can decrease the viral 
load and delay immunologic decline. The reverse transcriptase inhibition associated 
with nucleoside analogues (e.g., zidovudine) protects uninfected cells, primarily CD4 
lymphocytes, from infection [14-17]. However, they have no antiviral effect on cells 
already infected [14-18]. Antiretroviral therapy has been found in other studies to 
result in a non-significant improvement in survival. Chaisson et al. observed the same 
result and argued that "the survival advantage conferred by Zidovudine is constrained 
by time"; and that "although Zidovudine clearly prolongs survival in advanced HIV 
disease, recent studies have indicated survival is prolonged only for one to two years" 
[19]. 
Relatively few HIV infected patients in South Africa can afford antiretroviral therapy. 
The survival effect of such therapy on HIV-infected South African patients thus has 
yet to be documented. 
5.1.4.2 Co-trimoxazole prophylaxis 
In the different analyses done in this study, co-trimoxazole prophylaxis was an 
independent predictor of improved survival. In the general cohort, use of co-
trimoxazole prophylaxis reduced mortality by nearly half in the group using it as a 
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prophylaxis against AIDS-defining illness, compared to those who did not. The 
efficacy of co-trimoxazole prophylaxis in reducing mortality and morbidity was 
specifically examined in the tuberculosis group, and is discussed in a later section of 
this study. 
5.1.4.3 Sociodemographic factors 
Sociodemographic factors, such as age, gender, race or ethnic ongm and 
socioeconomic status, may play a role in survival after HIV infection. Although it is 
not possible to alter most of these factors, their relationship with survival may provide 
clues to the underlying pathogenesis of infection with HIV. In addition, identification 
of the relationships between demographic factors and survival is important for 
predicting individual patients' prognosis. 
Age, in some reports, was argued to be an important factor that may confound the 
association between active tuberculosis and mortality [20-21]. It was observed that 
older people are more likely to experience shortened survival following HIV 
infection. The underlying reason for this association, which is also found when 
considering the time from HIV infection to development of AIDS, is not known. 
However, Mackall et al. have related this association to a poorer capacity for 
lymphocyte production in older persons [22]. Ben-Yehuda et al. have argued further 
that age may be a marker for some characteristic that makes it more difficult for older 
people to resist the pathological effect of HIV [23]. 
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In this cohort, however, older age was not significantly predictive of mortality, (risk 
ratio RR= 1.23, 95% confidence interval = 0.81-1.87, p = 0.3). Age in this cohort 
ranged from 18 to 69 years [median = 32 years, interquartile range 25-37]. Only 3 
patients were older than 65 years, and most of the patients were much younger. This 
may explain the non-significant effect of older age in survival on this cohort. 
To investigate the effect of socioeconomic status on survival in this cohort, patients 
were classified into two groups. The reference group included patients of higher 
socioeconomic status as defined by higher employment, education, occupation, 
coverage by a medical aid schemes, number of dependents, and residence in areas 
characterized by better living conditions, relative to the comparison group of lower 
socioeconomic status. Using this classification scheme, it was effectively the same as 
comparing the different "racial" groups in this cohort, as higher status group included 
95.5% of the "white" patients in this cohort, and the comparison group included 
97.3% of the "Black" and "Coloured" patients. The median survival of the group of 
higher socioeconomic status (50 months) was significantly greater than that of the 
group of lower socioeconomic status (30 months). However, this difference was not 
observed after controlling for other differences between the groups viz. baseline CD4+ 
lymphocyte count, antiretroviral therapy, co-trimoxazole prophylaxis, age, history of 
AIDS-defining illness at baseline and active tuberculosis. This result suggests that 
factors such as background prevalence of tuberculosis, and access to medical care 
may play an important role in the poorer survival associated with socioeconomic 
status, or alternatively, "race" among HIV infected patients. 
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There is controversy over whether race or ethnicity affects survival of HIV-infected 
patients independently of socioeconomic status. This may be due to the under-
representation of the minority ethnic groups in some studies in developed countries. 
Historically, early studies from the United States that were of sufficient size to 
consider survival differences between racial groups showed that African American 
and Hispanic patients had poorer survival than whites after HIV infection [24-25]. 
This difference in survival may be explained by poorer access to medical care. 
Minority ethnic groups tend to reside in areas where there is less medical care and 
treatment. Also their disease may go unnoticed for longer, making it more life 
threatening and serious when it is finally diagnosed. In contrast, the majority of more 
recent studies show no survival differences by race or ethnicity [26-27]. A recent 
study by Chaisson has placed many aspects of the early survival studies into 
perspective. He has demonstrated that provided patients have equal access to medical 
care, there is no difference in survival or disease progression. This pertains 
irrespective of gender, race or socieconomic group. He argued that differences in 
survival rates are most probably related to availability of medical care and compliance 
with prophylactic medication, rather than biologic differences in subgroups of patients 
[19]. Studies of African patients who live in London have suggested no marked 
differences in survival compared with estimates from developed countries [28]. In 
common with the studies from Brazil and Thailand [29,30], survival in HIV-infected 
patients in Africa is generally thought to be poorer as compared with that in 
developed countries, probably reflecting limitations in access to treatment and care 
and the high prevalence and incidence and poor control of other infectious diseases, 
such as tuberculosis. 
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There are, however, other potential explanations of the observed reduced survival in 
the active tuberculosis group in this study, reflecting limitations in the study. 
It is difficult to determine what proportion of deaths in the case group where directly 
due to active tuberculosis alone. This is because no information about cause of death 
was available. 
Furthermore, death from tuberculosis may be associated with non-compliance with 
treatment, or failure to response to antituberculosis therapy particularly if patients are 
infected with a drug resistant strain of M tuberculosis [31]. No information about 
compliance was available in this study. It is therefore not possible to exclude 
treatment non-compliance as a contributor to the observed differences in survival. 
However, in the general cohort to which the patients of this study belong, Post et al. 
have shown that HIV infection is not associated with an increased rate of drug-
resistant tuberculosis [32]. The regimen used for treating tuberculosis in this cohort is 
the standard therapy to which HIV-infected patients generally respond well. 
There were 38 tuberculosis patients who did not meet the inclusion criteria of this 
study and were thus excluded because either they appeared in the cohort only once or 
did not avail themselves regularly to follow-up. If these patients experienced a 
different pattern of survival from that observed in the cases retained in this study, this 
systematic exclusion may have introduced a biased estimate of the true association 
between active tuberculosis and mortality. However, it is difficult to determine the 
magnitude or the direction of this bias. 
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Referral bias can also not be excluded, since subjects were recruited from teaching 
hospitals. Such subjects usually present with more advanced disease when they were 
referred to the HIV clinics for evaluation and proper management. Therefore it is 
possible that there may be HIV-infected patients with different characteristics ( e.g. 
less immunosuppression or any other characteristics that may affect the prognosis of 
HIV-infected patients) who did not present to the two hospitals in this study. If the 
proportion of such patients is significantly large in Cape Town, this clinic bias may 
account for the poor prognosis observed in this cohort, and may also affect the 
generalizability of the findings of this study to the general population of adult HIV-
infected in Cape Town. However, no other HIV clinics in the public sector in the 
region were available for HIV-infected patients between 1992 and 1996 other than 
two HIV clinics in this study. 
Viral load is a more specific measure of immunodeprression but was not measured in 
the present study. Possible differences in viral burden at baseline existed between the 
two groups of this cohort, may account for the observed differential survival and 
incidence of AIDS-defining illness. It has been shown that viral load measured by 
polymerase chain reaction predicts progression of disease even when controlling for 
the level of CD4+lymphocyte count (33). 
5.2 EFFECT OF SITE OF TUBERCULOSIS ON SURVIVAL OF HIV-
INFECTED PATIENTS 
The reported non-significant difference between the survival of patients with 
pulmonary and extrapulmonary tuberculosis in this study suggests that patients with 
extrapulmonary tuberculosis have no worse prognosis than those diagnosed with 
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pulmonary tuberculosis. In another study done in Cape Town, Post et al. observed the 
same result [34]. Patients with extrapulmonary tuberculosis were observed to have a 
survival pattern comparable to the survival of other patients without extrapulmonary 
involvement. Shafer et al. observed a similar finding in 54 consecutive HIV-
seropositive patients with newly diagnosed tuberculosis and no other AIDS-defining 
illnesses in the USA [35]. They found no survival difference between patients with 
pulmonary and extrapulmonary tuberculosis (risk ratio RR = 1.1; 95% confidence 
interval= 0.4-2.9). However, Whalen et al. observed a different result. In their study, 
also done in the USA, the median survival was shortest in patients with both 
pulmonary and extrapulmonary disease (8.4 months), followed by extrapulmonary 
disease alone (15.6 months), while those with pulmonary disease alone survived the 
longest (30.4 months) (p < 0.001) [4]. 
5.3 EFFECT OF CO-TRIMOXAZOLE PROPHYLAXIS ON MORBIDITY 
AND MORTALITY OF HIV-INFECTED PATIENTS WITH 
TUBERCULOSISS 
A wide range of severe AIDS-defining illnesses occur in HIV-infected patients with 
advanced immunodeficiency. Prophylaxis against AIDS-defining illnesses is known 
to prolong life, decrease morbidity and delay the progression of HIV disease [36]. The 
success of the prophylaxis against some AIDS-defining illnesses which were reported 
to be associated with substantial morbidity or mortality [ e.g. Pneumocystis carinii 
pneumonia (PCP)] [37] led to a search for effective regimens for the prevention of 
other AIDS-defining illnesses. 
Trimethoprim was specifically developed in the late 1960s as a sulphonamide and was 
launched in combination with sulfarnethxazole as co-trimoxazole (TMP-SMX or 
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Bactrim®). Co-trimoxazole is a mixture of trimethoprim and sulphamethoxazole in 
the proportions of 1 part to 5 parts [38]. Co-trimoxazole prophylaxis in HIV-infected 
patients prevents Pneumocystis carinii pneumonia (PCP), a major cause of morbidity 
and mortality in AIDS patients from developed countries [39-40] This intervention is 
not widely used in sub-Saharan Africa where PCP is uncommon [39-40]. However, 
co-trimoxazole also prevents other AIDS-defining illnesses (salmonellosis, 
isoporiasis, cerebral toxoplasmosis, and other bacterial pneumonia) which occur 
commonly in HIV-infected patients in Africa [41-42]. 
Many authors have advocated the use of co-trimoxazole prophylaxis, and documented 
in their studies an improved prognosis and a decreased incidence of many AIDS-
defining diseases among their patients [35-50]. Wiktor et al., in a recent study done in 
Cote d'Ivoire, have shown that in HIV-infected patients with active tuberculosis, daily 
co-trimoxazole prophylaxis significantly decreased mortality ( 46% risk decrease, 95% 
confidence interval = 23 - 62, p < 0.001) and hospital admission rates (43% risk 
decrease, 95% confidence interval = 10 - 64, p = 0.02) [43]. Fischi et al. found that 
only 4 (13%) of 30 patients assigned to co-trimoxazole developed Pneumocystis 
carinii pneumonia (PCP) compared with 16 (53%) of 30 patients who were not 
receiving prophylaxis (p <0.005) [44]. The four patients who developed Pneumocystis 
carinii pneumonia (PCP) in the co-trimoxazole arm discontinued prophylaxis before 
the diagnosis because of drug toxicity. Co-trimoxazole prophylaxis was associated 
with longer median survival (23 months compared with 13 months, p < 0.002 ). Edge 
et al. in a case-control study found a protective benefit of co-trimoxazole on the 
development of bacteraemia (odds ratio = 0.28; p = 0.001) [45]. Furthermore, co-
trimoxazole has been found to be effective in preventing cerebral toxoplasmosis. In 
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one study, none of the 60 patients receiving co-trimoxazole prophylaxis developed 
toxoplasmosis compared with 12 (13%) of95 patients of a comparison group who did 
not receive co-trimoxazole prophylaxis; (p < 0.05) [ 46]. 
In this study, the efficacy of co-trimoxazole prophylaxis in prolonging survival was 
firstly examined among the HIV-infected patients in the general cohort when 
controlling for co-trimoxazole prophylaxis as a probable confounder for the effect of 
active tuberculosis on mortality, and then specifically in the group of active 
tuberculosis. The effect of co-trimoxazole prophylaxis in the general cohort was 
discussed in section [5.1.4.2]. In this section the efficacy of co-trimoxazole 
prophylaxis in tuberculosis group is discussed. 
The tuberculosis group was stratified according to use of co-trimoxazole prophylaxis. 
Mortality and incidence of AIDS-defining illnesses which could be prevented by co-
trimoxazole (PCP, cerebral toxoplasmosis, non-typhoid salmonellosis and bacterial 
pneumonia) were significantly lower in the co-trimoxazole group compared to the 
comparison group, and the median survival of the co-trimoxazole group was longer. It 
is noteworthy that the better outcome in patients given co-trimoxazole was achieved 
despite their lower CD4+ lymphocyte count at baseline (median 174 cells/µl, 
interquartile range 33-199, compared to 308 cells/µl, interquartile range 290-745; 
p<0.001). 
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5.4 RISK FACTORS FOR DEVELOPING TUBERCULOSIS IN HIV-
INFECTED PATIENTS 
5.4.1 Risk of developing TB 
The high cumulative incidence (9%) reported during the 5 years among this cohort can 
be attributed to the development of the HIV epidemic in a population with one of the 
highest recorded tuberculosis prevalence rates in the world. The incidence of active 
tuberculosis in this cohort is considerably greater than that reported in the general 
population of Cape Town during the period of this study (Table 2-4). This suggests that 
the HIV epidemic is one of major contributors to the rapidly growing incidence of 
tuberculosis in Cape Town. 
HIV infection confers the greatest known risk for the development of tuberculosis, both 
for the reactivation of latent infection and for progressive primary disease. Indeed HIV 
infection is the only factor which has been able to disturb the balance between the 
tubercle bacillus and man, in the absence of man-made interference. The impact of HIV 
infection on the epidemiological situation of tuberculosis is so large that, under certain 
conditions, the tools available at present for tuberculosis control will fail to restrain the 
increase in the incidence of tuberculosis caused by HIV infection. A strong association 
exists between tuberculosis and HIV in Africa. The interaction between HIV and 
tuberculosis fuels the growth of active tuberculosis within the community, thereby 
enhancing the tuberculosis epidemic. During the last decade, countries to the north of 
South Africa experienced a dramatic increase in the incidence of tuberculosis [51-53]. 
Percentage increases compared with the pre-HIV era, have been quoted to be between 
250% (Kinshasa and Bangui) and 700% (Lusaka) [53]. However, the current risk of 
tuberculosis infection and its trend is the most decisive factor in containing the 
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deterioration of the epidemiologic situation of tuberculosis in developing countries in the 
future, caused by HN infection. 
In countries with high prevalence of both tuberculosis and HIV infection it is imperative 
to achieve and maintain a high cure rate of all diagnosed smear positive tuberculosis 
cases with short-course chemotherapy. Since many tuberculosis cases among HIV-
infected persons are smear-negative but culture positive, or smear-negative and culture 
negative, or culture-positive, it is necessary, whenever possible, to improve case 
detection of smear-negative cases through screening by X-ray of the chest patients 
suspected of having tuberculosis, and to examine those with pathology on the X-ray but 
with negative microscopy, by culture for the tubercle bacilli (54-56]. 
5.4.2 Effect of advanced immunosuppression on developing overt TB disease 
A maJor finding of this study was that the risk of developing active tuberculosis 
increased markedly with advancing HIV disease. The analysis which was done to 
ascertain the factors predictive of active tuberculosis in HIV-infected patients, 
suggests that HIV-infected patients presenting without evidence of active tuberculosis 
and with advanced immunnodeficiency, as measured by CD4+ T lymphocyte count 
(< 200 cells / µL), have a 6-fold increased risk of developing active tuberculosis 
compared with those with counts > 200 cells/ µL. 
The analysis suggests further that patients presenting with higher stages of HIV-
infection, (WHO stage 3 and 4) or with an AIDS-defining illness are at an increased 
risk of developing active tuberculosis. AIDS-defining illnesses are markers of a high 
level of immunosuppression; a level at which the risk of active tuberculosis increases 
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for patients infected with both HIV and tuberculosis. The significant association 
between active tuberculosis and the other AIDS-defining illnesses observed in this 
study may be due to the common underlying immunosuppression. The onset of the 
AIDS-defining illness leads to a great depletion in CD4+ T-lymphocyte count and 
thus set the stage for the active tuberculosis to develop. 
5.4.3 Effect of race group and socioeconomic status on developing overt TB 
disease in HIV-infected patients 
A higher risk of developing TB was observed among the Black and Coloured HIV-
infected patients of this cohort (RR= 3.41) than in White patients . The higher 
incidence of tuberculosis in these groups is a reflection of the endemicity of 
tuberculosis in this population group. The racial group variations in the risk of 
developing TB in this cohort are similar to those reported in other studies done in 
South Africa [57-58]. This finding indicates that HIV-infected patients with active 
tuberculosis in Cape Town tend to belong to the less privileged sector of society, and 
that the risk of developing TB in HIV-infected patients correlates with poverty areas. 
This fact has implications for access to health services, disease progression and 
survival. 
The basis of the racial difference in tuberculosis has been ascribed to social factors , 
such as malnutrition, stress, overcrowding, poor access to medical facilities, delay in 
seeking treatment, (which leads to greater dissemination of the disease), and poverty 
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[59-61]. However. other studies have suggested that group variation in susceptibility 
to tuberculosis may be due to genetic differences in the ability of unstimulated 
macrophages to ingest and lyse the bacilli. In a study done in the USA, Crowle has 
that there is considerable variation in the vigour with which human macrophages 
ingest and kill M. tuberculosis [62]. He investigated the cellular basis of this putative 
susceptibility in vitro by comparing responses of blood-derived macrophages from 
Black and White donors to experimental infection with virulent tubercle bacilli. Using 
microscopic count, the uptake and replication of the tubercle bacilli in these cells in 
his study were measured at 0,4, and 7 days. He observed that Black-donor phagocytes 
killed more bacilli during phagocytosis than White-donor phagocytes did. However, 
the bacilli grew consistently and significantly faster in successfully infected 
macrophages from Black than from White donors, especially in the presence of Black 
donor serum (p < 0.001). He argued that " these results demonstrate some inherent 
and environmental liabilities in the monocytic phagocytes and serum of Black people 
compared with White people, which may contribute to their greater susceptibility to 
tuberculosis. This appear to furnish an explanation at the cellular level of the 
difference in infectibility" observed in his study. Stead et al. In astudy done in the 
USA, observed that there were " individual variations in the threshold that an 
inoculum of M tuberculosis must exceed to establish an infection". He argued that 
this threshold was significantly higher in the White than in the Black patients in his 
study [63]. However, the generalizability of these results to the universal "racial' 
differences remains controversial. 
The prevalence of past M. tuberculosis infection is known to be higher in older 
people. The lack of association between older age and tuberculosis in this study could 
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be explained by the fact that the majority of the patients in this cohort were of young 
age. 
It was difficult to ascertain whether the high percentage of unemployed patients in 
this cohort was a consequence of their HIV status. Even without HIV infection, 
unemployment in many Western Cape suburbs easily exceeds 50%. However, HIV 
infected people are less likely to maintain their occupational status than seronegative 
persons, as they are more likely to lose their jobs and become financially dependent 
upon family and friends . In the cohort of this study where unemployment is high 
among HIV-infected patients, a household of several adults and children was 
frequently dependent on the earnings of a single member. That person is usually the 
young adult who is also sexually active, unmarried, uneducated and most at risk of 
acquiring HIV. 
Higher level of education was observed to be protective against the risk of active 
tuberculosis. Higher education in this study is likely to be a marker of higher 
socioeconomic status which is a known protective factor against developing active 
tuberculosis. Lack of education has been reported previously to be associated with 
risk of developing active tuberculosis and poorer survival in patients with and without 
HIV-infection in African countries [64]. 
While previous studies in Africa have shown a strong association between HIV infection 
and the risk of tuberculosis, they have not demonstrated a marked increase in 
tuberculosis incidence with HIV disease progression. Two studies from Central and 
West Africa have reported higher CD4+ T-lymphocyte count of patients with 
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tuberculosis and HIV-infection than in the present study (63,65]. Differing methodology 
for tuberculosis diagnosis may partially explain the apparent conflicting findings. A 
cross-sectional study in Zaire (65] reported that pulmonary tuberculosis occurred across 
the spectrum of HIV disease, with the majority of tuberculosis (67%) associated with 
CD4+ T-lymphocyte count above 200/µL. The study was limited to sputum smear 
positive pulmonary disease, which may have under-diagnosed the more atypical 
presentations associated with advanced immune suppression (67]. A study in Cote 
d'Ivoire of smear positive pulmonary TB and clinically diagnosed extrapulmonary 
tuberculosis, reported 57% of cases occurred at CD4+ T-lymphocyte count above 
200/µL (66]. In contrast, post mortems from Zaire and Cote d'Ivoire showed histological 
and culture evidence of disseminated tuberculosis in 41 % and 54% of AIDS patients 
respectively (42,68] with a median CD4+ T-lymphocyte count of 88/µL in the Zaire 
study [ 42]. The facilities for histology and tuberculosis culture available at the 2 
hospitals in the present study may have increased case finding, as radiographic 
presentation of pulmonary tuberculosis in the HIV-infected patients in the general cohort 
to which the patients in this study belong is frequently atypical and 52% are sputum 
smear negative (67]. A recent prospective multicentre USA cohort study found the risk 
of developing TB was significantly higher in patients with a CD4 CD4+ T-lymphocyte 
count <200/µL (69]. 
The cellular mechanisms underlying the development of tuberculosis in HIV-infected 
patients have been discussed in a previous section. In brief, inhaled tubercle bacilli 
enter the lungs as droplet nuclei where they are engulfed by alveolar macrophages 
which process the mycobacterial antigens and resent them to CD4+ T helper 
lymphocytes. In healthy individuals, infection with M. tuberculosis is probably 
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controlled by a dynamic interaction between CD4+ helper T lymphocytes and tissue 
macrophages containing intracellular tubercle bacilli, resulting in granuloma 
formation . Macrophages are activated to kill intracellular organisms by lymphokines, 
but whereas most intracellular infections can be inhibited or killed by interferon y 
induced activation [70], M tuberculosis in human macrophages systems seems 
relatively resistant suggesting that other mechanisms are involved [71]. Forte et al. 
suggest that a class of CD4+ cytotoxic T- lymphocyte is involved in the control of M 
tuberculosis latent infections by causing cytolysis of infected macrophages, thus 
releasing tubercle bacilli and exposing them to further immune attack [72]. HIV 
disturbs this process by infecting macrophages and upsetting their function [73]. 
Thus, HIV infection is associated with a steady decrease in both numbers and activity 
of CD4+ lymphocytes [74]. In conclusion, the findings of this study confirm that 
HIV-infected patients are at higher risk of developing active tuberculous disease. 
5.4.4 Prophylaxis and treatment of TB in HIV-infected patients 
Despite the higher risk of tuberculosis described above, there is evidence from several 
sources that tuberculosis may respond well to treatment, even in the presence of HIV 
infection. Furthermore, the efficacy of isoniazid (INH) prophylaxis has been 
demonstrated in various studies. Pozniak argued that isoniazid is "the most potent 
bactericidal drug and kills more than 90% of bacilli within 7 days by acting on 
metabolocally active bacilli, and effective at preventing the emergence of drug 
resistance"[?]. Pape et al. found that the administration of INH for one year in Haitian 
patients reduced the frequency of tuberculosis from 10 to 1.7/100 person-years [75]. In 
addition, INH was shown to reduce the risk of tuberculosis in persons with HIV 
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infection in Zambia, Uganda, Mexico and the United States [76]. In all these countries, 
the protective effect of INH was greater when the incidence of tuberculosis was high 
than when it was low. 
However, while antituberculosis prophylaxis is believed to eradicate the HIV-infected 
patient's bacilli and therefore prevent reactivation tuberculosis, this is unlikely to 
subsequently protect from a new tuberculosis infection several years later [75]. This 
necessitates constant screening for tuberculosis in HIV-infected patients even after 
successful treatment. 
5.5 VALIDITY OF HIV STAGING SYSTEMS IN HIGH TB PREY ALEN CE 
SETTING 
In this cohort, a median survival of 24 months was observed following the diagnosis 
of active tuberculosis. Furthennore, it was shown that the prognosis of this group was 
significantly different from that of patients diagnosed with an AIDS-defining illness. 
These findings suggest that the diagnosis of active tuberculosis in HIV-infected 
patients is not necessarily associated with a prognosis similar to that of other AIDS-
defining illnesses. 
Using the WHO and CDC staging systems, survival of active tuberculosis patients 
was comparable to WHO stage 3 and to CDC stage B. More specifically, the 
prognosis of HIV-infected patients with active tuberculosis was equivalent to that of 
HIV-infected patients with oral hairy leukoplakia or oral candidiasis. 
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More than a decade has now elapsed since the initial description of AIDS and much 
more information is now available about the natural history of infection with HIV. 
Observations from a number of prospective studies have provided insight into the 
characteristic changes in laboratory parameters (most notably CD4 lymphocyte count 
and appearance of symptoms) that are markers of progression of HIV disease [78-81]. 
Since the beginning of the epidemic, a number of classifications have been proposed 
to stage HIV infected individuals throughout the course of their disease. The clinical 
case definition for AIDS in adults was developed at a WHO workshop on AIDS in 
Bangui, Central African Republic, in October 1985 [82], and later revised [83]. 
Staging systems play a critical role in management of HIV infected patients because 
they assist clinicians in selecting appropriate prognostic stratification for clinical 
studies, and identify intermediate measures of disease progression that can be used to 
expedite the assessment of potentially promising therapies. The effectiveness of an 
HIV staging system will depend on consistent prognostic utility despite heterogeneous 
populations. As has been discussed in a previous section of this thesis, a major 
limitation of the existing staging systems is that the clinical case definitions lack 
specificity in distinguishing cases of tuberculosis from cases of AIDS. Some other 
disadvantages of these systems are that they are not necessarily based on severity of 
illness, and a large number of people cannot be classified. These staging system often 
place all patients with AIDS into one group, whereas the heterogeneity in survival of 
patients with AIDS suggests that a finer distinction might be more useful. 
Furthermore, differences in the spectrum of disease and in the population may 
significantly decrease the specificity of these staging systems, e.g. in a high endemic 
tuberculosis setting. 
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Few studies, however, have specifically addressed the ranking of AIDS-defining 
diseases and survival after each diagnosis [82-83]. A natural order of AIDS-defining 
diseases, based on the average CD4 lymphocyte count at which they occur, has been 
suggested [78-81,85-86]. This order ranges from diseases such as lymphomas, 
tuberculosis and Kaposi's sarcoma, which typically occur at higher CD4 lymphocyte 
counts, to diseases such as cytomegalovirus (CMV), which are frequently observed in 
patients with CD4+ T-lymphocyte count below 50 cells/µl [85]. 
In many African and other developing countries, laboratory facilities are insufficient 
to allow reliable diagnosis of the opportunistic infections and malignant disorders 
required to meet the definition. Strict adherence to the CDC HIV staging systems in 
African countries would lead to greater-under recognition of the disease. Furthermore, 
the clinical spectrum of AIDS in Africa may differ substantially from that described 
in Europe and North America. Testing for HIV antibodies by currently available 
technology may not be feasible. 
The findings of this study may contribute to clarify why in a high tuberculosis 
prevalence setting and in absence of co-infection with an AIDS-defining illness active 
tuberculosis may not qualify as an AIDS-defining illness. 
These findings suggests further that the CDC criteria (Appendix I) for staging HIV-
infected patients is of a limited utility in predicting the course of HIV progression in a 
high tuberculosis prevalence setting. The CDC staging system may be useful in the 
setting for which it was initially proposed and validated, but its applicability in other 
settings is controversial. The universal use of the CDC system has been compromised 
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by its limited prognostic utility in the past, and a lack of international consensus 
concerning recent revisions to the original system. 
Conclusion and recommendations 
Tuberculosis is one of the most important infections affecting HIV-infected patients 
in the world. A strong interaction between tuberculosis and HIV has been shown in 
this study and in other seroprevalence surveys in places as diverse as Burundi, the 
United States, France, Italy, Tanzania, and Haiti. Based on the findings of this study, 
some observations need emphasis. 
o The high prevalence of tuberculosis in the Western Cape makes it mandatory to 
screen every HIV-patient for tuberculosis. Suppression of active disease by anti-
tuberculosis chemotherapy in HIV-infected patients with active tuberculosis 
should be started immediately following the diagnosis of tuberculosis. 
o On the other hand, all adults presenting with tuberculosis need to be assessed for 
HIV infection because the medical management of tuberculosis may needed to be 
altered in the presence of HIV infection. Problems arise both when HIV-infected 
patients are contemplating starting antiretroviral therapy and when they are 
already on such therapy and tuberculosis is diagnosed. Some guidelines regarding 
the treatment of tuberculosis and HIV already exist and usually require 
modification of either tuberculosis therapy or the antiretroviral drugs regimen 
[87]. Major drug-drug interactions can occur especially between the rifampicin 
and protease inhibitors and non-nucleoside reverse transcriptase inhibitors 
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(NNRTI) [87]. In addition, tuberculosis patients who are infected with HIV will 
benefit by being monitored for early diagnosis of AIDS-defining illnesses and 
other manifestations of HIV infection. 
o Based on the findings of this study, active tuberculosis, in the absence of co-
infection with other AIDS-defining illnesses, must not be considered as an AIDS-
defining illness. Further studies are needed to replicate the findings of this study, 
and to evaluate the clinical case definition of AIDS in areas where tuberculosis is 
highly endemic. 
o The findings of this together with those of Wiktor et al.[43] indicate a dramatic 
benefit of prophylactic co-trimoxazole against a variety of AIDS related illnesses 
in HIV-infected patients with active tuberculosis and confirm that the lower dose 
of 480 mg daily is also effective in an African context. Co-trimoxazole is an 
affordable intervention which would help improve the therapeutic nihilism which 
surrounds HIV in many African countries. 
o Many patients in this study presented at late stage and were severely 
immunocompromised when their HIV status was initially diagnosed. This 
deprived them of the opportunity of receiving interventions aimed at improving 
their prognosis. This may be due to a lack of awareness or knowledge of 
HIV/AIDS in the areas from which the subjects of this cohort were drawn. Delay 
in seeking medical attention can be viewed as integral to the poor survival 
observed in this study. This clearly indicates the need to educate the groups at 
high risk for HIV with regard to the importance of early diagnosis, and the 
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monitoring and suppression of HIV infection. However there are many practical 
difficulties in screening for HIV in its early stages. 
o This study indicates that both Mycobacterium tuberculosis and HIV have their 
impact on certain categories of the Western Cape population. The most affected 
are young adults at the beginning, or in the prime, of their productive lives. This 
has serious implications for the burden of both diseases in the affected 
communities. Furthermore, students were reported in this study to be the third 
highest category affected by HIV infection. It is vital to ensure that young people 
understand the nature of the AIDS epidemic and the specific actions they can take 
to prevent HIV infection. 
o Antiretroviral therapy is expensive and generally unaffordable for the vast 
majority of HIV-infected patients in South Africa. At present, few HIV-infected 
patients are able to afford combination anti-retroviral therapy. Providing these 
drugs to those who cannot afford to pay for them should be viewed as a priority of 
the health authorities in South Africa. However the cost implications are great, 
and this will remain a major barrier in South Africa. 
o Co-infection may make the diagnosis of tuberculosis extremely difficult in some 
HIV-infected patients. The absence of cavitation and the scarcity of tubercule 
bacilli in the sputum of patients with advanced immunosuppression, may lead to 
disastrous exclusion of the diagnosis. Failure to diagnose and manage tuberculosis 
appropriately can result in reduced survival and death of the patient and infection 
of contacts, including other patients and health-care personnel. To establish the 
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diagnosis, a variety of specimens, including respiratory secretions, bronchial 
washings, gastric lavage, lung tissue, pleural fluid, lymph node tissue, bone 
marrow, blood, urine, stool , brain biopsy, and cerebrospinal fluid, may need to be 
obtained for mycobacterial culture. Specimens must be examined microscopically, 
but the inability to demonstrate acid-fast bacilli and the absence of granuloma 
formation does not exclude the diagnosis of tuberculosis [54-56]. This is 
particularly relevant to South Africa, were laboratory screening of sputum 
(without subsequent culture) for AFBs may jeopardise a more aggressive pursuit 
of mycobacterial infection. However, diagnosing tuberculosis by culture only is 
both expensive and slow. This clearly indicates the need for developing evidence-
based algorithm for clinical diagnosis of smear negative tuberculosis in HIV-
infected patients. 
o In conclusion, access to decent health care must be viewed as a priority for all 
South Africa's diverse people. Determination of HIV status, the exclusion of 
tuberculosis and the provision of a relatively cheap drug such as INH and co-
trimoxazole can be all successfully integrated at the primary care level and are 
suited to the current proposals for health care reform in this country. Should 
improved control not occur within the next few years, the prevalence of HIV in 
the adult population will rise to 17-30%. Every effort should be made to undo the 
cycle of HIV and tuberculosis and reduce their devastating impact on South 
African socie_ty. 
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APPENDICES 
APPENDIX I 
1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS Among Adolescents and Adults. 
The revised CDC classification for HIV-infected adolescents and adults categorizes 
persons on the basis of clinical conditions associated with HIV infection and CD4+ T-
lymphocyte counts. The system is based on three ranges of CD4+ T-lymphocyte 
counts and three clinical categories and is represented by a matrix of nine mutually 
exclusive categories. This system replaces the classification system published in 1986, 
which included only clinical disease criteria and which was developed before the 
widespread use of CD4+ T-cell testing. 
CD4+ T-lymphocyte Categories 
The three CD4+ T-lymphocyte categories are defined as follows: 
* Category 1 : greater than or equal to 500 cells/el 
* Category 2 : 200-499 cells/ £1 
* category 3 : less than 200 cells/ £1 
Clinical Categories : 
The clinical categories of HIV infection are defined as follows: 
Category A 
• Asymptomatic HIV infection 
• Persistent generalized lymphadenopathy 
• Acute ( primary) HIV infection with accompanying illness or history of acute 
HIV infection 
Category B 
• Bacillary angiomatosis 
• Candidiasis, oropharungeal (trush) 
• Candidiasis, vulvovaginal, persistent, frequent, or poorly responsive to 
therapy 
• Cervical dysplasia (moderate or severe)/ cervical carcinoma in situ 
• Consistutional symptoms, such as fever (35 .5 C) or diarrhoea lasting> 
1 month 
• Hairy leukoplakia, oral 
• Herpes zoster (shingles) 
• Idiopathic thrombocytopenic purpura 
• Listeriosis 
• Pelvic inflammatory disease 
• Peripheral neuropathy 
Category C (AIDS) 
• Candidiasis of bronchi, trachea, or lungs 
• Candidiasis, oesophageal 
• Cervical cancer, invasive 
• Cryptococcosis, extrapulmonary 
• Cryptococcosis, chronic intestinal(> 1 month) 
• Cytomegalovirus disease (other than liver, spleea, or nodes) 
• Cytomegalovirus retinitis ( with loss of vision) 
• Encephalopathy, HIV-related 
• Herpes simplex 
• Histoplasmosis, extrapulmonary 
• Isosporiasis, chronic intestinal ( > 1 month) 
• Kaposi,s sarcoma 
• Lymphoma, Burkitt's ( or equevalent term) 
• Lymphoma, imunoblastic ( or equivalent) 
• Lymphoma, primary, of brain 
• Mycobacterium avium complex or M. Kansasii, dissiminated or 
extrapulmonary 
• Mycobacterium tuberculosis, any site ( pulmonary or extrapulmonary) 
• Mycobacterium, other speices or unidentified speices, disseminated or 
extrapulmonary 
• Pneumocystis carinii pneumonia 
• Pneumonia, recurrent 
• Progressive multifocal leukopencephalopathy 
• Salmonella septivaemia, recurrent 
• Toxoplasmosis of brain 
• Wasting syndrome due to HIV 
APPENDIX II 
World Health Organization Clinical Staging System 
I Laboratory Staging 
CD4+ count cells/mmj Total lymphocyte count cellsxlO<>/L 
A. >500 >2000 
B 200-500 1000-2000 
C <200 <1000 
2 Clinical Stages 
Stage 1 
• Acute retroviral infection 
• Asymptomatic HIV infection 
• Persistent generalised lymphadenopathy 
• Performance scale 1: asymptomatic, normal activity 
Stage 2 
• Weight loss, less than 10% of normal body mass 
• Minor mucocutaneous manifestation ( seborrhoeic dermatitis, purigo, fungal 
nail infections, recurrent oral ulcerations, and angular chelitii- · 
• Herpes zoster ( shingles) within the last five year . 
• Recurrent upper respiratory tract infections 
• And/ or performance scale 2: symptomatic, normal activity 
Stage 3 
• Weight loss (> 10%) 
• Unexplained chronic diarrhoea lasting for longer than a month 
• Unexplained prolonged fever (intermittent or consistent) > 1 month 
• Oral candidiasis 
• Vulvovaginal candidiasis 
• Vulvovaginal candidiasis, chronic (> 1 month) or poorly responsive to therapy 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis within the last year 
• Severe bacterial infections such as pneumonia 
• And/or performance scale: bedridden< 50% of the day in the last month 
Stage 4 (AIDS) 
• HIV wasting syndrome 
• Pneumocystis carinii f neumonia (PCP) 
• Toxoplasmosis of the brain 
• Cryptosporidiosis with diarrhoea> 1 month 
• Cryptococcosis ( extrapulmonary) 
• Cytomegalovirus (CMV) 
• Herpes simplex virus 
• Progressive multifocal leukocephalopathy 
• Oesophageal, tracheal, bronchial or pulmonary , 
• Atypical mycobacteriosis ( disseminated) 
• Non-typhoid salmonella septicaemia 
• Extrapulmonary tuberculosis 
• Lyphoma (most commonly Non4'$dgkin's lymphoma) 
• Endemic mycosis 
Name: 
Number: 
---------------
DOB: R/S: 
-----
Hospital: GSH or Somerset 
Date of HIV diagnosis: 
CD4 lymphocyte count : 1. ____ _ 
2. 
3. 
Total lymphocyte count: 1. 
2. 
3. 
Date of TB diagnosis: 
Method of TB diagnosis: 
I Culture 
Smear 
Histology 
TEST 
Transmission: 
Date: 1. 
2. 
3. 
1. 
2. 
3. 
-----
-----
SPECIMEN 
Site of TB: 1. Pulmonary 2. Extrapulmonary(meningitis, nodal, pericardial) 
CXR: Glands- Y / N 
Infiltrate- YIN; if Y- diffuse, 
Effusion- Y / N 
Date last seen: 
Date of death: 
Cause of death: 
cavities, other 
1 
Name: 
Other HIV-related morbidity (WHO staging): 
Condition 
1) Acute retro viral infection, PGL 
2) Weight loss <10% 
Minor Mucocutaneous (inc. zoster) 
Recurrent URI 
3) Weight loss >10% 
Unexplained chronic diarrhoea, > 1 month 
Unexplained fever, > 1 month 
Thrush/OHL 
Severe bacterial infections (pneumonia) 
4) HIV wasting syndrome 
PCP (Pneumocystis carinii pneumonia) 
Toxoplasmosis of the brain 
Cryptosporidiosis w/ diarrhoea, > 1 month 
Cryptococcosis, extrapulmonary 
Cytomegalovirus ( organ other than liver, spleen, nodes 
Herpes simplex virus, mucocut > 1 month or visceral 
Candidiasis of oesophagus, trachea, bronchi, or lungs 
Atypical mycobacteriosis, disseminated 
Non-typhoid salmonella septicaemia 
Kaposi's sarcoma 
HIV encephalopathy 
Cervical cancer 
Progressive multifocal leuko-encephalopathy 
Any disseminated endemic mycosis (histo .. ) 
Lymphoma 
Pneumonia, recurrent 
2 
YES/NO 
Date- @ TB diagnosis Date- after TB 
or w/in 6 mo prior diagnosis 
APPENDIX IV DATA SHEET 
PATIENT NUMBER I I I I I CURRENT VISIT NO. 
DATE OF BIRTH I I I I I DEPENDANTS SPOUSE 1 
AGE 1 CHILED 2 
2 CHILDREN 3 
GENDER MALE 1 0 3 OR MORE 4 
FEMALE 2 NON 5 
SEXUAL PREFERENCE HOMOSEXUAL 1 EDUCATION PRIMARY 1 
HETEROSEXUAL 2 
' r 
SECONDARY 2 
BISEXUAL 3 L. TERTIARY 3 
UNKNOWN 4 UNKNOWN 4 
OTHER RISK FACTORS NONE 1 MEDICAL AID I YES 1 
IVDA 2 NO 2 
BLOODT/F 3 
MULTI. PARTNERS 4 REFERRED BY GP 1 
OTHER DAY HOSP. 2 
G.S.H 3 
POPULATION GROUP WHITE 1 RED CROSS 4 
COLOURED 2 TB HOSP. 5 
AFRICAN 3 POLLSMOOR 6 
ASIAN 4 
OTHER 
MARITAL ST A TUS SINGLE 1 
MARRIED 2 
OCCUPATION STATUS EMPLOYED I 1 
UNEMPLOYED 2 HEP BAG POSITIVE 1 
PENSIONER 3 NEGATIVE 2 
HOMEMAKER 4 UNKNOWN 3 
DISABILITY 5 
STUDENT 6 VDRL POSITIVE 1 
OTHER 7 NEGATIVE 2 
CURRENT I PREVIOUS PROFESSIONA I TPHA POSITIVE 1 
EMPLOYMENT MANAGERIAL 1 NEGATIVE 2 
WHITE COLLAR/ 
MIDDLE MANAGEMENT 2 PLACE OF RESIDENCE \ 
SKILLED/ ARTISAN 3 PLACE OF ORIGIN 
o r SEMI-SKILLED 4 PLACE OF DIAGNOSIS 
l UNSKILLED 5 DA TE OF DIAGNOSIS 
NOT APPLICABLE 6 DATE OF 1'" VISIT 
HOSPITAL NUMBER 
VISIT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
MONTH 
DAY 
WHO STAGING 
CLINICAL ST AGE 
PERFORMANCE SCALE 
WEIGHT 
LABORATORY 
CD4 
TOTAL LYMPHOCYTE 
HB 
PLTS 
ESR 
MINOR HIV RELATED CONDITIONS 
ORAL CANDIDIASIS {I) 
PERSISTENT G. L. (2) 
OHL (3) 
DIARRHOEA UNEXPLAINED (4) 
HERPES ZOSTER (5) 
PULMONARY TB (6) 
MAJOR HIV RELATED CONDITIONS 
EXRA PULMONAR TB (1) 
P.C.P. (2) 
TOXOPLASMOSIS. CNS (3) 
CRYPTOCOCCSI (4) 
KAPOSI' S SARCOMA (5) 
DRUGS 
ZIDOVUDINE (I) 
BACTRIM (2) 
PENTAMIDINE (3) 
TB DRUGS (4) 
OUTCOME 
DOCTOR'S INITIALS 
The scheme used for stratifying the patents' sociodemographic status 
Variable: Score 
1. Occupation status : 
1. Employed. 1 
2. Unemployed 0 
2. Employment status: 
1. Professional/ managerial I White collar/ Meddle 1 
management/Skilled/ Artisan. 
2. Semi-skilled/ Unskilled. 0 
3. Education level: 
1. Secondary/tertiary 1 
2. Primary/Uneducated. 0 
4. Medical aid coverage: 
1. Covered. 1 
2. Uncovered. 0 
5. Place ofresidence: 
1. High socioeconomic area. 1 
2. Lower socioeconomic area. 0 
6. Number of dependants: : 
3. Two dependants or less. 1 
4. Three dependents or more. 0 
Total ( i.e. highest score) 6 
The place of residence was categorized as a lower or higher "sociodemographic area" 
according to the classification system used by the Cape Metropolitan Council (CMC). 
Based on the variables in the above table, higher socidemographic status was defined 
as a score equal to or higher than 4. This cut-off is similar to the "Best-off' criteria 
used by the CMC, except for the medical aid variable included in the above scheme. 
